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ABSTRACT 
 
Recent evidence suggests that the expression of some candidate genes in cumulus cells (CC) 
have the potential to serve as markers of oocyte quality. The aims of this study were: 1) to 
validate a multiplex quantitative polymerase chain reaction (QPCR) method to measure four 
genes simultaneously in extracts from individual CC and; 2) to investigate the relationships in 
individual cumulus-oocyte-complexes (COC) amongst the expression levels of a range of 
candidate genes (N=8) from individual CC, the numbers of CC per COC and developmental 
indicators (good blastocyst development and live birth outcome) of the associated oocytes 
following in vitro fertilization (IVF) with intra-cytoplasmic sperm injection (ICSI).  
 
Sixty eight women were recruited for this study following approval from NZ Multi-Regional 
Ethics Committee and classified into four research groups: young and healthy women (<38 
years, N=25), young women with polycystic ovarian syndrome (<38 years, N=11), young 
with diminished ovarian reserve (<38 years, N=12) and older and healthy women (≥40 years, 
N=20). Following exogenous rFSH-assisted ovarian stimulation, 608 COC were collected and 
subjected to ICSI. Oocyte and embryo quality, and pregnancy outcomes were recorded. 
Expression levels of the following candidate genes HAS2, FSHR, SLC2A4 (GLUT4), ALCAM, 
SFRP2, VCAN, NRP1 and PR in CC extracts from individual COC were measured by 
TaqMan QPCR and normalized against the house-keeping gene, RPL19. The numbers of CC 
from individual COC were calculated from RPL19 expression levels plotted against a 
standard curve of CC number. These results were then assessed against the outcomes of the 
associated oocytes following ICSI.  
 
HAS2, FSHR, ALCAM, VCAN, NRP1 and PR mRNA were detectable in most samples 
(98.5%) whereas those for SLC2A4 and SFRP2 were generally undetectable. The minimum 
number of CC required for QPCR was estimated to be ~70. The mean levels of FSHR mRNA 
were up-regulated in young women with PCOS compared to those in the other two groups of 
women <38y. Expression levels of HAS2 across all four groups of women were correlated to 
both biological (age, basal serum FSH and serum AMH) and treatment (amount of rFSH used 
for stimulation, follicle numbers and COC retrieved) variables. Investigations related to 
oocyte development in young and healthy women showed that 1) mean mRNA levels of 
VCAN, HAS2 and PR were higher (P=0.002, P<0.05, P<0.05, respectively) in CC associated 
with oocytes that resulted in good quality blastocysts and those of VCAN were higher 
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(P<0.05) in CC associated with oocytes that resulted in a live birth, compared with those with 
developmental failure. However, the expression levels of all measurable candidate genes were 
highly variable for individual CC from COC from each woman. Indeed, 99.7% of individual 
COC were different in CC mRNA levels and cell composition. The application of a ranking 
method to score the relative CC mRNA levels of selected candidate genes from each COC 
recovered from individual women was evaluated. This approach demonstrated a predictive 
power of 80% efficiency for selecting good quality oocytes (at least one), whilst requiring the 
insemination of no more than three oocytes in any treatment cycle. Furthermore, this selection 
method resulted in a pregnancy and live birth rate of 60 and 52% respectively (N=25 women). 
This outcome is similar to that achieved when all metaphase II (MII) oocytes are inseminated.  
 
In conclusion, this study has validated a multiplex QPCR method to quantify the expression 
levels of four genes in CC of individual human COC simultaneously using as few as 70 cells. 
Moreover, that there is sufficient cDNA so that many more candidate genes can be measured 
in the same extract.  From the knowledge of the mRNA levels of at least four genes, VCAN, 
FSHR, HAS2 and PR in CC, it is possible to improve upon existing biological indicators the 
potential to predict good blastocyst formation and a successful pregnancy outcome. It is 
concluded that the application of a multiplex QPCR approach to assess the expression levels 
of a limited number of marker genes in CC can be used to select the best oocytes for 
successful pregnancy outcomes. 
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Chapter 1 INTRODUCTION 
 
1.1 Short history of ART and the development of human IVF 
 
The process of reproduction has long fascinated mankind from both philosophical and 
scientific perspectives. The discovery of reproductive gametes was associated with the 
development of microscopy as an investigative tool. The first observation of the human male 
gamete (spermatozoa) dates back to 1677, when Antonj van Leeuwenhoek conveyed his 
observations in a letter to the Royal Society, published in the Philosophical Transactions in 
1679. At that time Leeuwenhoek described the spermatozoa as ‘animalcules’ or ‘spermatic 
worms’. On the other hand, female gametes were discovered much later. Although Niels 
Stensen in 1667 proposed that the ‘female testes’ contained oocytes, it wasn’t until 1826, 
when Carl Ernst von Baer identified first the mammalian oocyte during his studies on the 
ovary of a dog. The first in vitro fertilization (IVF) attempt dates back to 1770, when Lazaro 
Spallanzani experimented with frogs, and discovered that oocytes would only develop in 
tadpoles after contact with semen (Clarke 2006). Later in the early nineteenth century, Jean-
Louis Prevost and Jean-Baptiste Dumas demonstrated that one spermatozoon can fertilize 
only one egg (Clarke 2006). The first report on human IVF was by Robert Edwards and 
colleagues in 1969, when they observed pronuclear formation following fertilization of 
oocytes (Edwards et al. 1969). In 1970, these researchers reported that they had obtained 
embryonic development to the 16-cell stage (Edwards et al. 1970). In 1973, a team from 
Monash University, Australia reported the first IVF pregnancy (De Kretzer et al. 1973). 
However, it wasn’t until 1978 when the first live birth resulting from IVF was reported by 
Steptoe and Edwards, following the birth of Louise Brown on 25
th
 July 1978 (Steptoe and 
Edwards 1978; Clarke 2006). On 4
th
 October 2010, the Nobel Prize in Physiology or 
Medicine was awarded to Robert Edwards for his pioneering work on IVF (Kirby 2010; 
Watts 2010). 
 
Human IVF can be described as a medical laboratory technique by which oocytes (eggs) are 
fertilized by sperm under artificial conditions, outside the body. A human IVF procedure 
involves the following stepwise events: ovarian stimulation, oocyte retrieval, oocyte 
fertilization, embryo transfer and the support of implantation and pregnancy (Smulders et al. 
2010). IVF has been developed and improved upon over many years of research with the 
intention of helping infertile couples to have a healthy offspring and establish a family. 
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1.2 The origin of the female gametes 
 
The formation of female gametes is associated with the development of the ovaries in the 
foetus. The ovary is a multi-compartmental organ with two key functions: 1) generation of 
fertilizable, developmentally competent female gametes (oocytes) and; 2) the secretion of 
steroid hormones required for preparation of the reproductive tract for fertilization of the 
oocyte and subsequent establishment of pregnancy (Knight and Glister 2006). Around the 
fifth month of gestation in humans, the ovaries contain peak numbers (ca. 6-7 million) of 
female germ cells (i.e. oogonia) (Baker 1963), the precursor cells for the development of 
oocytes. At this stage of gestation, oogonia enter meiosis which is the process by which a 
single oocyte and the polar bodies form (Ohno et al. 1962). During the transition through 
meiosis to prophase, most (>70%) germ cells die by apoptosis, leaving between 1-2 million 
oocytes at the prophase stage in the first meiotic division. These surviving oocytes with an 
associated layer of somatic cells known as granulosa cells constitute what is often referred to 
as the primordial follicle pool or “ovarian reserve” (see reviews by van Wagenen and 
Simpson 1965; Baker 1972; Rabinovici and Jaffe 1990; McNatty et al. 2000). As primordial 
follicles form during foetal life, they start to leave the primordial pool asynchronously and 
begin to grow towards ovulation (Peters et al. 1975; Byskov et al. 2005). Due to inadequate 
hormonal support before puberty, the fate of these growing follicles is atresia, resulting in a 
decline in follicles numbers to approximately 3-400,000 at puberty. Thereafter during the 
reproductive life in women, only about 400 will eventually complete development, and lead 
to oocytes being released at ovulation. At the time of menopause, ≤ 1000 oocytes remain 
(Baker 1963; Peters 1976; Maltaris et al. 2009). Nevertheless, from the time follicles form in 
foetal life, the initiation of growth of follicles from the primordial pool towards ovulation is a 
process that continues throughout life, regardless of reproductive state (i.e. puberty, 
pregnancy etc.) until the pool becomes exhausted around the time of menopause (Peters et al. 
1975). 
 
As discussed, oogonia that enter meiotic prophase are termed oocytes. During their 
development, oocytes undergo two meiotic cell divisions. Each meiotic division is divided 
into four phases: prophase, metaphase, anaphase and telophase. The first meiotic prophase in 
oocytes is unique in that it lasts much longer compared to that in any other cell. Whilst 
prophase is completed within hours in any other cell, it lasts for weeks, months or years in the 
oocyte. The various stages of meiotic prophase are defined by the homologous recombination 
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of the DNA and the distinct arrangement of the chromosomes, and therefore are 
morphologically distinguishable. They can be divided into the transitory phase (leptotene, 
zygotene and pachytene) and the stationary phase (diplotene). The stages are of different 
duration and become progressively longer as prophase progresses: leptotene is shortest and 
diplotene the longest. As the cells enter diplotene they begin the stationary phase in which the 
oocytes remain until shortly before ovulation. The first meiotic division is reductional, i.e. the 
diploid (2N, 46 chromosomes or 23 pairs of chromosomes) primary oocyte divides into two 
haploid (N, 23 chromosomes, each consisting two sister chromatids) cells, namely the 
secondary oocyte and the first polar body. The secondary oocyte begins the second meiotic 
division but is arrested during a stage called metaphase II. The process by which the oocyte is 
released from the ovary is called ovulation. If fertilization occurs, the secondary oocyte 
completes the second meiotic division by halving its genetic material to 23 chromosomes 
(single chromatids) and releasing the second polar body containing the other pair of the 23 
chromosomes. Then the 23 chromosomes from the nucleus of the spermatozoa will join the 
23 chromosomes of the oocyte to form a zygote and complete fertilization (Figure 1A) (Ohno 
et al. 1962; Peters and McNatty 1980). 
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Figure 1A: Diagram showing the process of oogenesis in mammals and humans. N = number 
of chromosomes (i.e. 23 chromosomes in humans). 
 
1.3 The ovarian cycle 
 
The ovarian cycle is a term used to describe the cyclical functions of the ovary during 
sequential ovulatory intervals under the control of the hypothalamic-pituitary axis. In women, 
this first begins at puberty (11-13 years) and ends at menopause (45-55 years). Normally, 
each cycle lasts 28 days and is divided in two phases of similar duration. The follicular (or 
proliferative) phase begins on the first day of menses and ends with ovulation. The luteal 
phase (or secretory phase) is the latter phase of the menstrual cycle and begins after ovulation 
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with the formation of the corpus luteum and ends with either a pregnancy or luteolysis and 
the initiation of a follicular phase (Chabbert Buffet et al. 1998). Most follicles within the 
ovary are present as primordial structures (about 30-60 µm in diameter) consisting of a 
primary oocyte encompassed by a single layer of flattened granulosa cells, and separated 
from the stromal tissue by the basal lamina membrane (Oktem and Oktay 2008). Whilst the 
level of functional activity in primordial follicles is low, over 500 genes related to 
housekeeping functions and DNA repair are activated (McNatty et al. 2006; Gougeon 2010). 
Nevertheless these follicles can sense their microenvironment as they express numerous 
receptors for growth factors and some components of post-receptor signalling pathways 
(Eppig 2001; Skinner 2005; McNatty et al. 2006; Gougeon 2010). The process of activation 
of primordial follicles for growth still remains to be elucidated. However, there is compelling 
evidence that the signalling between the oocyte and surrounding granulosa cells and 
interstitium are important for normal follicular recruitment and development (Knight and 
Glister 2006; Franks et al. 2008). Primordial follicles that have initiated growth undergo a 
sequential series of morphological changes. During the first step, the oocyte begins to enlarge 
in diameter, and the surrounding granulosa cells become cuboidal in shape and thereafter 
increase in number to form a primary follicle (Gougeon and Chainy 1987; Lundy et al. 1999; 
Braw-Tal 2002). During this time, the oocyte genome is further activated to include 
rudimentary paracrine signalling pathways that are vital for communication between the 
follicular somatic cells and the oocyte (McNatty et al. 2006; Gougeon 2010). Whilst these 
primary follicles develop receptors to follicle stimulating hormone (FSH), they remain 
essentially gonadotrophin-independent until antrum formation. After the primary stage of 
growth, a glycoprotein matrix called the zona pellucida (ZP) forms around the oocyte, 
separating it from the granulosa cells. Granulosa cells continue to proliferate further with the 
formation of several concentric layers around the primary oocyte (Knight and Glister 2006). 
As soon as the oocyte is surrounded by more than one-two layers of granulosa cells, the 
follicle is commonly referred to as a secondary follicle (Eppig 2001). The diameter of a 
follicle increases from 40-60 µm at the primary stage to 120-150 µm at the late pre-antral 
stage (Gougeon and Chainy 1987; Gougeon 1989). New evidence supports the theory that the 
transition from primary to secondary stage and the growth to the preantral/early antral follicle 
stage is regulated by local factors, most notably by members of the transforming growth 
factor-β (TGF-β) super-family. As the multiple concentric layers of granulosa cells develop, 
fluid-filled spaces form amongst the granulosa cells, and stromal cells immediately outside 
the basal lamina differentiate into the theca layer around the follicle (Knight and Glister 
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2006). This thecal layer is intermingled amongst a blood capillary network that increases in 
prominence as follicular growth continues. With increasing growth, the fluid-filled spaces 
amongst the granulosa cells coalesce to form an antrum thereby displacing the oocyte to a 
more eccentric location. The newly-formed antral follicle is marked by a relatively large 
oocyte around 85% of its final diameter and surrounded by the ZP, approximately 8-9 layers 
of FSH-responsive GC, a basal lamina, an LH-responsive theca interna, a capillary network, 
and a theca externa (Figure 1B).  
 
 
 
Figure 1B: Section through ovary of a sheep showing three antral follicles of different sizes. 
Image supplied by Prof Ken McNatty. 
 
Growth beyond the small-antral stages of development becomes critically dependent on the 
gonadotrophins, FSH and LH with an increase in the rate of follicular growth (Gougeon 
1998). Under the control of the oocyte-secreted factors, the GCs immediately adjacent to the 
oocyte differentiate into cumulus cells (CC), and develop a different functional phenotype 
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compared to the more distantly-located (mural) granulosa cells (GC) that will line the 
basement membrane (Li et al. 2000). Differences in gene expression between the CC and GC 
populations likely reflect their different roles during follicular maturation (Gilchrist et al. 
2008). The CC are clustered in multiple layers around the oocyte (see Figure 1C). Their 
major role is to support oocyte development with an essential role in nurturing oocyte growth 
and metabolism by providing nutrients such as amino acids and substrates for energy 
production (Sugiura et al. 2005). In contrast, the murally-located GC play a major role in 
follicular steroidogenesis by co-operating with the theca interna to secrete oestradiol 
(Armstrong and Dorrington 1977; McNatty et al. 1981a). Follicular growth after the antral 
stage is characterized by further proliferation of GC and theca cells, increased vascularisation 
around the theca interna and oocyte growth (Oktem and Urman 2010). In women, the 
development of large antral follicles from ~4mm diameter is critically dependent on FSH 
support together with, as yet, an undetermined level of oocyte growth factor support. 
Although each small antral follicle has the potential to reach full maturation, only those with 
GC having the greatest sensitivity to FSH will develop further (McNatty et al. 1981b). As the 
FSH concentrations gradually decline during the follicular phase, a single large follicle 
(>8mm diameter) under the control of pulsatile LH secretion will gain dominance and reach a 
diameter of 15-25mm, and thereafter ovulate in response to the preovulatory LH surge 
(Figure 1D) (Fauser and Devroey 2003; Palermo 2007).  
 
 
 
Figure 1C: High resolution image (200 x magnification) showing a sheep COC. The oocyte 
in the middle is surrounded by multiple layers of CC. Image supplied by Dr Janet Pitman. 
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Figure 1D: Graphical representation of the process of folliculogenesis in the ewe developed 
by Scaramuzzi et al., 1993, 2011. The initiation of follicular growth from the pool of 
primordial follicles takes place in a continuous and asynchronous manner. Those follicles that 
start to grow, continue to grow without rest until they become atretic or ovulate. Permission to 
use this figure in the present thesis was granted by the authors and by CSIRO PUBLISHING 
(link to original paper: http://www.publish.csiro.au/nid/44/paper/RD09161.htm). 
 
During ovulation, the mature follicle ruptures and the follicular fluid containing the oocyte 
and associated CC is released onto the ovarian surface from where it is swept into the 
fallopian tube by the fimbriae (Kolle et al. 2010). Once the egg is within the fallopian tubes, 
it migrates to the segment known as the ampulla, where the oocyte may be fertilized (Devoto 
et al. 2009). Thereafter, the fertilized egg (i.e. embryo) continues to travel towards the uterus. 
After approximately 5 days, the embryo reaches the uterine cavity, and about a day later, 
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begins to implant in the anterior wall of the uterus, known as the fundus. It is at this site that 
the embryo it will continue to grow and develop (Croxatto 2002). 
 
The preovulatory LH surge, which is responsible for the induction of ovulation, also results in 
the ruptured follicle undergoing a transformation to form a highly vascularised corpus luteum 
(CL). The CL is composed of luteal cells (formed from theca and granulosa) and non-
steroidogenic (endothelial, immune and fibroblast) cells. The major role of the CL in women 
is to secrete the steroid hormones (progesterone, androgens and oestradiol), which play a 
critical role in establishing endometrial receptivity for successful implantation and are 
essential for the maintenance of early pregnancy. If implantation takes place, the 
trophoblastic cells of the embryo secrete human chorionic gonadotrophin (hCG) that prevents 
the regression of the CL. Thereafter, the CL enlarges and remains capable of producing 
steroids throughout most of the pregnancy. On the other hand, if pregnancy does not occur, 
the CL undergoes a process of regression, known as luteolysis: this process results in the loss 
of both functional and structural integrity of the gland, shrinkage and eventually its 
disappearance. And as a consequence, a new menstrual cycle begins (Devoto et al. 2009). 
 
The hormonal regulation of the folliculogenesis 
 
Folliculogenesis during the menstrual cycle is regulated mainly by the endocrine system. In 
1977 Andrew Schally shared the Nobel Prize with Roger Guillemin for the “discoveries 
concerning the peptide hormone production of the brain" for describing the neurohormone 
GnRH (Hodgen 1991). At the beginning of a new follicular phase, there is an increase in the 
frequency of pulsatile secretion of gonadotrophin-releasing hormone (GnRH) from the 
hypothalamus. Thereafter, it binds to specific GnRH receptors on gonadotrophic cells in the 
anterior pituitary gland where it stimulates the synthesis, secretion and release of the 
gonadotrophins, FSH and LH. In turn, these two hormones stimulate the growth and 
maturation of antral follicle(s) to ovulation (Huirne et al. 2004). 
 
FSH is a complex heterodimeric glycoprotein produced in the anterior lobe of the pituitary 
gland. The role of FSH during the antral stages of follicular development is critical (Huirne et 
al. 2004). Only follicles that respond, and gain increased sensitivity, to FSH will enter the 
final stages of follicular development and ovulate (Ross et al. 1970; Brown 1978; Macklon 
and Fauser 1998). Each growing follicle possesses a threshold requirement for stimulation by 
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circulating FSH. This threshold needs to be passed to ensure ongoing follicular development. 
During a typical menstrual cycle, normally only one follicle will become responsive to FSH 
above this threshold (Brown 1978; McNatty et al. 1983). Other less developed antral follicles 
during this growth phase undergo atresia as the FSH levels start to fall due to rising oestradiol 
secretion from the most developed follicle (Huirne et al. 2004). 
 
LH is also a heterodimeric glycoprotein secreted from the anterior pituitary gland. LH is the 
most critical hormone with respect to the timing of ovulation and the production of steroid 
hormones. The LH-stimulated androgen synthesis by the thecal cells, and the acquisition of 
LH receptors on the GC results in the aromatization of androgen to oestradiol and increasing 
amounts of oestradiol being produced in and secreted from the dominant follicle, that in turn 
triggers the preovulatory GnRH and LH surge. As a result, the oocyte resumes meiotic 
maturation and the dominant follicle ruptures to release the oocyte into the fallopian tube 
(Huirne et al. 2004).  
 
1.4 Ovarian stimulation in human IVF 
 
The first attempts at in vitro fertilization (IVF) therapies in the 1970s involved ovarian 
stimulation using human menopausal gonadotrophin (hMG). However this approach did not 
lead to successful pregnancies, presumably due to abnormal luteal function. These 
stimulation protocols were discarded temporarily, and new approaches were commenced 
through natural cycles. (Fauser and Devroey 2003) which resulted in the first successful IVF 
baby (Steptoe and Edwards 1978). Following this, pregnancies were reported using anti-
oestrogen clomiphene citrate, hMG, urinary FSH and later recombinant FSH (rFSH) (Fauser 
and Devroey 2003). Over the years, the hormonal stimulation protocols have become more 
sophisticated, and by 1985, stimulated IVF cycles resulted in much higher success rates than 
for natural IVF cycles (Fishel et al. 1985). A recent review compared the success rates for 
natural IVF cycles with stimulated IVF cycles and reported that stimulated IVF cycles result 
in significantly higher pregnancy rates compared with natural IVF cycles in both young (<35 
years of age) and older (35-38 years of age) women: the pregnancy rate per treatment 
initiated for young women was 45.4% in stimulated compared with 15% in natural cycles and 
for older women, it was 34% compared with 4% (Pelinck et al. 2002).  
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Currently in IVF cycles, FSH is administered to stimulate the development of numerous 
preovulatory follicles to enhance the numbers of mature oocytes for recovery and thereby 
increase the likelihood of obtaining embryos suitable for intrauterine embryo transfer or 
cryopreservation (Huirne et al. 2004; Phillips et al. 2007). The application of high doses of 
exogenous gonadotrophins can result in prematurely raised oestrogen levels that in turn, can 
lead to a premature onset of the preovulatory LH surge. Therefore, a GnRH analogue is co-
administered to reversibly inhibit the endogenous secretion of gonadotrophins (Smulders et 
al. 2010). Thereafter, exogenous LH or hCG is used to initiate the timing of ovulation. This 
latter approach has become the standard protocol for the induction of the final stages of 
oocyte maturation before oocyte retrieval (Shoham et al. 1995; Huirne et al. 2004). Without 
the use of GnRH analogues, LH surges occur in ~20% of stimulated IVF cycles which 
usually leads to cancellation of treatment (Edwards et al. 1996; Janssens et al. 2000).  
 
There are two different kinds of GnRH analogues: agonists and antagonists. The difference 
lies in their mechanism of action. The GnRH agonists bind to the GnRH-receptors in the 
pituitary gland and initially stimulate an excessive release of gonadotrophins (“flare-up”). 
Subsequently, this leads to a decrease in the number of responsive GnRH receptors, which 
results in a reduced secretion of gonadotrophins. In the traditional protocol, a GnRH agonist 
is administered before commencing exogenous FSH and hCG treatments, thereby ensuring 
that the “flare-up” will be over before the gonadotrophin treatments. Conversely, a 
gonadotrophin antagonist may be used after exogenous gonadotrophin therapy because the 
antagonist binds in a competitive manner to block the receptor, thereby causing suppression 
of endogenous FSH and LH secretion (Tarlatzis et al. 1984). Not only do the GnRH 
analogues effectively prevent a premature LH-surge (Smulders et al. 2010), their 
combination with exogenous gonadotrophins improves the stimulation of large antral 
follicles, decreases treatment cancellation rates and overall, improves the efficacy of IVF 
treatment (Meldrum et al. 1989; Muasher 1992). 
 
There are three main protocols involving GnRH agonist administration, namely the short, 
ultra-short and long protocols. In the short and ultra-short protocols, GnRH is administrated 
on Day one or two of the cycle for either three successive days (ultra-short protocol) or until 
LH/hCG treatment (short protocol). In contrast, the long protocol involves the administration 
of a GnRH agonist for at least 14 to 18 days to achieve suppression of ovarian activity before 
commencing the administration of exogenous gonadotrophins. In the long protocol, the 
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administration of the hormone agonist is continued until LH/hCG treatment (Maheshwari et 
al. 2011). The long-term GnRH agonist protocol is the most commonly adopted protocol for 
assisted reproductive treatments worldwide (Huirne et al. 2007) due to better oocyte yield 
and pregnancy rate (Daya 2000; Huirne et al. 2007; Maheshwari et al. 2011). 
 
In contrast, GnRH antagonists inhibit gonadotrophin release rapidly thereby allowing for 
their use at any time during the follicular phase. The large majority of protocols start the 
GnRH antagonist at Day six of a treatment cycle. The antagonist is commonly given by daily 
subcutaneous administration up to, and including, the day of hCG administration in the ‘fixed 
time’ protocol or depending on the size of the dominant follicle (in most cases, ≥14mm) in 
the ‘flexible protocol’ (Huirne et al. 2007; Al-Inany et al. 2011). 
 
Often ovarian stimulation treatments include pre-treatment with oral contraceptives (OCP; 
consisting of oestrogen and progestogen) to facilitate the timing of egg collections, (Gonen et 
al. 1990), and to reduce the occurrence of large follicles before Day eight but increase the 
number of large follicles at the time of LH/HCG treatment. As a consequence, more oocytes 
are retrieved as compared with untreated women (Gonen et al. 1990; Huirne et al. 2006). The 
evidence also suggests that OCP pre-treatment decreases ovarian cyst formation and enables 
the duration of GnRH analogue treatment to be shortened without negatively affecting 
pregnancy rates (Biljan et al. 1998) or number of live births (Smulders et al. 2010). 
 
In a natural menstrual cycle, the maturation of the endometrium is synchronized to the stage 
of follicular development and this allows for the appropriate timing of implantation of the 
embryo. However, hormonal treatments that lead to the growth of multiple large follicles 
commonly result in a suboptimal uterine environment. This has been attributed to insufficient 
progesterone levels during the luteal phase (Smitz et al. 1988; Balasch et al. 1991). The most 
common methods used to correct the deficient luteal phase are the administration of 1) 
progesterone (vaginally, orally or intramuscularly) alone, or in combination with oestrogen 
(orally) or, 2) hCG (intramuscularly or subcutaneously), in order to stimulate luteal 
progesterone secretion (Devroey et al. 2004; van der Linden et al. 2011). A 2008 survey 
revealed that vaginal progesterone is the most commonly-used method in IVF clinics around 
the world (Aboulghar et al. 2008) and is also the standard procedure in the protocols used by 
Fertility Associates (NZ).  
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1.5 The oocyte’s central role in follicular development 
 
From recent studies, it is now evident that the oocyte does not play a passive role in the 
ovarian follicle, but is centrally involved in the regulation of folliculogenesis and thereby in 
its own development (Eppig 2001; Eppig et al. 2002). Mammalian oocytes grow and develop 
in an intimate and mutually-dependent relationship with adjacent follicular somatic cells (CC 
and mural GC). Thus, the differentiation of the CC is controlled by the oocyte itself and that 
this, in turn, affects oocyte development (Gilchrist et al. 2008). CC possess highly specialized 
trans-zonal cytoplasmic projections that penetrate through the zona pellucida to form gap 
junctions with the oocyte and results in a cumulus cell-oocyte complex (COC) (Albertini et 
al. 2001; Gilchrist et al. 2008). Oocyte-somatic cell communication is a bidirectional process 
involving gap-junctional and paracrine signalling (Eppig 2001). Specific oocyte-secreted 
factors (OSF) form the basis of this communication axis (Salustri et al. 1989; Buccione et al. 
1990b; Eppig et al. 1993; Vanderhyden and Tonary 1995; Gilchrist et al. 2008). The most 
important OSF identified so far are growth-differentiation factor 9 (GDF9) and bone 
morphogenetic protein 15 (BMP15) which are members of the transforming growth factor β 
(TGFβ) super-family. There is very little information for OSF outside the TGFβ super-
family: one study however has reported that a critical interaction exists between BMP15 and 
the oocyte-secreted fibroblast growth (FGF) factor 8B (Sugiura et al. 2007). These oocyte 
secreted factors function during at least two stages in the development of GC in mice: first, 
the differentiation of GC in preantral follicles to CC in antral follicles; and second, during the 
process of cumulus expansion initiated by the LH surge. In turn, appropriate development of 
CC promotes the development and function of the oocyte. If production of normal levels of 
BMP15 and GDF9 is curtailed, development and function of both the CC and the oocyte are 
impaired (Su et al. 2004).  
 
The role of oocyte secreted factors (OSF) 
 
The evidence suggests that oocytes control the rate of follicular development. Eppig et al. 
(2002) tested this hypothesis by separating mid-sized oocytes from secondary follicles and 
transferring them to primordial follicles. As a result of the oocyte transfer, the rate of 
follicular development was doubled and the differentiation of somatic cells was observed. 
Moreover, the oocytes recovered from these follicles were competent to undergo fertilization 
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and embryonic development. This demonstrated that the rate of follicular development is 
based on the developmental program intrinsic to the oocyte (Eppig et al. 2002). 
 
Studies in mice show that oocytes also influence follicular development by regulating kit 
ligand (KL) secretion. KL is produced by pre-antral GC and promotes oocyte growth through 
the Kit receptor located on the oocyte (Packer et al. 1994). In vivo, oocyte-regulated 
expression of KL mRNA is related to the stage of oocyte development. Growing oocytes 
stimulate, whereas fully grown oocytes suppress, GC expression of KL mRNA (Joyce et al. 
1999). Further evidence suggests that the level of KL mRNA expression is controlled by both 
paracrine and hormonal factors. Moreover, the overall expression and the relative abundance 
of KL isoforms are influenced by GDF9, BMP15 and FSH at various stages of follicular 
development (Thomas and Vanderhyden 2006). 
 
The oocyte actively directs the extent of differentiation of CC and mural GC phenotypes most 
likely via a concentration gradient of OSF (Hussein et al. 2005). During follicular growth the 
mural GC are inhibited from luteinisation and progesterone synthesis by the OSF however 
they maintain their steroidogenic activity of synthesizing oestradiol from precursor steroids 
under the influence of FSH (el-Fouly et al. 1970; Vanderhyden et al. 1993; Vanderhyden and 
Tonary 1995; Eppig et al. 1997b). In the absence of OSF, the default pathway of GC 
differentiation is toward a luteal (progesterone-secreting) phenotype (Eppig et al. 1997a; Li et 
al. 2000; Gilchrist et al. 2008). Elimination of oocyte paracrine signalling either by physical 
removal of the oocyte or by blocking the signalling pathway through which GDF9 and 
BMP15 act (i.e. SMADs) in CC, causes CC to lose their distinctive phenotype and to function 
more like mural GC. However, CC characteristics can be fully restored by treating these cells 
with OSF, demonstrating also, that the oocyte actively abrogates FSH-induced luteinisation 
of CC (Gilchrist et al. 2008). Further evidence suggests that in mouse follicles, OSF interact 
with oestradiol to promote the development and function of CC (Sugiura et al. 2010). COC 
cultured in vitro rapidly lose their ability to maintain oocyte meiotic arrest unless cultured in 
oestradiol-containing media, indicating the importance that oestradiol may have in 
maintaining a CC phenotype and oocyte meiotic arrest in Graafian follicles in mouse ovaries 
in vivo (Zhang et al. 2011). 
 
During the final stages of follicular development just before ovulation, the COC undergoes 
mucification and expansion (Figure 1E). This process is initiated by gonadotrophins or 
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epidermal growth factor (EGF)-like peptides and is regulated by OSF that enables the CC to 
synthesize extracellular matrix (ECM) molecules in response to the gonadotrophin/EGF 
signal (Dekel and Kraicer 1978; Eppig 1979; Salustri et al. 1989; Buccione et al. 1990b; 
Eppig et al. 1993). CC expansion is essential for ovulation and successful fertilization. The 
failure to synthesize components of the cumulus matrix results in suboptimal cumulus 
expansion leading to reduced fertility or sterility (Russell and Robker 2007; Kolle et al. 
2010).  
 
 
 
Figure 1E: High resolution image (200 x magnification) showing an expanded mouse COC. 
The oocyte in the middle is surrounded by multiple layers of CC. Image supplied by Dr Janet 
Pitman. 
 
OSF also actively prevents CC death. In antral follicles undergoing atresia, the COC is the 
last compartment of the ovarian follicle to undergo apoptosis (Yang and Rajamahendran 
2000), most likely by establishing a morphogenic gradient of OSF, particularly BMP15 and 
BMP6 (Hussein et al. 2005). Under in vitro experimental conditions, the prevalence of 
apoptosis in COC is the lowest in immediate proximity of the oocyte and highest in the most 
outer layers. FSH also prevents apoptosis in CC and GC, and its actions are additive to those 
of OSF. It was revealed that oocytes prevent apoptosis within CC by altering the ratio of 
BAX to BCL-2 in favour of cell survival (Hussein et al. 2005). 
 
Oocytes regulate metabolic cooperativity with CC and GC (Sugiura et al, 2005). In the mouse 
at least, glycolysis in oocytes is lacking and is dependent on the provisions of glycolysis 
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products such as pyruvate from the CC as an energy source for growth and resumption of 
meiosis (Biggers et al. 1967; Donahue and Stern 1968). In turn, oocytes regulate the extent of 
glycolysis and the tricarboxylic acid (TCA) cycle in GC/CC relative to the stage of growth 
and development of the oocyte. Therefore, this indicates a metabolic cooperativity between 
oocytes and CC/GC whereby oocytes require energy substrates from the CC/GC and in turn, 
the OSF regulate somatic cell function and in turn, follicular development (Sugiura et al. 
2005) in a developmentally-coordinated manner.  
 
Paracrine factors from fully grown oocytes also stimulate the acquisition of amino acids from 
CC (Eppig et al. 2005). Certain amino acids (e.g. L-alanine) required for protein synthesis are 
supplied to the oocyte from the CC via gap junctions (Buccione et al. 1990a). In the mouse, 
the expression of amino acid transporters, such as solute carrier family 38 (Slc38a3) mRNA 
in CC is regulated by the oocytes according to the stage of oocyte development. Slc38a3 is a 
sodium-coupled neutral amino acid transporter and transporters from this family exhibit a 
preference for L-glutamate, L-histidine and L-alanine. 
 
Recent studies of genetic mutations in sheep also highlight the importance of OSF in 
regulating ovarian follicular development and ovulation rate. Alterations to the 
concentrations of GDF9 and BMP15 protein in vivo leads to significant changes in ovulation 
rate in sheep (Galloway et al. 2000; McNatty et al. 2003). These findings, together with 
immunization results with BMP15 and GDF9 peptides, demonstrate that by altering the 
bioavailability of GDF9 and BMP15 in vivo, it is possible by exogenous means to enhance 
ovulation rate in sheep, cattle and mice (Juengel et al. 2002; Juengel et al. 2009; McIntosh et 
al. 2012) and increase lamb production or alternatively induce infertility in sheep (McNatty et 
al. 2004).  
 
The importance of OSF on oocyte quality was tested under in vitro maturation (IVM) 
conditions. When bovine COC were co-cultured with denuded oocytes or were cultured in 
media pre-conditioned with OSF, a ~20% increase (~60% compared to ~40%) in blastocyst 
formation rate was observed. Moreover, the addition of OSF to the culture media also 
improved subsequent embryo quality as evidenced by total cell and trophectoderm cell 
numbers (Hussein et al. 2006). Similarly in mice, oocytes from COC treated with OSF 
(GDF9) during IVM, resulted in blastocysts with significantly increased total cell and inner 
cell mass (ICM) cell numbers. Although blastocyst formation rates were similar, the 
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percentage of hatching blastocyst per cleaved embryo was significantly increased in culture 
media supplemented with exogenous GDF9. Whilst the addition of GDF9 to COC cultured in 
vitro had no effect on implantation rate, the embryos derived from the GDF9-treated group 
had almost doubled the rate of foetal survival compared to controls (Yeo et al. 2008). 
Therefore, under in vivo conditions, the reduction of biologically active GDF9 or BMP15 
both increases ovulation rate, oocyte yield and lambs born whereas under in vitro conditions, 
supplementary OSF increased the numbers of blastocysts recovered following IVM of 
oocytes. This represents a paradox that remains to be resolved.  
 
1.6 The outcome of human oocytes following oocyte collection: IVF, pre-
implantation genetic diagnosis and fertility preservation 
 
The main reasons why women undergo ovarian-stimulation and oocyte collection are: 1) they 
are unable to conceive naturally; 2) are at a high risk of transmitting genetic defects to their 
offspring and; 3) to preserve their fertility. In the first two scenarios, the most common 
treatment is to recover COC via a transvaginal retrieval method followed by IVF on the same 
day, whilst in the third case, oocytes are cryopreserved after COC retrieval and IVF usually 
takes place months or years later.  
 
IVF treatment and associated therapies for increasing healthy offspring outcomes 
 
Based on the most commonly used definition of infertility (lack of pregnancy after one year 
of unprotected regular intercourse), 10-15% of reproductive age couples are diagnosed with 
infertility (Forti and Krausz 1998). For these couples, IVF offers the best chance of having a 
healthy offspring (Reindollar et al. 2010). Over the last decade the annual increase in ART 
services has been estimated to be 5-10% in developed countries (Chambers et al. 2009). The 
increasing demand for assisted reproduction in Western countries can be attributed to various 
factors such as the tendency of delaying childbearing, an increase in the effectiveness of 
ART, an increased awareness for these treatments and in some cases demographic strategies 
aimed at reducing declining fertility rates (Forti and Krausz 1998; Ziebe and Devroey 2008). 
Legislation, public funding and treatment costs vary significantly amongst countries (Collins 
2002; Chambers et al. 2009). The utilization of ART services depends highly on availability, 
cost and consumer price, as IVF and intra-cytoplasmic sperm injection (ICSI) treatments are 
expensive technologies that employ highly skilled professionals from multiple fields of 
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practice and involve sophisticated laboratory facilities (Collins 2002; Chambers et al. 2009). 
It was reported that even in developed countries, treatment utilization rates are strongly 
correlated to low treatment costs or generous public funding (Chambers et al. 2009).  
 
The average chance of conception for normally fertile couple having regular, unprotected 
intercourse is approximately 25% during each menstrual cycle. In most couples, conception 
occurs within a year of unprotected intercourse. If pregnancy has not been achieved within 
this period, an underlying pathological condition is sometimes at cause (De Sutter 2006). The 
causes of infertility can be divided if four major categories: 1) the female factor (i.e. 
ovulatory disorders, tubal disease and endometriosis) affecting approximately 35% of cases ; 
2) male factor (i.e. low sperm concentrations, poor sperm motility and/or morphology) 
present in 30% of couples; 3) combined factors present in 20 % of couples; and; 4) 
unexplained infertility in about 15 % of the cases (Forti and Krausz 1998). In these instances, 
couples have little hope of having children by natural conception and they form the base of 
people seeking help in the form of assisted reproduction.  
 
Another reason why couples seek IVF treatment is to assess the genetic condition of their 
embryos and to select only unaffected embryos for replacement (Basille et al. 2009). The 
majority of couples undergoing preimplantation genetic diagnosis (PGD) treatment are 
usually those with a high probability of conceiving a child with an incurable disease. Most of 
the time, these couples have a traumatic obstetrical history: birth of a child with genetic 
disease or previous termination of pregnancy after chorionic villus sampling or 
amniocentesis. Secondly, they are couples with genetic disease, either known from family 
history or discovered during infertility investigations (Basille et al. 2009).  
 
Fertility preservation 
 
The most common reasons why women seek fertility preservation are due to the need for 
cancer therapy and for social reasons (Paynter 2000; Goold and Savulescu 2009). Currently, 
oocyte cryopreservation is the best option available for women to preserve their fertility. This 
method facilitates the long-term storage of gametes and allows greater flexibility in fertility 
services (Paynter 2000). Cryopreservation below -130 ºC allows virtually indefinite storage 
of cells and tissues (liquid nitrogen at a temperature of -196ºC is the usual holding medium) 
(Paynter 2000). By 2009, cryopreservation allowed for around 4,300 oocytes to be collected 
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from which more than 80 children thus far have been born (Maltaris et al. 2009). Several 
recent studies confirmed that oocytes frozen by current cryopreservation methodologies have 
similar success rates to those from fresh IVF cycles or frozen embryos replacements (Noyes 
et al. 2010). Moreover, it was reported that the mean birth weight and the incidence of 
congenital anomalies from children born from vitrified oocytes are similar to those of 
spontaneous conceptions in fertile women or infertile women undergoing IVF treatment 
(Chian et al. 2008). 
 
1.7 Oocyte quality  
 
Development of the human embryo begins with the fusion of spermatozoon and oocyte, the 
epigenetic reprogramming of the pronuclei of the gamete and a series of cleavage divisions 
that culminate with the activation of the embryonic genome (Wong et al. 2010). The oocyte 
occupies a central role in the development of the embryo. This role is acquired progressively 
during oogenesis, through a range of cellular and molecular attributes that provide the oocyte 
with the ability to complete meiosis, ensure normal fertilization, undergo preimplantation 
development and accomplish successful implantation as a consequence of the action of stored 
maternal mRNAs and proteins (Coticchio et al. 2004). The finding that blastocyst 
development can be predicted before embryonic genome activation suggests the critical role 
that oocytes and maternal transcripts have in the successful outcome of an embryo (Wong et 
al. 2010). Utilization of the most competent oocytes during IVF is crucial to ensure the 
derivation of high-quality embryos and successful pregnancy. This is especially the case for 
human IVF given the very low (<7%) oocyte to live baby rate (Li et al. 2008; Patrizio and 
Sakkas 2009). 
 
Factors associated with oocyte quality 
 
Antral follicle count 
The antral follicle count refers to the number of antral follicles in the ovary that measure 2–5 
mm in diameter at the beginning of the menstrual cycle (day one-two) as determined from an 
ultrasound scan. There is a highly significant correlation between the antral follicle count and 
the ovarian response to exogenous gonadotrophin stimulation with respect to the number of 
oocytes retrieved and the utilization rate of embryos in the same cycle (Chang et al. 1998). 
Conversely, a decreasing antral follicle count correlates with decreasing pregnancy rate. 
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Patients who have a low antral follicle count require more gonadotrophins for ovarian 
stimulation, which increases costs. Moreover, IVF treatments in these women result in higher 
treatment cancellation rates and lower pregnancy outcomes (Chang et al. 1998; De Sutter and 
Dhont 2003; Saldeen et al. 2007).  
 
BMI 
Offering patients elective, publicly funded procedures in New Zealand is done according to 
clinical priority access criteria (CPAC) which was introduced in the mid-1990s for several 
procedures (Hadorn and Holmes 1997). In 2000, a new section covering assisted reproduction 
was added to the CPAC with the objective of providing a mechanism for rationing limited 
public funds. The seven criteria developed for CPAC included some of the most common 
factors known to influence oocyte quality and pregnancy outcome, such as women’s age (<40 
years), BMI (≤32 kg/m2) and basal serum FSH level (<15 IU/mL) (Elective Services 2011). 
A 2008/2009 survey by the New Zealand Ministry of Health based on the 2007 World Health 
Organization (WHO) criteria concluded that in females of 15 years and older, 1.5% were 
underweight, 37.9% were normal weight, 32.8% were overweight and 27.8% were obese. 
Moreover, the prevalence of obesity in 19-30 year old and 31-50 year old women is 25.1% 
and 27.9%, respectively (University of Otago and Ministry of Health 2011). Studies that 
investigated the effect on increased BMI on delivery rate revealed that women with a BMI of 
>32 kg/m
2
 had a 38% birth rate, whilst those with a BMI of <32 kg/m
2
 had a 52 % birth rate 
following a treatment-related pregnancy or spontaneous pregnancy (Gillett et al. 2006). 
Further, clinical trials revealed that treatment cancellation, poor response and gonadotrophin 
use per cycle rose with increasing BMI. More importantly, the pregnancy rate amongst obese 
women was lower compared with normal weight women following IVF treatment (Orvieto et 
al. 2009; Pinborg et al. 2011).  
 
Age 
Previous studies showed that with increasing patient age, there is a highly correlated decrease 
in antral follicle count (Chang et al. 1998). Moreover, genetic studies confirmed that genomic 
abnormality rates in oocytes increase with age: embryos from women 37 years and older have 
a higher incidence of chromosomal abnormalities (Gianaroli et al. 1999; Wells and Delhanty 
2000). Human IVF studies have confirmed that the pregnancy rate following IVF is 
significantly lower in women ≥ 40 years of age, decreases sharply in women > 42 and is 
essentially absent in women > 45 years of age (Lass et al. 1998). Other studies investigating 
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the links between oocyte development and live births reveal that while women ≤ 37 years of 
age have an oocyte to baby rate of 4.3-4.5% following IVF, their 41-42 year old counterparts 
have significantly less at 1% (Patrizio and Sakkas 2009). The low reproductive potential of 
aging oocytes was further confirmed by the high embryo wastage rate, where 95% of the 
embryos transferred in women over 40 years of age failed to result in a live birth (Bromer et 
al. 2009).  
 
Basal serum FSH levels 
The rise of basal serum FSH levels begins on average a decade or more before menopause 
begins. A significant progressive increase in FSH levels as early as age 29-30 years can be 
detected in women with regular ovulatory cycles. This increase continues throughout the 30s 
and becomes more marked in the early 40s (Ahmed Ebbiary et al. 1994). Increased basal 
serum FSH levels are regarded as a basic endocrine marker of reproductive ageing. There is a 
high correlation of antral follicle count and serum FSH levels at Day 3 of the menstrual cycle 
due to antral follicles being the main source of inhibin-B secretion and its subsequent 
negative feedback effects on the pituitary gland. As a consequence, a decrease in the number 
of antral follicles leads to increases in the serum FSH levels (Cahill et al. 1994; Groome et al. 
1996).  
 
Serum Anti-Müllerian hormone (AMH) levels 
Anti-Müllerian hormone (AMH) is a member of the TGF-beta super-family. It is synthesized 
by GC in women, and by Sertoli cells in the testes of men (Vigier et al. 1984; Josso 1990). 
During foetal development, its principal function is to induce regression of the Müllerian 
ducts during male sex differentiation; however in women it appears to play an important role 
in folliculogenesis (Durlinger et al. 2002). During follicular development, expression of 
AMH is low in primary follicles and high in secondary, and small antral follicles (≤4 mm in 
diameter) but levels gradually decline again in larger antral follicles (4-8 mm) (Weenen et al. 
2004). During in vitro culture of human ovarian tissue, the presence of AMH in the media is 
significantly correlated with the proportion of follicles that have initiated growth (i.e. primary 
and secondary follicles). This finding suggests that AMH is a functional marker for early 
growing follicles (Schmidt et al. 2005). Moreover, since AMH is produced only by growing 
ovarian follicles, and the number of growing follicles is proportional to the size of the 
primordial pool, it was proposed that AMH could be used as a measure of the size of the 
ovarian reserve (van Rooij et al. 2002). Indeed, following IVF treatment it was observed that 
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there is a highly significant correlation between serum AMH levels and ovarian reserve. Low 
baseline serum AMH concentrations were associated with a low number of oocytes retrieved 
following IVF treatment that was consistent with, and indicative of, a diminished ovarian 
reserve. Indeed the AMH test was found to have a predictive performance comparable with 
that of an antral follicle count. The testing of serum AMH levels during human IVF 
procedures as a predictor of ongoing pregnancy however appears to be somewhat limited 
since AMH levels do not assess oocyte quality (van Rooij et al. 2002).  
 
PCOS 
Polycystic ovarian syndrome is the most common endocrine disorder, affecting 
approximately 5-7% of women of reproductive age (Knochenhauer et al. 1998; Asuncion et 
al. 2000). In 2003, the Rotterdam consensus established the most recent diagnostic criteria. 
According to this consensus, women are diagnosed with PCOS, if they are affected by at least 
two of the following three features: 1) oligo/anovulation; 2) hyperandrogenism characterized 
clinically by hirsutism, acne, and androgen-dependent alopecia and elevated serum 
concentrations of androgens, particularly testosterone and androstenedione (Goldzieher and 
Green 1962) and; 3) polycystic ovaries (Rotterdam ESHRE/ASRM consensus 2004). PCOS 
is typically associated with hyper-secretion of LH and androgens but normal or low serum 
concentrations of FSH (Yen et al. 1970; Holte et al. 1994). Moreover, insulin resistance and 
hyperinsulinaemia are conditions frequently associated with PCOS (Legro et al. 1999). 
Previous studies suggested that women with PCOS may be subfertile and oocyte 
developmental potential could be compromised. Indeed, insulin-mediated glucose 
metabolism is abnormal and lactate production is impaired in granulosa-lutein cells following 
IVF of oocytes from women with PCOS (Barbieri et al. 1988). Moreover the enhanced 
response to LH-stimulated progesterone production adds further evidence to the hypothesis 
that raised insulin, LH and androgen concentrations in women with PCOS are all involved in 
premature differentiation and luteinisation of GC and possibly the arrest of follicle growth 
(Willis et al. 1998; Rice et al. 2005). Indeed, morphologically indistinguishable MII oocytes 
from PCOS and healthy women have been reported to exhibit different gene expression 
profiles, including genes involved in the meiotic or mitotic cell cycle and maternally linked 
genes (i.e. NLR family, pyrin domain containing 5 (NALRP5) gene, required for early 
embryogenesis) (Wood et al. 2007).  
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The majority of clinical studies investigating pregnancy rates in women with PCOS report 
similar results compared to healthy women following multiple-embryo replacements (Esinler 
et al. 2005; Sahu et al. 2008; Swanton et al. 2010; Mellembakken et al. 2011). However in 
IVF treatments where more than 20 oocytes were collected, the clinical and ongoing 
pregnancy rates were significantly reduced in women with PCOS (Weghofer et al. 2007). In 
addition, the clinical abortion rate/ pregnancy loss in these women were significantly higher 
compared with reproductively-normal women, indicating that oocyte or/and uterine quality 
may be impaired (Sagle et al. 1988; Carmina and Lobo 1999; Ludwig et al. 1999). 
 
1.8 Selection of healthy oocytes 
 
Non-invasive selection of developmentally competent human oocytes would represent a very 
significant technological advance. A reliable selection method could enhance the efficiency 
of human assisted reproduction and would be particularly relevant in countries where legal, 
social or religious factors restrict the number of oocytes that can be inseminated or embryos 
selected (Rienzi et al. 2011). Furthermore, the use of reliable oocyte quality markers would 
allow better planning of assisted reproductive treatments for women where cryopreservation 
of embryos is not a possible option (i.e. women undergoing cancer therapy or single women) 
and the collection and cryopreservation of mature oocytes gives the best chance for 
establishing a family in the future (Paynter 2000; Goold and Savulescu 2009). The selection 
and the cryopreservation of eggs would also alleviate many of the ethical concerns associated 
with embryo preservation (Goold and Savulescu 2009).  
 
There is very limited information about the financial cost of an IVF cycle. Most of the data 
published on financial implications of IVF are patient related (Bouwmans et al. 2008), 
however it is equally important for cost-effectiveness from the perspective of the provider. A 
reliable selection for good quality oocytes for insemination has the potential of maximizing 
time and financial spending of clinics for one cycle. It is not unreasonable to think, that in the 
future with the selection of oocytes, follicle aspirations, inseminations and oocyte transfers 
could be programmed for the same day, thus organizations no longer requiring facilities and 
culture related expenses (i.e. media) for embryo culture. Furthermore, it would allow for the 
maximizing of patient numbers in accessing treatments and minimizing staff involved in care 
and administration of treatment. A further benefit of early oocyte or embryo selection would 
be to minimize the potential harmful effects (epigenetic reprogramming) of extended in vitro 
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culture on the long-term health and physiology of the child born (Le Bouc et al. 2010; Calle 
et al. 2012). 
 
Oocyte selection according to morphological characteristics 
 
Morphological assessment of embryos at the preimplantation stage is a key element of the 
laboratory work in human assisted reproduction. Routine evaluations that follow 
internationally-acknowledged criteria are performed at predetermined checkpoints by 
microscopy. The current view of most human embryologists is that all MII oocytes that meet 
the basic criteria (about 85% of oocytes collected) should be subjected to fertilization 
procedures. The morphological evaluation of oocytes by light microscopy is rather more 
inexact compared with that for embryos. Nevertheless, even embryo selection based on 
morphological and developmental characteristics is a superficial method, as seemingly 
morphologically ‘normal’, but intrinsically handicapped, embryos are routinely cultured and 
transferred resulting in compromised in vitro development, low pregnancy rates, abortions 
and further negative consequences (Rienzi et al. 2011).  
 
The application of exogenous ovarian treatments in human reproduction further complicates 
the situation. In contrast to the in vivo process, where oocyte maturation occurs as the result 
of a long and meticulous natural selection procedure, common ovarian stimulation procedures 
override this process allowing for the seemingly successful maturation of oocytes but with 
inherently compromised quality. These are often destined for fertilization failure, 
compromised embryo development or long-term consequences in vivo (Rienzi et al. 2011).  
 
Amongst human embryologists, it is widely accepted that routine morphological 
investigations are simply unable to predict developmental competence and fertilization 
potential of the oocyte. Correlations between the morphological characteristics of the COC, 
structure of the zona pellucida, size of perivitelline space, morphology of the first polar body, 
shape of the oocyte and appearance of the ooplasm with that of oocyte developmental 
competence revealed inconclusive and often contradicting results (Rienzi et al. 2011). The 
most promising morphological assessment appeared to be visualization of the meiotic spindle 
by polarized light microscopy (Petersen et al. 2009). However, this technique offers limited 
selection potential as meiotic spindles can be imaged in about 90% of MII oocytes collected 
(Rienzi et al. 2003) increasing the efficiency of selection by only 10%. Also, this technique 
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requires strict implementation of protocols due to parameters such as time of analysis, oocyte 
rotation, temperature and other environmental conditions (e.g. pH) compromising spindle 
visualization (Petersen et al. 2009). 
 
Oocyte selection according to COC morphology 
 
It was proposed that morphological grading of the degree of expansion of the CC mass could 
be related to developmental potential of associated oocytes. However, studies that 
investigated the degree of expansion in relation to oocyte maturity, fertilization, embryo 
cleavage and pregnancy outcome concluded that there was no or little association between 
the degree of expansion of the CC mass and maturity of the oocyte. Although, it appeared 
that women who had a higher proportion of expanded COC had a better pregnancy outcome, 
COC grading performed poorly and was deemed unsuitable as a marker for the selection of 
single good quality oocyte with high chance in pregnancy (Ng et al. 1999; Rattanachaiyanont 
et al. 1999).  
 
Similarly, authors who investigated the incidence of apoptosis in CC in relation to oocyte 
quality, showed that the proportion of apoptosis in CC is relatively similar across samples, 
and is not correlated to blastocyst development and/or pregnancy/live birth outcome (Lee et 
al. 2001; Host et al. 2002; Moffatt et al. 2002; Corn et al. 2005). It can be concluded that 
morphological evaluation of CC apoptosis provides limited prognosis on oocyte quality and 
is an unreliable marker in human IVF. 
 
Oocyte selection according to cumulus cell gene expression 
 
The need to develop objective and reliable non-invasive predictors of oocyte developmental 
competence has led researchers to investigate CC as potential biomarkers of oocyte quality. 
As discussed previously, the developmental competence of an oocyte is closely associated 
with follicular somatic cell development, in which the oocyte plays an active role in 
regulating the surrounding CC. In return, CC provide essential support for the development 
and maturation of oocytes. The identification of key molecules and signalling pathways 
within the COC regulatory loop could provide new insights into the mechanism underlying 
oocyte development and novel molecular predicators for the selection of high quality oocytes 
(Li et al. 2008).  
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In the late 1980s and early 1990s, new polymerase chain reaction (PCR) technologies 
emerged, that allowed the relative and absolute quantification of nucleic acids (Wang et al. 
1989; Noonan et al. 1990). Early publications demonstrated that the quantitative capability of 
PCR was similar to classical methods such as Northern blot or slot blot analyses (Murphy et 
al. 1990; Noonan et al. 1990). Moreover, quantitative PCR (QPCR) has been shown to 
correlate with in-situ hybridization results, where equivalent proportionality in the relative 
amounts of RNA was obtained by both methods (Park and Mayo 1991). Indeed, if 
optimization and validation of the method is done properly, QPCR is a very powerful 
quantitative tool (Ferre 1992).  
 
In 2004, McKenzie et al. proposed for the first time, that gene expression levels in human CC 
measured by QPCR could potentially act as quality markers for the associated oocytes. For 
the first time, individual human CC samples were subjected to mRNA extraction using 
sensitive commercial RNA isolation kits with the intention to quantify selected target genes 
using QPCR methods (McKenzie et al. 2004). Further investigations by QPCR and 
microarray technologies have revealed that gene expression in CC, and specifically 
transcripts related to the down-stream effects of OSF, in particular GDF9 and BMP15 
mRNA, are correlated with oocyte development (Hasegawa et al. 2005; Zhang et al. 2005; 
Cillo et al. 2007; Feuerstein et al. 2007; Assou et al. 2008; Hamel et al. 2008; van Montfoort 
et al. 2008; Anderson et al. 2009; Adriaenssens et al. 2010; Assidi et al. 2011; Gebhardt et al. 
2011; Wathlet et al. 2011).  
 
The first genes that have been investigated were not surprisingly, genes responsible for the 
synthesis of the COC extracellular matrix proteins, hyaluronan synthase 2 (HAS2), pentraxin 
3 (PTX3), tumour necrosis factor α–induced protein 6 (TNFAIP6) and genes involved in 
cumulus cell signalling such as gremlin 1 (GREM1) and prostaglandin-endoperoxide synthase 
2 (PTGS2) (McKenzie et al. 2004). Other CC genes in subsequent studies showed some 
correlation to positive outcomes are those involved in steroidogenesis (3-beta-hydroxysteroid 
dehydrogenase 1 (3βHSD1) and ferrodoxin 1 (FDX1) involved in progesterone synthesis, 
cytochrome P450 aromatase (CYP19A1) responsible of metabolizing androgen into 
oestradiol-17β) (Hamel et al. 2008), in neuronal traffic through the cytoskeleton (neuropilin 1 
(NRP1)) and cell cycle and signalling (ubiquilin 1 (UBQLN1) and cyclin D2 (CCND2)) (van 
Montfoort et al. 2008; Assidi et al. 2011). 
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Currently, many more genes have been investigated, such as those involved in the secretion 
of the extracellular matrix (versican) of the COC, cumulus cell signalling (for example, 
amphiregulin, connexin 43, aryl hydrocarbon receptor, steroid sulfatase, steroidogenic acute 
regulatory protein, syndecan 4 and calmodulin 2) and metabolic pathways (for example, 
stearoyl-CoA desaturase 1 and 5, aldolase A, lactate dehydrogenase A, phosphofructokinase 
and pyruvate kinase) (Feuerstein et al. 2007; Adriaenssens et al. 2010; Gebhardt et al. 2011; 
Wathlet et al. 2011). 
 
Although the above mentioned studies similarly suggested that possible links between CC 
gene expression and embryological outcome exist, the results are variable and more in-depth 
studies were required (Zhang et al. 2005; Cillo et al. 2007; Feuerstein et al. 2007; Assou et 
al. 2008; Anderson et al. 2009). A possible reason for these variable results could be due to 
biological and treatment variables. The first study to question the relationship between 
biological variables and CC gene expression (PR gene) was in 2005, when the effect of 
follicular characteristics such as size and steroid concentrations in follicular fluid were 
investigated (Hasegawa et al. 2005). Although no significant associations were found, later 
studies revealed that other biological variables such as age may alter gene expression in both 
oocytes (Grondahl et al. 2010) and CC (Adriaenssens et al. 2010). It was further suggested 
that BMI, serum FSH concentrations, the gonadotrophin preparation used for ovarian 
stimulation and serum oestradiol concentrations at the time of the ovulation trigger, also alter 
the expression levels of certain genes in CC (Adriaenssens et al. 2010). Indeed, recent studies 
have confirmed that increased basal serum FSH levels do indeed affect the levels of gene 
expression in COC and that it might be one of the possible causes behind the reduced fertility 
potential in young women with diminished ovarian reserve (Greenseid et al. 2011; Jindal et 
al. 2012). 
 
Most importantly however, none of these studies have identified a reliable assessment system 
or molecular marker capable of efficiently selecting from a total pool of MII oocytes, those 
that will go on to form successful pregnancies. Whilst the above mentioned studies carried 
out their investigations using SYBR Green or TaqMan singleplex QPCR, recent 
investigations revealed that single oocytes and individual CC masses provide sufficient 
mRNA for quantification by multiplex QPCR (Crawford and McNatty 2012; Crawford & 
McNatty; unpublished results). The multiplex QPCR method has the advantage of 
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simultaneously measuring multiple genes in a single reaction, saving time and maximizing 
the use of minimal amounts of template available. However this method has yet to be tested 
in human CC studies.  
 
1.9 Aims of study 
 
The objectives of this research programme were to: 
 
1. Test the feasibility of multiplex QPCR technology to measure the expression of 
numerous candidate genes in individual CC masses during collection of COC for IVF. 
This includes the validation of an appropriate housekeeping gene for human follicular 
tissues. In this context, the housekeeping properties of two widely used reference genes 
were investigated: ribosomal RNA 18S and 60S ribosomal protein L19 (RPL19).  
2. Investigate COC morphology and CC numbers in relation to embryo development and 
pregnancy outcome in women undergoing IVF treatment with ICSI. 
3. Assess the expression levels of candidate genes in CC in relation to embryo 
development and pregnancy outcome in women undergoing IVF treatment with ICSI.  
 
To fulfil the aims of Objective 3, eight CC-derived candidate genes were selected as potential 
oocyte quality markers on the basis that: several had previously shown promise in human CC 
studies (McKenzie et al. 2004; Cillo et al. 2007; Assidi et al. 2011; Gebhardt et al. 2011; 
Wathlet et al. 2011) or; were genes that might be influenced by the oocyte during the final 
steps of folliculogenesis and ovulation (Otsuka et al. 2005; Hernandez-Gonzalez et al. 2006; 
Robker et al. 2009). The eight candidate genes selected for this study were:  
 
hyaluronan synthase 2 (HAS2) which is known to be critical for the formation and 
expansion of the CC mass and previously shown to be correlated with early 
embryological development (McKenzie et al. 2004; Cillo et al. 2007) and to have a 
positive correlation with age (Adriaenssens et al. 2010);  
 
follicle stimulating hormone receptor (FSHR) in which expression levels have been 
shown to be regulated by OSF which in turn are thought to mediate the actions of 
FSH on follicular cells (Otsuka et al. 2005); 
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solute carrier 2, member 4 (SLC2A4, also known as GLUT4) which is associated with 
energy metabolism in COC and is previously reported to be one of the glucose 
transporters in CC (Roberts et al. 2004);  
 
versican (VCAN) is a major component of the COC extracellular matrix, previously 
reported as one of the most promising oocyte quality markers in CC (Adriaenssens 
et al. 2010; Gebhardt et al. 2011; Wathlet et al. 2011); 
 
activated leukocyte cell adhesion molecule (ALCAM) mediates homophilic (ALCAM - 
ALCAM) and heterophilic (ALCAM-CD6) cell to cell interaction, is known to be 
involved in the initial step of human embryo implantation (Fujiwara et al. 2003), 
expressed in CC and is a potential oocyte quality marker (Adriaenssens et al. 2010; 
Wathlet et al. 2011);  
 
secreted frizzled-related protein 2 (SFRP2) is a soluble modulator of Wnt signalling, 
and has been reported to be expressed in mice CC at peak levels in ovulated COC 
(Hernandez-Gonzalez et al. 2006);  
 
progesterone receptor (PR) is expressed in the dominant follicle and the active corpus 
luteum of women and is essential for a successful implantation although little is 
known about the role of this gene during the peri-conception period (Robker et al. 
2009) and;  
 
neuropilin 1 (NRP1) is a membrane-bound co-receptor to tyrosine kinase receptor for 
vascular endothelial growth factor and members of the semaphorin family proteins. 
Neuropilin 1 is involved in the angiogenic and neuronal traffic through the 
cytoskeleton, in cell assembly and interaction and more importantly in vesicle 
guidance and transport in follicles following oestradiol induction. Moreover, in a 
preliminary study it was reported that up-regulation of NRP1 expression in CC may 
potentially indicate an oocyte with a positive pregnancy outcome (Assidi et al. 
2011). 
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Chapter 2 METHODOLOGY 
 
2.1 Ethical approval 
 
In New Zealand, health and disability research involving humans requires ethical approval. 
The review of health and disability research is carried out by seven Health and Disability 
Ethics Committees. The Multi-region Ethics Committee considers applications for research 
that is to be carried out in more than one of the four Ethics Committee regions 
(http://www.ethicscommittees.health.govt.nz/).  
 
Fertility Associates clinics operate in four different locations: Wellington, Christchurch, 
Auckland and Hamilton. For the studies reported herein, ethical approval was requested for 
Fertility Associates Wellington clinic, and granted by the Multi-region Ethics Committee on 
17 November 2008 until November 2013 (Permit number MEC/08/10/121). All persons 
(women and partners) that were participated in this study provided informed consent 
(Appendix 1). 
. 
2.2 Subjects 
 
The subjects of this study were women undergoing IVF treatment. Patient enrolment was 
undertaken by clinicians at Fertility Associates under the management of Prof. John Hutton. 
For this study, four different groups were established. The groups were identified according 
to the likely causes of infertility.  
  
All Groups (except Group 4) were to be aged ≤37 years; 
All Groups (except Group 2) were to have a BMI of <28, and no evidence of androgenicity  
 
Group 1: Young and healthy women 
 
Period Cycle   Regular 26-32 days 
Reason for Infertility  Male Factor or Tubal Disease  
Day 2 FSH (Basal E2) < 9 iu/l 
FSH stimulation  stimulation protocol: ‘5.85’ (see below) 
daily dose of FSH: 150IU  
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IVF treatment (cycle) number: 1 or 2 (women who qualified for the above criteria, but 
had two or more previous IVF treatments were not enrolled). 
 
Group 2: Young women with PolyCystic Ovarian Syndrome (PCOS) 
The diagnosis of PCOS was based on the 2003 Rotterdam ESHRE/ASRM consensus (2004). 
Patients were enrolled in this group if they were diagnosed by the presence of at least two of 
the following conditions: oligo/anovulation, hyperandogenism and polycystic ovaries. 
 
Period Cycle   Irregular/unpredictable  
Medical Disease   None indicated 
Reason for Infertility  PCOS (but can also include male factor/icsi) 
Day 2 FSH (Basal E2) <9 iu/l 
FSH stimulation  Stimulation protocol: ‘5.85’ (see below);  
Daily dose of FSH: 150IU, or preferably less  
IVF treatment number:  1 or 2 (women who qualified for the above criteria, but had two 
or more previous IVF treatments were not enrolled). 
 
Group 3: Young women with diminished ovarian reserve 
Reason for Infertility Low antral follicle count (but can also include male 
factor/ICSI) 
Day 2 FSH (Basal E2) >9 iu/l 
Antral Follicle Count  < or = 4 each ovary 
FSH stimulation  Stimulation protocol: ‘5.9’ or ‘5.85’ (see below)   
     Daily dose of FSH: 225IU or 300IU 
IVF treatment number:  1 or 2 (women who qualified for the above criteria, but had two 
or more previous IVF treatments were not enrolled). 
 
Group 4: Older and healthy women 
Age      40 years 
Period Cycle   Recorded – not restricted 
Reason for Infertility  Not endometriosis or PCOS 
Day 2 FSH (Basal E2) Recorded – not restricted  
Antral Follicle Count  Recorded – not restricted but not PCOS 
FSH stimulation  Stimulation protocol: ‘5.9’ or ‘5.85’ (see below)  
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Daily dose of FSH: 225IU or 300IU 
IVF treatment number:  Not restricted  
 
The following background information was recorded from women undergoing treatment:  
Blood and scan results: FSH (IU/L), AMH (ng/mL), LH (basal) (IU/L), testosterone (for 
PCOS patients), oestradiol (pmol/L) levels during stimulation. 
Physical condition: height, weight, BMI (kg/ m
2
). 
Other drug treatments: diabetes, asthma, blood pressure, other. 
Lifestyle factors: smoker/ non-smoker. 
Ethnicity: Maori, Pacifica, Caucasian, Asian, Indian, other. 
Family History: genetic background, occupation. 
 
 
2.3 Hormonal stimulation for IVF 
 
The hormonal stimulation of women undergoing IVF treatment was carried out according to 
Fertility Associate’s stimulation protocols: a) the “down regulation protocol (5.85)” and b) 
the “micro-dose flare protocol (5.9)”. These protocols are based on the two most commonly-
used hyper-stimulation methods in the world. In the period of 2007-2010 at Fertility 
Associates Wellington ~60% and ~30% of women underwent stimulation using the “5.85” 
and “5.9” protocol respectively. In 2011, about 44 and 40% of women underwent IVF 
procedures with the use the down-regulation protocol and the micro-dose flare protocol, 
respectively. 
 
The long agonist protocol (“5.85”) used was based on that described by Damario et al. 
(1997). This protocol employs pre-treatment with an oral contraceptive pill (Levlen® ED or 
Microgynon® 30 ED, Bayer HealthCare, Auckland, New Zealand) for 25 days followed by 
the administration of a GnRH agonist, which is overlapped with the final 5 days of oral 
contraceptive. Patients begin taking the OCP following onset of a spontaneous menstrual 
period or progestin-induced withdrawal bleed. The Fertility Associate’s long protocol 
recommends the pre-treatment with OCP for at least 21 days, where GnRH agonist 
(Buserelin, Suprafact, Sanofi-Aventis, Paris, France) treatment (400 µg subcutaneous/day) 
starts from the 15
th
 day of the OCP, and overlaps the OCP treatment for 7 days. 
Gonadotrophin treatment (rFSH, Puregon, Merck & Co./MSD, New Jersey, USA) is initiated 
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in daily doses (75-300 IU, depending on the woman and her predicted ovarian response) after 
14 days of GnRH agonist. Monitoring of serum oestradiol levels and follicular development 
by ultrasound commence on day 7 of gonadotrophin treatment. The timing of hCG 
administration was based on the extent of follicular development and serum oestradiol levels. 
Ovulation was initiated using choriogonadotrophin alpha (250 µg Ovidrel, Merck KGaA, 
Darmstadt, Germany) when at least three follicles had reached ≥18 mm diameter, or after two 
follicles had reached ≥20 mm (Appendix 2.1). 
 
The “micro-dose flare” protocol (“5.9”) was based on that described by Scott and Navot 
(1994) (Appendix 2.2). The “5.9” protocol employs pre-treatment with OCP for 21 to 28 
days, followed by the subcutaneous administration of 50 µg GnRH agonist (Buserelin) every 
12 hours for three days after discontinuing the OCP. On the third day of administration of 
GnRH agonist, ovarian stimulation is augmented with 225-300IU exogenous rFSH. 
Monitoring of serum oestradiol levels and follicular development by ultrasound commenced 
on Day 4 or Day 6 depending on the daily dose of rFSH stimulation (225IU or 300IU, 
respectively). The initiation of ovulation was done similarly to that in the long protocol, when 
at least three follicles had reached ≥18 mm diameter, or after two follicles had reached ≥20 
mm (Appendix 2.2).  
 
2.4 Embryological manipulations and CC collection 
 
Oocytes and embryos were handled and cultured according to Fertility Associate’s protocols 
(Appendix 3.1-3.3), with the exception that throughout the entire in vitro culture, oocytes and 
embryos were cultured individually. 
 
In brief, at 36 hours following the administration of an ovulation trigger (i.e. hCG; 250 IU, 
Ovidrel, Merck KGaA, Darmstadt, Germany), the women underwent ultrasound guided 
transvaginal oocyte retrieval. Follicular fluid containing the COC was aspirated and collected 
into 14 ml tubes (Cat. No. 352057, BD Falcon, NJ, USA), before being transferred to IVF 
culture dishes (Cat. No. 353652, BD Falcon) incubating on a heated stage (37ºC) of a stereo 
microscope. The COC were recovered into 1-well IVF culture dishes (Cat. No. 353653, BD 
Falcon) containing 1 ml G-MOPS Plus media (Vitrolife, Göteborg, Sweden) and rinsed. 
Following rinsing in G-MOPS Plus media, COC were transferred to individual culture wells 
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(Cat. No. 144444, Nalge Nunc International, Rochester, NY, USA) containing 0.5 ml G-IVF 
Plus culture media (Vitrolife) under paraffin oil (OVOIL, Vitrolife) until denudation.  
 
At 38 hours post-hCG treatment, the morphological characteristics of the CC were recorded 
(Appendix 4). Following scoring, the individual COC were exposed to 0.5 ml (10 IU) of 
hyaluronidase solution (HYASE-10x in G-Mops Plus media, Vitrolife) in 4-well dishes 
(#144444, Nunc) for several seconds before being transferred to 0.5 ml G-MOPS Plus media. 
With the use of a denudation pipette (Cat. No. 14302, Vitrolife), the CC were mechanically 
dissociated from the oocyte (Appendix 3.1). Each denuded oocyte was then transferred into 
individual 15 µL culture drops (G-IVF Plus) under paraffin oil (OVOIL) in IVF culture 
dishes (BD Falcon). After denudation, the morphological characteristics of the oocyte were 
recorded (Appendix 4).  
 
Both residual solutions (G-MOPS Plus media and HYASE solution) containing the 
dissociated CC for each individual oocyte were pooled in a 1.5 ml tube (#2230-00, SSI, Lodi, 
CA 95240 USA) and centrifuged at 894g for 1 minute. Most of the supernatant was removed 
and the pellet containing the CC was snap-frozen in liquid nitrogen for total RNA extraction.  
 
The oocytes were subjected to intra-cytoplasmic sperm injection (ICSI) at 39 hours post-hCG 
treatment (Appendix 3.1) and cultured individually in a 15 µL micro-drop culture media 
under paraffin oil (OVOIL) in IVF culture dishes (#353652, BD Falcon). Embryos were 
cultured in sequential culture media (G5 Series, Vitrolife) in 37 ºC incubators (MINC; 
COOK, Brisbane, Australia) under 5% O2 and 6% CO2 culture conditions according to both 
the manufacturer’s and Fertility Associate’s protocols. Embryo transfer was carried out 
according to Fertility Associate’s embryo transfer protocol. In brief, embryos selected for 
transfer were first moved into a designated transfer dish (Cat. No. 353653, BD) in 50 µl 
Embryo Glue media (Vitrolife) under paraffin oil (Vitrolife). Embryos were then aspirated 
with ~20 µl transfer media into embryo transfer catheters (G20683, Sydney IVF catheter, 
COOK, Brisbane, Australia or Labotect, Labor-Technik-Göttingen GmbH, Göttingen, 
Germany) and were handed to the clinician, who introduced the catheter content (fluid with 
embryo) into the lower third portion of the uterine cavity of the patient.  
 
All manipulations (except ICSI) were performed with the aid of a stereo-microscope (SZ61, 
Olympus, Olympus Corporation, Shinjuku, Tokyo, Japan) fitted with a heated stage set at 37 
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ºC. The ICSI procedure was performed using an inverted microscope at 37 ºC (TE300, 
Nikon, Tokyo, Japan). Manipulations of COC were carried out using sterile Pasteur pipettes 
(Cat. No. PP-5.75-90, Charlottesville, VA, USA) and denuded oocytes and embryos were 
handled with micro-pipettes (Cat. No. 40270570, LabServ, Thermo Fisher Scientific, 
Waltham, MA, USA) fitted with sterile tips (Cat. No. T-200-C-R-S, Axygen, Union City, 
CA, USA). 
 
The morphological appearances of COC, oocytes and embryos were recorded from the day of 
COC collection (Day 0) until Day 6 of embryo culture. As previously mentioned, the CC 
from each COC was graded according to morphological appearance under a stereo-
microscope. For statistical purposes, COC graded as 0 and 1 were classified “light’, where 0 
represents a light shaded CC mass with no abnormalities and 1 represents a light shaded 
small CC mass (“ball like”). Those COC graded as 2 and 3 were classified as “dark”, where 
grade 2 stands for dark shaded CC masses and 3 stands for a CC mass with a light shaded 
base incorporating large dark patches. Oocytes were classified according to meiotic stage; i.e. 
GV, MI, MII or abnormal (Appendix 4). Morphologically, germinal vesicle (GV) oocytes are 
characterised by the presence of the nucleus with a single large nucleolus (germinal vesicle), 
eccentrically located in the ooplasm. Methaphase I (MI) oocytes are those oocytes that have 
undergone germinal vesicle breakdown (display no GV) and display no polar body. 
Methaphase II (MII oocytes) are characterised by the presence of the first polar body in the 
perliviteline space (Mandelbaum 2000). Embryos were assessed at 18 hours post-ICSI for 
fertilization, 25 hours for early cleavage, 42 and 66 hours for cleavage stage and 114 and 138 
hours for blastocyst development (Appendix 3.2 and Appendix 3.3). Cleavage-stage embryos 
were graded according to widely used selection criteria such as cell number and 
morphological appearance (Cummins et al. 1986; Sakkas et al. 1998). Embryos were 
considered top quality if they presented early cleavage, divided to 4 cells on day 2 and 
reached at least 7 cells on day 3 of in vitro culture. Blastocyst development was assessed on 
Day 5 and Day 6 of culture. Blastocysts were given a numerical score from 1 to 6 
representing their degree of expansion and hatching status: (1) early blastocyst with the 
blastocoel being less than half the volume of the embryo; (2) blastocyst with the blastocoel 
being greater than or equal to half of the volume of the embryo; (3) full blastocyst with the 
blastocoel completely filling the embryo; (4) expanded blastocyst with the blastocoel volume 
being larger than that of the early embryo and the zona is thinning; (5) hatching blastocyst 
with the trophectoderm starting to herniate though the zona and; (6) hatched blastocyst where 
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the blastocyst has completely escaped from the zona. Furthermore, blastocysts were graded 
according to the morphological appearance of their inner cell mass (ICM): (A) tightly packed 
with many cells; (B) loosely grouped with several cells and; (C) very few cells. Similarly, the 
trophectoderm was graded as: (A) many cells forming a tightly knit epithelium; (B) few cells 
and; (C) very few cells forming a loose epithelium (Gardner and Sakkas 2003). Blastocysts 
were selected for transfer or freezing if they were graded at least 1 for expansion, B for ICM 
and B for trophectoderm.  
 
2.5  Pregnancy monitoring and live birth follow-up  
 
The recording of pregnancies and live births was carried out according to Fertility 
Associate’s and the Australia and New Zealand Assisted Reproduction Database (ANZARD) 
requirements (http://www.preru.unsw.edu.au/preruweb.nsf/page/ANZARD).  
 
In brief, pregnancy was determined initially from plasma hCG and progesterone levels on 
Day 14 after egg collection followed by a second measurement of these parameters on Day 
18. A positive pregnancy was recorded if the hCG level at Day 14 was ≥ 18iu/l. Depending 
on the result of Day 18 progesterone levels, luteal support was stopped, reduced or continued 
until ~ Week 8, when the presence of yolk sac and foetal heart beat (FHB) was measured by 
ultrasound scan. Positive implantation was considered if a FHB was present. Following birth, 
the gestation period, weight and gender of the live born baby was recorded for this study. 
 
2.6  Cell count and viability index for cumulus cells after OPU  
 
Following collection and re-suspension of single CC masses in 50 µl of G-MOPS Plus 
culture media, total CC numbers were counted using a haemocytometer under an inverted 
microscope at 400x magnifications. The total number of CC in the cell suspension (as an 
indication of CC mass) was calculated according to the formula: 
 
Total number of CC in one COC = Navg x DF x SV 
 
Key: Navg = average number of cells in one large square of the haemocytometer 
 DF = dilution factor (if suspension was further diluted) 
 SV = cell suspension volume (50 µl) 
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For assessment of cell viability, an equal amount of 0.4 % Trypan blue stain solution (Ajax 
Finechem Pty Ltd, Auckland, New Zealand) was added to the cell suspension. Dead cells 
incorporate Trypan blue and appear blue under the microscope, whilst intact (viable) cells are 
able to exclude Trypan blue and remain transparent. Cell viability was calculated according 
to the formula:  
 
% viable cells = N viable cells / Total N of cells x 100 
 
2.7  RNA Extraction and cDNA Synthesis 
 
Total RNA was extracted from individual CC masses using the ArrayPure™ Nano-scale 
RNA purification kit (EPICENTRE Biotechnologies, Cat. No. MPS04050, Wisconsin, USA) 
and stock solutions of 70% ethanol and isopropanol (Global Science, Cat. No. 
APPA39281000PE, New Zealand). For the preparation of 70% ethanol, 100% analytical 
grade ethanol (Sigma-Aldrich, Cat. No. 24106) was diluted to 70% in Diethylpyrocarbonate 
(DEPC) water and was stored at room temperature. DEPC water was prepared according to 
the formula: 1ml of DEPC (Sigma-Aldrich, Cat. No. 40718) was dissolved in 1L of distilled 
water and stirred overnight in the fume hood and sterilized under standard autoclave 
conditions. The RNA purification procedure involved adding 30 µl of nano-scale lysis 
solution containing 1 µl Proteinase K to the tube containing the captured cell pellet. The 
contents were mixed thoroughly by vortexing followed by 15 minutes incubation at 65 ºC. 
Thereafter, the samples were placed on ice for five minutes, followed by the addition of 18 µl 
of 5 M ammonium acetate solution (MPC Protein Precipitation Reagent). In the next step, the 
lysed samples were vortexed vigorously, and centrifuged for seven minutes at 12,000g to 
pellet the debris. The supernatant was transferred to a clean microcentrifuge tube and total 
RNA was precipitated by the addition of 50 µl of isopropanol, mixing by vortexing and then 
pelleting by centrifugation at 4ºC for five minutes at 12,000g. Following the removal of the 
residual isopropanol and air drying the pellet, contaminating DNA was removed by re-
suspending the pellet in 20 µl DNase solution (prepared by the addition of 0.5 µl of RNase-
Free DNase I to 20 µl of 1X DNase Buffer). The tubes containing the samples were incubated 
at 37ºC for 30 minutes. In the next step, 20 µl of 2X nano-scale lysis solution was added to 
the samples and mixed by vortexing. Contaminating proteins were removed again by treating 
the samples with 20 µl of MPC Protein Precipitation Reagent, vortexing, cooling (five 
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minutes on ice) and centrifuging at 4ºC for five minutes at 12,000g. Following the transfer of 
the supernatant to a clean microcentrifuge tube, total RNA was precipitated by the addition of 
50 µl of isopropanol and pelleted by centrifugation at 4ºC for five minutes at 12,000g. The 
isopropanol was aspirated and the RNA pellet was rinsed with 70% ethanol. After a final 
centrifugation step and aspiration of the ethanol, the pellet was air dried and re-suspended in 
10 µl of ultra-pure H2O. Total RNA samples were either stored at -80ºC until further use, or 
used immediately for cDNA synthesis. 
 
Following extraction, the total RNA samples were reverse-transcribed to cDNA using the 
SuperScript® VILO™ cDNA Synthesis Kit (Cat. No. 11754-050, Invitrogen, CA, USA). 
This kit provides the high-temperature capability of SuperScript® III Reverse Transcriptase 
in an optimized format for generating first-strand cDNA for use in QPCR. This formulation is 
reported to enhance the efficiency of cDNA synthesis and can be used with very low to very 
high amounts of total RNA (up to 2.5 μg total RNA in a 20-μl reaction), giving a linear 
response in message abundance as measured by QPCR. 
 
For a single reaction, the following components were combined in a tube on ice: 4 μl of 5x 
VILO™ reaction Mix, 2 μl of 10x SuperScript® enzyme Mix, 10 μl of RNA (up to 2.5 μg) 
and 4 μl of ultra-pure H2O. The contents of tube were mixed by brief vortexing. Thereafter, 
the samples were incubated for ten minutes at 25 ºC, one hour at 42 ºC and five minutes at 85 
ºC. Following the incubation, the cDNA samples were stored at -80 ºC until QPCR analysis.  
 
2.8 Quantitative PCR (QPCR) 
 
For primer optimization and validation of the housekeeper gene, QPCR using SYBR green 
chemistry was used. For probe optimization and quantification of candidate/housekeeper 
genes, QPCR using TaqMan chemistry was used (see page 54 for more details). The reaction 
kits for both methods came from Agilent Technologies, USA (Cat. No. 600548 and 600553, 
respectively).  
 
2.8.1 SYBR Green Method  
 
This method uses a DNA dye, SYBR® Green I, which in an unbound state exhibits little 
fluorescence. However, when SYBR® Green I binds to double-stranded (ds) DNA, it 
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exhibits significantly increased fluorescence signal. Thus during the denaturation step when 
all DNA becomes single-stranded, the dye produces little fluorescence. In contrast, during the 
annealing step when primers attach to the target sequence and dsDNA is synthesized, the 
SYBR Green I dye binds to the dsDNA and exhibits a strong fluorescent signal. This 
fluorescence signal is then monitored in a linear fashion as the PCR product is amplified over 
a range of PCR cycles. Therefore the cycle at which the intensity of the fluorescence signal 
becomes significantly higher than the background (i.e. cycle threshold, CT), will depend on 
the initial concentration of the gene target present (Brilliant SYBR® Green QPCR, 
Instruction Manual, Agilent Technologies).  
 
2.8.2 Multiplex (TaqMan) Method  
 
The multiplex QPCR method allows multiple genes to be amplified simultaneously in the 
same reaction vessel. This method utilizes a probe-based chemistry in which each probe has a 
spectrally different fluorophore and quencher attached. The TaqMan probes used in this 
reaction are linear, with the fluorophore usually at the 5’ end of the probe and the quencher is 
either internal or at the 3’ end. In the intact form (either hybridized or not with the target) the 
probe exhibits no fluorescent signal. However, in the annealing step after the probe 
hybridizes to the target, the DNA polymerase separates the fluorophore from the quencher 
resulting in the emittance of fluorescence. As with the SYBR green chemistry, this 
fluorescence signal is then monitored in a linear fashion as the PCR product is amplified over 
a range of PCR cycles. Therefore the cycle at which the intensity of the fluorescence signal 
becomes significantly higher than the background (i.e. CT), will depend on the initial 
concentration of the gene target present (Brilliant Multiplex QPCR Master Mix, Instruction 
Manual, Agilent Technologies).  
 
2.8.3 Fluorescence Monitoring in Real-Time 
 
The change of fluorescence signal is monitored in real-time over the course of the PCR 
reaction. The results are displayed as an amplification plot. This information is then used to 
quantify the initial target copy number, which is calculated from values provided by a 
threshold cycle (CT). CT is defined as the cycle at which fluorescence is determined to be 
statistically significant above background, and it is inversely proportional to the log of initial 
copy number. The more template that is initially present, the fewer the number of cycles it 
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takes to reach the point where the fluorescence signal is detectable above background. 
Quantification based on CT has the advantage over endpoint quantification in that 
measurements are taken during the exponential phase of the PCR amplification, when the 
reaction efficiency is not yet influenced by limiting reagents. The more template that is 
initially present in the reaction, the lower the CT value (Brilliant Multiplex QPCR Master Mix 
– Instruction Manual). 
 
2.8.4 Primers and Probes  
 
All primers and TaqMan probes (Table 2A) were designed using the computer package 
‘Beacon Designer’ (Premier Biosoft International, CA, USA) based on sequences obtained 
through NCBI and were obtained from Invitrogen and Sigma-Proligo (TaqMan probes; 
Proligo-France SAS 1, Paris, France or Proligo-Singapore Pte Ltd, Helios, Singapore), 
respectively. 
 
Table 2A: Nucleotide (nt) sequences for primers and TaqMan probes for QPCR including the 
size of the resultant amplicon in regards to number of nt for human ALCAM (NM_001627.3), 
SFRP2 (NM_003013.2), NRP1 (NM_003873.5), PR (NM_001202474.1), VCAN 
(NM_004385.4), HAS2 (NM_005328), FSHR (NM_000145), GLUT4 (NM_001042), RPL19 
(NM_000981) and 18S (NR_003286) mRNA. F=5’; R=3’. 
 
Gene Taqman probe (5’-3’) Primers (5’-3’) 
Size 
(nt) 
ALCAM (HEX) TTCCTGCCGTCTGCTCTTCTGCCTCTT (BHQ1) 
F-CACCAAGAAGGAGGAGGAATATG 
R- GCAAGGTATGATAATGGTATCTCCA 
149 
SFRP2 (ROX)AAACAACAAACAACAACCAACCAGACCCAAGT(BHQ2) 
F- GCCCACCCGAATCTTGTAGAAA 
R- CAACCTCAGTGGGAAGTGAAAATC 
173 
NRP1 (ROX)CATCTTCCAGTCCGAGCCGTTGTTG(BHQ2) 
F- GCACCTCATTCCTACATCA 
R- CTTGCGTTTGCTGTCATC 
183 
PR (HEX)CACTTTCTTCTCCCATGCTTTATCTCCATCAAT (BHQ1) 
F- GTGGTCAATAGTGTTTGCTG 
R- GTAGGAAGCAAAGGTGGAA 
193 
VCAN (6FAM)TCCCATTCGCAGCCTTTAGCATCAT(BHQ1) 
F- ATGGCTTTTCCTGGACAG 
R- GGAGTCCTTAGTTCCATCAG 
130 
HAS2 (HEX)AACTGCCCGCCACCGACCCTCC(BHQ1) 
F-GGTCGTCTCAAATTCATCTGATCTC 
R-GGATACATAGAAACCTCTCACAATGC 
145 
FSHR (6FAM)TCTGCTGTAGCTGGACTCATTGTCTTCTGCC(BHQ1) 
F-AAGTTGATTATATGACTCAGGCTAGG 
R-AACTCAGTGTACGTCATGTCAAATC 
100 
GLUT4 (ROX)CCCGCCCTCGCACGTCACTCCG(BHQ2) 
F-TCTCCGGGTCCTTGGCTTG 
R-GCGAAGATGAAAGAACCGATCC 
137 
RPL19 (CY3)CCAATGCCAACTCCCGTCAGCAGATCCG(BHQ3) 
F-GACCCCAATGAGACCAATGAAATC 
R-GGAATGGACCGTCACAGGCTTG 
105 
18S  
F-GCCGCTAGAGGTGAAATTCTTG 
R-CGGAACTACGACGGTATCTGATC 
128 
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Optimum primer and probe concentrations were obtained by titrating concentrations of 
forward and reverse primers and TaqMan probes from 50nM to 300nM. The optimal 
concentrations were deemed to be that which gave the lowest CT value. The optimum primer 
and probe concentrations are shown in Table 2B. 
 
Table 2B: Final concentrations of primers and TaqMan probes in QPCR reactions for human 
ALCAM, SFRP2, NRP1, PR, VCAN, HAS2, FSHR, GLUT4, RPL19 and 18S.  
 
 Primers (nM) Taqman 
probe 
Gene Forward Reverse (nM) 
ALCAM 300 200 50 
SFRP2 200 300 50 
NRP1 200 300 100 
PR 300 300 50 
VCAN 200 300 50 
HAS2 300 200 50 
FSHR 100 100 50 
GLUT4 100 100 100 
RPL19 100 100 50 
18S 300 200 - 
  
 
 
2.8.5 QPCR Analysis 
 
The Corbett Rotor-Gene 6000 Series Software 1.7 was used to analyze all QPCR results. The 
optimal amount of cDNA template per QPCR reaction was deemed to be that resulted in a CT 
value within the measurable range (15-29), therefore 1.04 µl of original template was used 
for each reaction. 
 
Quantification of gene mRNA levels using the SYBR Green method was done according to 
manufacturer’s instructions. In brief, for each cDNA sample, a singleplex reaction mix was 
prepared in 0.2 mL microtubes containing forward and reverse primers at optimized 
concentrations (Table 2B), 26 µl of 2x Brilliant
®
 Green QPCR Master Mix (Cat. No. 600548, 
Agilent Technologies CA, USA), 1.04 µl of cDNA template and an appropriate aliquot of 
Ultra-Pure H2O (Invitrogen) to a total volume of 52 µl. After thorough vortexing, aliquots of 
25 µl were transferred in duplicate to 0.1 ml strip-tubes and capped (Corbett Research; NSW, 
Australia 2137). The amplification reaction was run using a Rotor-Gene
TM
 6000 Rotary 
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Analyzer (Corbett Research) under the following conditions: 1 cycle of 95°C for 10min; 40 
cycles of 95°C for 15sec and 58-60°C (depending on the gene) for 60sec. 
 
Quantification of mRNA levels using the quadriplex TaqMan method was undertaken 
according to the manufacturer’s protocols. In brief, the reaction mixes were prepared 
containing forward and reverse primers and TaqMan probes for one housekeeping (RPL19) 
and up to three genes of interest at optimized concentrations (Table 2B), 26 µl of 2x 
Brilliant
®
 Multiplex QPCR Master Mix (Cat. No. 600553, Agilent Technologies), 1.04 µl of 
neat cDNA and an aliquot of Ultra-Pure H2O to a total volume to 52 µl. After vortexing, 
aliquots of 25 µl were transferred in duplicate to 0.1 ml strip-tubes and capped. The 
amplification reaction was run using the Rotor-Gene
TM
 6000 Rotary Analyzer under the 
conditions described above. 
 
Controls included samples that underwent reverse transcription PCR with the exclusion of 
Superscript III/RNaseout enzyme mix to check the effectiveness of DNase treatment, and 
reactions that omitted addition of the template. 
 
2.8.6 Confirmation of genes by DNA sequencing 
 
Genes of interest were amplified by SYBR Green QPCR using the method described above. 
Thereafter, the amplification product was purified using the PureLink
TM 
PCR Micro kit (Cat. 
No. K310010, Life Technologies Corporation, NY, USA) or the MinElute PCR purification 
kit (Cat. No. 28704, Qiagen, Hilden, Germany), following the manufacturer’s protocols. 
 
In short, the QPCR product was treated with a 4-5x volume of binding buffer and vortexed 
thoroughly. The entire volume was transferred to a column containing a silica membrane for 
binding the DNA, and the column was placed in a collection tube, to collect the eluate. The 
sample was then centrifuged for one minute at 10,000g and the eluate was discarded. 
Thereafter, the column was treated with 650-750 µl wash buffer and the tube was centrifuged 
again for one minute at 10,000g. Again, the eluate was discarded and the column was 
centrifuged again to remove any residual washing buffer. Subsequently, the column was 
moved to a new collection tube and 10 µl elution buffer or ultra-pure H2O was added to the 
silica membrane of the column. Thereafter, the sample was incubated for 1 minute at room 
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temperature and centrifuged for one minute at 10,000g to collect the purified DNA into the 
elution tube. Samples were stored at -80ºC until further use.  
After purification, the purified QPCR product was sent for sequencing to the Waikato DNA 
Sequencing Facility (Department of Biological Sciences, University of Waikato, Hamilton, 
New Zealand). 
 
Results were matched against gene sequences provided by NCBI and in the case of a positive 
match, genes were confirmed. 
 
2.8.7 Validation of the QPCR analysis 
 
After the conditions for the QPCR reactions were optimized, the amplification efficiency for 
each gene was tested. Serial dilutions (1:1-1:32) of at least two samples were made to 
validate the amplification efficiency for each gene. A reaction efficiency of ≥ 80% was 
considered satisfactory (the reaction efficiencies for each gene are listed in Table 2C). This 
included the calculation of the line of best fit (slope ±0.1) for each gene when CT values were 
plotted against the log of input RNA or the log of total cell number in each CC mass. 
Additionally, CT values (≤0.4 cycles different) for identical samples for all mRNA transcripts 
were compared between results from singleplex and multiplex reactions.  
 
Table 2C: Table of QPCR efficiency for each candidate gene in multiplex reactions. 
 
 Gene Efficiency (%) 
Reaction 1 HAS2 83 
 FSHR 91 
 GLUT4 87 
 RPL19 93 
Reaction 2 ALCAM 91 
 SFRP2 88 
 RPL19 93 
Reaction 3 NRP1 80 
 PR 80 
 VCAN 84 
 RPL19 81 
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2.8.8 Quantification of gene expression by multiplex QPCR 
 
Expression levels of the candidate genes in each sample were calculated by the 2
-( ΔΔC
T
) 
method (Livak and Schmittgen 2001). Expression levels were standardised against a 
calibrator sample and normalized with respect to the house-keeping gene, RPL19. Results are 
therefore presented as fold-changes. Thus for each CC-specific gene, the CT value for RPL19 
expression for each sample was subtracted from the CT value for the gene of interest resulting 
in a ΔCT value. Then the calibrator’s ΔCT value was subtracted from the ΔCT value of a 
specific CC sample resulting in a ΔΔCT value. To convert these values to linear volumes (i.e. 
fold change) for analyses, the following equation was performed: 2
-(ΔΔC
T
)
. 
 
The standard errors of the mean (SEM) were calculated by the formula 2
-(ΔΔC
T 
± SEM)
. 
 
The ratio of mRNA expression between genes was calculated using the formula, 2
-(1st gene C
T 
-
2nd gene C
T
)
, resulting in a relative fold difference. Correlations between two genes of interest 
were undertaken using 2-tailed Pearson’s R test and the SPSS statistical package (PASW 
Statistics 18, IBM, New York, USA). 
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Chapter 3 VALIDATION OF RPL19 AS A HOUSEKEEPING GENE FOR HUMAN 
CUMULUS CELLS  
 
3.1 Introduction 
 
Quantitative PCR is an invaluable technique used for the measurement and comparison of 
target genes in biological samples. Moreover, in small biological samples and with respect to 
genes expressed with low abundances, QPCR represents the only technique sensitive enough 
to measure mRNA expression reliably (Huggett et al. 2005). The accurate measurement of 
target mRNAs and normalization across data sets is strongly influenced by the choice of 
reference genes (housekeeping genes). In gene expression analyses, the abundance of the 
target transcript is normalized against the housekeeping gene, whilst comparing multiple 
samples is done by comparing the ratios of normalized expression levels for the gene of 
interest in each sample against a constant sample (calibrator). Ideally, the expression of the 
housekeeping gene should be constant in all samples and independent of different 
experimental conditions (i.e. cause of ovarian infertility in women undergoing IVF) (Livak 
and Schmittgen 2001; Quackenbush 2002; Dheda et al. 2004). In the process of 
normalization of the target genes with respect to the housekeeping gene, it is important to 
assess the integrity and quality of cells that are subjected to analysis (Huggett et al. 2005). 
The negative effects of cell apoptosis on DNA integrity and the precision of gene expression 
analysis are well documented in post-mortem tissue studies (Koppelkamm et al. 2011). In 
this context it is useful to know that the selected housekeeping gene correlates to the cell 
numbers from the specific sample (Huggett et al. 2005).  
 
In recent years, many papers have been published where classical housekeeping genes were 
chosen without appropriate validation. Reports that have investigated the stability of 
housekeeping genes in multiple tissues and samples have indicated significant variability in 
the expression of some putative housekeeping genes suggesting that great care is needed 
when selecting a reference gene for a tissue/cell-specific study (Chari et al. 2010). Indeed, it 
has been proposed that authors need to demonstrate the suitability of the reference gene of 
choice for the experiment in question (Huggett et al. 2005; Chari et al. 2010; Fu et al. 2010; 
Frota et al. 2011). The majority of the studies investigating gene expression levels in human 
CC samples have used ribosomal 18S RNA or glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as the housekeeping gene (Hasegawa et al. 2005; Zhang et al. 2005; Feuerstein et 
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al. 2007; Hamel et al. 2008; van Montfoort et al. 2008; Anderson et al. 2009; Gebhardt et al. 
2011). Researchers investigating the housekeeping properties of GAPDH in ovarian samples 
have reported its high variability, and inappropriateness as a reference gene in some instances 
(Fu et al. 2010; Frota et al. 2011). Ribosomal 18S RNA is recognised widely as a good 
housekeeping gene, however its abundance is one of the highest amongst the housekeeping 
genes, making it unsuitable when studying genes expressed with low abundances (Feuerstein 
et al. 2007; Fu et al. 2010). Moreover, 18S RNA is reported to have low expression stability 
in human ovarian cancer and in caprine ovaries (Fu et al. 2010; Frota et al. 2011). On the 
other hand, the 60S ribosomal protein L19 (RPL19) gene is expressed in a similar abundance 
to that of many of the target genes in CC and was one of the more stable housekeeping genes 
following studies in caprine ovaries and human lung tissues (Feuerstein et al. 2007; Chari et 
al. 2010; Frota et al. 2011). However, there appears to have been no studies that have 
investigated the relationship between the number of CC and RPL19 expression levels.  
 
The aim of this study was to verify a) the quality of CC samples collected for mRNA 
extraction as measured by CC viability, and b) the housekeeping properties of RPL19 and 
18S in human CC samples.  
 
3.2 Materials and Methods 
 
Following the removal of the multiple layers of CC (i.e. the CC mass), the oocytes underwent 
IVF and embryological procedures as described in general methodology. Cell viability was 
determined from 59 isolated individual CC masses. CC numbers were determined from a 
further 21 individual CC masses. The numbers of CC in each CC mass were counted using a 
haemocytometer under an inverted microscope at 400x magnification, and the viability of the 
cells was assessed using a 0.4 % (w/v) Trypan blue stain solution (Chapter 2). The 59 
samples collected for the assessment of viability were used only for validation of the 
denuding method and were discarded after vibility assessment. For validation of the 
housekeeper gene RPL19, expression levels in a total of 21 individual CC masses from three 
women were compared to that of another common housekeeper gene (18S) and to CC 
number. CC masses were collected and re-suspended in 50 µl of G-MOPS Plus media 
(Vitrolife). From this suspension, an aliquot of 20 µl was used for determining total CC 
number per mass and the remaining 30 µl of cell suspension were used for quantifying the 
expression levels of RPL19 and 18s mRNA.  
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QPCR methods: 
Total RNA was extracted and cDNA was synthesized using methods described in general 
methodology (see Chapter 2). Quantification of RPL19 and 18S mRNA levels was 
undertaken using the Brilliant SYBR® Green QPCR Master Mix kit (Stratagene, La Jolla, 
CA, USA) and 2x Brilliant
®
 Multiplex QPCR Master Mix kit (Stratagen) according to 
manufacturer’s instructions and methods described in Chapter 2. In short, for each cDNA 
sample, a singleplex reaction mix was prepared in 0.2 mL microtubes each containing 
forward and reverse primers for 18S or RPL19 at optimized concentrations (Table 2B), 26 µl 
of 2x Brilliant® Green QPCR Master Mix, 1.04 µl of diluted cDNA (1:50 for RPL19 and 
1:500 dilution for 18S) and an appropriate aliquot of Ultra-Pure H2O (Invitrogen) to a total 
volume of 52 µl. After thorough vortexing, aliquots of 25 µl were transferred, in duplicate, 
into 0.1 ml tubes and capped (Corbett Research). The amplification reaction was run on a 
Rotor-GeneTM 6000 Rotary Analyzer (Corbett Research) using the following conditions: 1 
cycle of 95°C for 10min; 40 cycles of 95°C for 15sec and 60°C for 60sec. For quantification 
of RPL19 mRNA levels by the TaqMan method, reaction mixes were prepared containing 
forward and reverse primers and TaqMan probes at optimised concentrations (Table 2B), 26 
µl of 2x Brilliant® Multiplex QPCR Master Mix (Stratagen), 1.04 µl of neat cDNA and an 
aliquot of Ultra-Pure H2O to adjust the total volume to 52 µl. After vortexing, aliquots of 25 
µl were transferred, in duplicate, to 0.1 ml tubes and capped (Corbett Research). The 
amplification reaction was run on the Rotor-GeneTM 6000 as described above. Finally, 
RPL19 and 18S cycle threshold (CT) values were plotted against log of total cell numbers in 
each associated CC mass. 
 
3.3 Results 
 
The viability of CC after denudation was 86.4 ± 1.3 % (mean ± S.E.M; N=59). Of the 21 CC 
masses collected for QPCR validation, 20 had detectable levels of 18S and RPL19 mRNA. 
The mean ± SEM number of CC per mass (cells counted by haemocytometer) was 19680 ± 
2744 (range 2650 – 44900). These samples were only used for validation purposes. The 
relationship between CC numbers and expression levels of RPL19 and 18S are shown in 
Figure 3. The slopes and correlation efficiencies for the lines of best fit were similar for the 
CT values for 18S using the SYBR green QPCR method, and for RPL19 using the SYBR 
green and TaqMan QPCR methods when plotted against the log number of CC.  
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Figure 3: Linear regressions of Log10 Cumulus Cell (CC) number versus Cycle Threshold 
(CT) value for the housekeeping genes RPL19 and 18S. Comparisons were made of Log10 CC 
number against 18S using SYBR Green QPCR (■), RPL19 using TaqMan QPCR (○) and 
RPL19 using SYBR green QPCR (▲). 
 
3.4 Discussion 
 
The current study has provided the first evidence that RPL19 is an appropriate housekeeper 
gene for studies of gene expression in human CC. A strong positive correlation (P<0.0001) 
was found between RPL19 expression levels and the number of CC. Moreover, the regression 
equation of log CC number = -0.2392*(RPL19 Ct value) + 8.7523 (Figure 4) that resulted 
from this preliminary study will permit the total number of CC in each CC mass collected to 
be estimated from RPL19 levels.  
 
A previous report that investigated the feasibility of RPL19 as a housekeeping gene in CC 
collected from patients following IVF treatment found that the expression of RPL19 and 18S 
in CC were similar in relation to oocyte maturity, and that expression of 18S was more 
abundant than that of RPL19 (Feuerstein et al. 2007). Indeed several studies have confirmed 
that many genes expressed in cumulus cells (i.e. GREM1, BDNF, TNFAIP6, PTX3, ALCAM, 
SDC4 and CALM2) can have similar expression levels in CC from mature as well as 
immature oocytes (McKenzie et al. 2004; Anderson et al. 2009; Adriaenssens et al. 2010; 
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Wathlet et al. 2011). Unlike previous studies, the expression of the RPL19 housekeeping 
gene in this study was compared to CC number, and a strong linear relationship was 
observed. Importantly, the results from this study indicate that it is possible to isolate CC of 
high viability, that provide an appropriate RNA template for the measurement of relative 
levels of candidate gene expression with respect to RPL19.  
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Chapter 4 OOCYTE DEVELOPMENTAL INDICATORS AND RELATIONSHIPS 
WITH CC NUMBERS  
 
4.1 Introduction 
 
Previous studies that investigated the degree of expansion of the COC (Ng et al. 1999; 
Rattanachaiyanont et al. 1999) and the incidence of apoptosis in CC (Lee et al. 2001; Host et 
al. 2002; Moffatt et al. 2002; Corn et al. 2005) in relation to oocyte quality, concluded that 
morphological evaluation of the COC provides limited prognosis on oocyte quality and is an 
unreliable marker in human IVF procedures.  
 
However, there is limited information available on the total number of CC in a CC mass after 
ovulation, or after oocyte collection for human IVF. To the best of our knowledge, no study 
has investigated how CC numbers correlate with oocyte quality. The aims of the present 
study were to determine the numbers of CC in COC from each of the four experimental 
groups (Gp 1, <38yr old and healthy; Gp 2, <38yr old with PCOS; Gp 3, <38yr old with 
diminished ovarian reserve and; Gp 4, ≥40yr old and healthy) and to examine possible 
associations between CC number and indicators of oocyte development (embryo cleavage 
and pregnancy outcome).  
 
4.2 Materials and Methods 
  
In total, 68 women were investigated for embryological and pregnancy outcomes. They were 
classified into the four research groups described above: Group 1 (Gp 1, N=25); Gp 2 
(N=11); Gp 3 (N= 12) and; Gp 4 (N=20). Hormonal stimulation, oocyte collection, embryo 
culture and transfer and luteal support were all performed as described in the general 
methodology (Chapter 2). CC counts were performed as described in Chapter 2 and 3. CC 
numbers in single CC masses were estimated from RPL19 mRNA levels (see Chapter 3) 
using the following equation: 
 
log CC number = -0.2392*(RPL19 Ct value) + 8.7523 (Figure 3). 
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Statistical analyses  
 
Indicators of oocyte development were established in accordance with internationally 
recognized embryological guidelines (ALPHA and ESHRE 2011), FAW protocols 
(Appendices 4.4 and 4.5) and with respect to recent reports to allow easy comparability 
between observations (Adriaenssens et al. 2010; Wathlet et al. 2011). Key embryological and 
pregnancy outcomes are reported as percentages. The comparisons of indicators of oocyte 
development between the four groups of women are represented as proportions and were 
analysed using the Chi-Square test and the SPSS statistical package (PASW Statistics 18, 
IBM, New York, USA). 
 
Statistical differences for mean numbers of CC associated with oocytes from different study 
groups or developmental potential were calculated by one or two-way ANOVA using the 
SPSS statistical package (PASW Statistics 18, IBM, New York, USA). In regards to oocyte 
developmental potential, statistical differences were investigated for CC numbers for the 
following developmental stages:  
1) COC grade (light or dark);  
2) Oocyte maturity (MII or MI+GV, for description see Chapter Methodology); 
3) Fertilization rate (2PN; fertilized oocyte) or failed fertilization (FF), including abnormal 
fertilization);  
4) Good embryonic development on Day 3 (≥ 7cell or ≤ 6cell, including FF at fertilization);  
5) Blastocyst development (good quality blastocyst used for replacement or frozen for 
subsequent use and Day 3 embryos that progressed to pregnancy compared to a negative 
outcome, i.e. embryos that failed to reach blastocyst stage, including those with FF));  
6) Pregnancy rate (oocytes that resulted in positive serum hCG level at Day 14 compared 
with a negative outcome that included unsuitable embryos or those that resulted in negative 
pregnancy and oocytes with FF) and;  
8) Live birth outcome (oocytes that resulted in a live birth compared with a negative 
outcomes that included unsuitable embryos or those that resulted in negative pregnancy and 
oocytes with FF) (see Table 4B).  
All comparisons were made relative to the total number of MII oocytes available after the 
denuding step (total N= 608; Gp 1, N=270; Gp 2, N=128; Gp 3, N=49; Gp 4, N=161).  
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4.3 Results  
 
Oocyte developmental indicators 
 
A total of 608 COC were collected for this study. The respective numbers of COC collected 
in Gp 1, 2, 3 and 4 were, 270, 128, 49 and 161, respectively. 
 
Morphological characteristics of the Cumulus Cell-Oocyte-Complexes 
The proportion of COC that were light-shaded compared to those with a dark appearance 
under the stereo-microscope was highest from women in Gp 2, followed by that from women 
in Gp 1, and were lowest in COC taken from women in Gp 3 and 4 (see Table 4A).  
 
Oocyte maturity 
Differences in the proportion of MII oocytes reached statistical values only in the comparison 
of young and healthy (Gp 1) and older and healthy women (Gp 4), where the proportion of 
MII oocytes in young women was significantly higher (P<0.05) (see Table 4A).  
 
Fertilization 
The fertilization rates in Gp 1, Gp 2 and Gp 4 were similar. The fertilization rate in young 
women with diminished ovarian reserve (Gp 3) was significantly lower (P<0.05) compared to 
other young women (Gp 1 and Gp 2) and was similar to older women (P=0.074) (see 
Table4A). 
 
Day 3 embryonic development  
Good embryonic development on Day 3 was similar in embryos from women in Gp 1 and 2, 
and each was significantly higher compared to that from women in Gp 3 (Gp 1: P<0.01, Gp 
2: P<0.005) and 4 (Gp 1: P<0.05, Gp 2: P<0.005). The Day 3 embryo cleavage rate was 
similar in women in Gp 3 and Gp 4 (see Table 4A).    
 
Blastocyst development 
Blastocyst development tended to be higher in Gp 1 women compared to Gp 2 women 
(P=0.051) and was significantly higher (P=0.015) compared to Gp 3 women., There were no 
differences in blastocyst development in women from Gp 2 and 3 (P=0.176). Due to double 
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embryo transfers and to low blastocyst formation rate in older women, the developmental 
potential in single oocytes was not possible (see Table 4A). 
 
Pregnancy rate 
All women in Gp 1 and 2 underwent single embryo transfer (SET), whilst 9 women in Gp 3 
underwent SET and one woman underwent a double embryo transfer (DET). Oocytes 
retrieved from two women in Gp 3 failed to undergo normal fertilization and thus no embryo 
was transferred. The majority of older (Gp 4) women underwent DET. The pregnancy rate as 
determined by circulating hCG levels and presence of a foetal heart beat (FHB) was 
significantly higher in young and healthy women (Gp 1) compared to that in women with 
PCOS (Gp2: hCG, P<0.05; FHB, P<0.01), and diminished ovarian reserve (Gp 3: hCG, 
P=0.001; FHB, P<0.0001) and those of older women (Gp 4: hCG, P=0.001; FHB, P<0.005). 
The pregnancy rate in women in Gp 2, 3 and 4 were similar (see Table 4A).  
   
Live birth outcome  
Following embryo transfer, 39.7% (27/68) of treatments (oocyte collections) resulted in at 
least one healthy live born child. All but one young women had singleton deliveries (one 
women in Gp 1 had identical twins), whilst from the four older women, three had singletons 
and one had non identical twins. The rate of successful IVF treatments measured by the 
delivery of a healthy live born child was significantly higher in young and healthy women 
(Gp 1) compared to young women with PCOS background (Gp 2; P<0.01), young women 
with diminished ovarian reserve (Gp 3; P<0.0001) and older and healthy women (Gp 4; 
P<0.0001). The live birth rates in Gp 2, Gp 3 and Gp 4 were similar (see Table 4A).  
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Table 4A: Summary of the indicators of oocyte development in the four study groups. 
Different letters (a, b and c) not shared by variables across the rows denote significant 
differences between Gps 1-4 (COC, P<0.005; Genomic maturity, P<0.05; Fertilization, 
P<0.05; Early development, P<0.05; Blastocyst development, P<0.05; hCG, P<0.05; FHB, 
P<0.01; Live birth, P<0.01. Indicators for COC, oocyte maturity and embryo development 
are relative to total COC collected. Indicators for pregnancy outcome are relative to the 
number of women (follicle aspirations). Abbreviations: n/a = not applicable, as number of 
blastocysts for Gp 4 could not be calculated due to double emvryo transfers. 
 
Indicators Unit Gp 1 Gp 2 Gp 3 Gp 4 
Oocyte (Day 0)      
COC (light) 
% 
(#) 
83.3 
b
 
(225/270) 
93.8 
a 
(120/128) 
61.2 
c 
(30/49) 
70.8 
c 
(114/161) 
Genomic maturity 
(MII) 
% 
(#)
 
85.9 
a 
(232/270) 
84.4 
ab 
(108/128) 
77.6 
ab 
(38/49) 
77.6 
b 
(125/161) 
Embryo (Day 1 – 6)      
Fertilization (2PN) 
% 
(#) 
80.6 
a 
(187/232) 
80.6 
a 
(87/108) 
63.2 
b 
(24/38) 
76.8 
ab 
(96/125) 
Early stage  
(≥7 cell) 
% 
(#) 
60.3 
a 
(140/232) 
68.5 
a 
(74/108) 
36.8 
b 
(14/38) 
48.8 
b 
(61/125) 
Blastocyst  
% 
(#) 
24.1 
a 
(56/232) 
15.7 
ab 
(17/108) 
7.9 
b 
(3/38) 
n/a 
Pregnancy      
hCG (Day 14) 
% 
(#) 
84.0
 a 
(21/25) 
45.5
 b 
(5/11) 
25.0
 b 
(3/12) 
35.0
 b 
(7/20) 
FHB (Week 8) 
% 
(#) 
76.0
 a 
(19/25) 
27.3
 b 
(3/11) 
8.3
 b 
(1/12) 
30.0
 b 
(6/20) 
Live birth 
% 
(#) 
76.0
 a 
(19/25) 
27.3
 b 
(3/11) 
8.3
 b 
(1/12) 
20.0
 b 
(4/20) 
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Relationships between CC numbers and oocyte developmental indicators  
 
Of the 608 CC samples collected, 603 (99.2%) had detectable levels of RPL19 mRNA (Gp 1: 
266/270, Gp 2: 127/128, Gp 3: 49/49, Gp 4: 161/161). The mean ± SEM number of CC per 
CC mass calculated (using the regression equation of log CC number = -0.2392*(RPL19 Ct 
value) + 8.7523 (derived from Figure 3) from RPL19 mRNA values was 28872 ± 808 (Gp 1: 
28817 ± 1279, Gp 2: 32675 ± 868, Gp 3: 26834 ± 2545, Gp 4: 26584 ± 1548). From the 603 
CC masses analyised in this study, 503 (83.4%) had a CT value for RPL19 that was within the 
range of the regression equation established based on CC numbers counted (N=20, Chapter 
3). The minimum number of CC required for a detectable RPL19 level (CT =28.99) was 
estimated to be 66. For the estimation of the minimum number of CC required for the 
measurement of candidate genes using the housekeeping gene RPL19 in the multiplex 
TaqMan method, a CT value of 28.99 was chosen; this value is in agreement with previous 
reports and manufacturers recommendations, where mRNA levels associated with a CT <29 
are considered in the measurable range, and those with a CT >29 are regarded as 
unmeasurable and no different from background fluorescence (Kuo et al. 2011). 
 
Mean number of CC per CC mass was significantly higher in Gp 2 compared with Gp 4 
(P<0.01), but not higher compared to Gp 1 (P=0.076) or Gp 3 (P=0.058). No differences were 
noted between Gp 1, Gp 3 and Gp 4 (Table 4B).  
 
CC numbers related to COC morphology 
COC graded as light had fewer (Gp 1, Gp 2, Gp 4: P<0.0001, Gp 3: P=0.001) CC compared 
to those that were graded as dark (Table 4B).  
 
CC numbers related to oocyte maturity 
COC associated with mature (i.e. MII stage) oocytes had fewer (P<0.01) CC compared to 
those associated with an immature (GV and MI stage) oocyte from women in Gp 1 and 4, 
whilst there was no significant difference in the same analysis between women in Gp 2 and 3 
(Table 4B; data from abnormal oocytes were excluded).  
 
CC numbers related to day 1-6 embryological development 
There were no significant differences in CC numbers of COC with respect to fertilization 
success or Day 3 of embryo development in the four groups (Table 4B). Similarly, there were 
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no differences in CC numbers in relation to blastocyst outcome in Gp 1, 2 and 3 (Table 4B). 
Due to DET and to low blastocyst formation rate in older women, single oocyte 
developmental potential in relation to the above criteria was not possible. 
 
CC numbers related to pregnancy and live birth outcome 
Comparisons for pregnancy and live birth outcomes were only carried out in Gp 1 women 
and there was no significant effect of CC number on positive outcome (Table 4B). It was not 
possible to use data from Gp 2 and 3 women due to low numbers of patients. As DET 
procedures were used in Gp 4 women, results associated with specific embryos that resulted 
in pregnancy and blastocyst outcomes were not possible.  
 
Table 4B: Summary of the relationship between CC numbers and oocyte developmental 
indicators in the four study groups. Different letters (a, b and c) not shared by variables across 
the rows denote significant differences between CC numbers (mean ± SEM) of individual 
COC between Gps 1-4 and; between CC numbers (mean ± SEM) of oocytes associated with 
positive and negative outcomes in each study group in relation to oocyte developmental 
indicators (# CC Gps 1-4, P<0.01; Day 0: COC, P=0.001; Oocyte genomic maturity, P<0.01; 
Day 1-6: Fertilization, not significant (NS), Day 3 embryonic development, NS, Blastocyst 
development, NS; Pregnancy, NS, Live birth outcome, NS; all indicators are relative to the 
total number of MII oocytes collected, with measurable RPL19 levels in associated CC). 
Abbreviations: NO = negative outcome that included unsuitable embryos or those that 
resulted in failed pregnancies or oocytes that failed to fertilize , n/a = not applicable due to 
low numbers of women in Gp 2 and 3 and due to DET procedures in Gp 4. 
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Indicators Gp 1 Gp 2 Gp 3 Gp 4 
# CC 
[mean±SEM] 28817 ± 1280 
ab 
32675 ± 869 
a
 26834 ± 2546 
ab
 26585 ± 1548 
b
 
Day 0         
COC Light Dark Light Dark Light Dark Light Dark 
# CC 
[mean±SEM] 
25273 
b
 
    ± 
1013 
46700 
a
 
   ± 
5049 
30885 
b
 
   ± 
1516 
59309 
a
 
   ± 
8305 
20493 
b
 
   ± 
1891 
36847 
a
 
   ± 
5136 
22206 
b
 
   ± 
1434 
37206 
a
 
   ± 
3584 
Oocyte 
maturity 
MII GV+MI MII GV+MI MII GV+MI MII GV+MI 
# CC 
[mean±SEM] 
27614 
b
 
   ± 
1156 
38500 
a
 
   ± 
6520 
32242 
± 
1723 
32321 
± 
4752 
27694 
± 
3124 
24726 
± 
5646 
25293 
b
 
   ± 
1559 
36992 
a
 
   ± 
5178 
Day 1-6         
Fertilization  2PN FF 2PN FF 2PN FF 2PN FF 
# CC 
[mean±SEM] 
28429 
± 
1339 
24209 
± 
2084 
32393 
± 
1888 
31625 
± 
4259 
25680 
± 
3593 
31147 
± 
5898 
25631 
± 
1886 
24175 
± 
2525 
Day 3 cleavage ≥7 cell ≤6 cell ≥7 cell ≤6 cell ≥7 cell ≤6 cell ≥7 cell ≤6 cell 
# CC 
[mean±SEM] 
28387 
± 
1573 
26452 
± 
1671 
31886 
± 
1948 
33006 
± 
3496 
23912 
± 
3785 
29901 
± 
4422 
22505 
± 
1925 
27951 
± 
2397 
Blastocyst Good NO Good NO Good NO Good NO 
# CC 
[mean±SEM] 
29519 
± 
2070 
27038 
± 
1370 
28719 
± 
3769 
32908 
± 
1921 
22847 
± 
4766 
28110 
± 
3369 
n/a n/a 
Pregnancy         
hCG (Day 14) ≥ 18 iu/l NO ≥ 18 iu/l NO ≥ 18 iu/l NO ≥ 18 iu/l NO 
# CC 
[mean±SEM] 
31857 
± 
3636 
27038 
± 
1370 
n/a n/a n/a n/a n/a n/a 
Live birth LB NO LB NO LB NO LB NO 
# CC 
[mean±SEM] 
30861 
± 
3951 
27038 
± 
1370 
n/a n/a n/a n/a n/a n/a 
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4.4 Discussion 
 
The major findings of this study were: 1) that as few as ~70 CC are needed to accurately 
measure the expression levels of multiple genes by multiplex QPCR using RPL19 as a 
housekeeping gene and; 2) that the mean ± SEM number of CC present in individual COC 
recovered for IVF treatment was 28872 ± 808. Previously, in a much smaller study, the mean 
CC number in a single COC was reported to be 11500 (Feuerstein et al. 2007). The 
differences in CC numbers reported in the present study compared to that by Feuerstein et al. 
(2007) are likely to be due  to 1) the significantly higher number of individual CC masses 
analysed in the present study, and/or 2) the differences in the follicular aspiration/oocyte 
denudation protocols (i.e. pressure of the aspiration pump), that could potentially have 
detrimental effects on the integrity of the outer layers of the CC mass, and therefore result in 
a higher cell loss (Larsen et al. 1986).  
 
In regards to the minimal number (~70) of CC needed for reliable QPCR measurements, it 
has to be noted, that these CC numbers have been validated for RPL19 and genes with similar 
abundance in CC. It is possible, that for the measurement of more lowly expressed genes, a 
higher number of CC would be needed. 
 
After morphological analyses of individual COC, it became evident that the shade grading 
(light to dark) of CC masses is related to cell number. Interestingly, CC masses that contained 
fewer cells were associated with mature oocytes in healthy patients. However, the 
relationship between cell number/CC mass and oocyte maturation may be associated with the 
breakdown of gap junctions in COC containing mature oocytes and thus fewer CC are still 
associated with the oocyte at collection: this breakdown of gap junctions occurs at the time of 
CC expansion (Gilula et al. 1978; Larsen et al. 1986). Therefore, the mechanical action of 
removing COC from those follicles containing a mature oocyte may result in CC loss. The 
finding that individual COC collected from women with PCOS tended to have a higher 
number of CC indicates a likely functional difference in CC of these women after the 
ovulation trigger. Previous studies have reported that morphologically indistinguishable MII 
oocytes from PCOS and healthy women exhibit different gene expression profiles (Wood et 
al. 2007) and our finding perhaps adds further evidence to the hypothesis that communication 
between the oocyte and the follicular environment is impaired or altered in women with 
PCOS (Willis et al. 1998; Rice et al. 2005). Nevertheless, the numbers of CC per CC mass 
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were no different for those that were associated with fertilization, good embryo development 
and blastocyst and pregnancy outcome compared to those that were associated with negative 
outcomes in the four groups. These findings add further evidence to the hypothesis, that 
morphological characteristics of CC are poor markers for oocyte quality. 
 
The pregnancy and live birth rates achieved by the SET procedures in young women, and the 
DET procedures in older women in this study were more than comparable with current 
international standards (Esinler et al. 2005; Klipstein et al. 2005; Saldeen et al. 2007; Sahu et 
al. 2008; Zander-Fox et al. 2011). Oocyte quality as measured by blastocyst development and 
pregnancy outcome (live birth) was highest in young and healthy women, and was 
significantly different to values in women with PCOS, diminished ovarian reserve or older 
women. These embryological results support the notion that when searching for molecular 
markers in CC for oocyte developmental potential, it becomes important to account for both 
age and reproductive health. In this context, the women recruited into Group 1 (i.e. healthy 
young women) of this study are a key subpopulation for identifying molecular markers to 
determine oocyte health based on blastocyst and pregnancy outcomes. 
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Chapter 5 EFFECT OF AGE, INFERTILITY BACKGROUND AND FSH 
TREATMENT ON HAS2, FSHR, SLC2A4 (GLUT4) mRNA LEVELS IN CUMULUS 
CELLS 
 
5.1 Introduction 
 
There have been reports describing the effects of age, BMI, antral follicle count, etc on the 
success of IVF treatments in women (Chang, Chiang et al. 1998; Gianaroli, Magli et al. 1999; 
Saldeen, Kallen et al. 2007; Orvieto, Meltcer et al. 2009). It has been reported that factors 
such as: 1) age (especially >37 years) is highly correlated with an increased incidence of 
embryonic chromosomal abnormalities (Gianaroli, Magli et al. 1999; Wells and Delhanty 
2000) and negatively correlated with pregnancy and live birth rate (Lass, Croucher et al. 
1998); 2) high BMI (>32 kg/m2) is positively correlated with cancellation rate, poor 
responses and the doses of gonadotrophins used per treatment cycle (Orvieto, Meltcer et al. 
2009; Pinborg, Gaarslev et al. 2011) and negatively correlated with pregnancy (Gillett, Putt et 
al. 2006); 3) increased basal serum FSH and decreased antral follicle count is positively 
correlated with treatment cancellation rates and negatively with pregnancy outcome (Toner, 
Philput et al. 1991; Chang, Chiang et al. 1998); 4) reduced serum AMH is indicative of a 
poor response and diminished ovarian reserve (van Rooij, Broekmans et al. 2002) and; 5) the 
presence of PCOS is indicative of compromised oocyte development (Wood, Dumesic et al. 
2007). 
 
Previous studies have revealed that some biological and/or treatment variables can influence 
the expression levels of certain genes in CC. For example, it was proposed that age may alter 
gene expression in oocytes (Grondahl, Yding Andersen et al. 2010) and in CC (Adriaenssens, 
Wathlet et al. 2010). It was further suggested that BMI, serum FSH concentrations, the type 
of gonadotrophin used for ovarian stimulation and serum oestradiol concentrations at the time 
of the ovulation trigger, can also alter the expression levels of certain genes in CC 
(Adriaenssens, Wathlet et al. 2010). Indeed, recent studies have confirmed that increased 
basal serum FSH levels affect the levels of gene expression in COC and that it might be one 
of the possible causes behind the reduced fertility potential in young women with diminished 
ovarian reserve (Greenseid, Jindal et al. 2011; Jindal, Greenseid et al. 2012). 
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The aims of this study were to investigate the influence of biological variables such as age, 
basal serum levels of FSH and AMH, BMI, PCOS and different gonadotrophin treatments 
(e.g. amount of rFSH and duration) on expression levels of candidate genes in CC isolated 
from individual COC recovered from women with different infertility backgrounds (see 
general methodology for details). For this specific study, the following three genes were 
selected:  
 
hyaluronidase synthase 2 (HAS2) is one of the key components in the extracelular matrix 
with an important role in cell proliferation (Toole 1997), cell migration (Turley 1992), tissue 
remodeling and wound healing (Kuroda et al. 2001) that is also expressed at peak levels in 
CC of pre-ovulatory follicles (Pienimaki et al. 2001). Indeed, the expression of HAS2 is 
critical for the formation and expansion of the CC mass and previously shown to have a 
positive correlation with age (Adriaenssens et al. 2010);  
 
follicle stimulating hormone receptor (FSHR) is expressed by granulosa cells (in the ovary) 
and by Sertoli cells (in the testis) and is required for the correct functioning of both female 
and male gonads (Griswold et al. 1995). In the ovary FSHR expression levels have been 
shown to be regulated by oocyte secreted factors which in turn are thought to mediate the 
actions of FSH on follicular cells (Otsuka et al. 2005) and;  
 
solute carrier 2, member 4 (SLC2A4, also known as GLUT4) is an insulin dependent glucose 
transporter protein with a role in glucose uptake, a process that is fundamental for any 
mammalian cell (Kaestner et al. 1990). In the COC, the oocytes have a poor capacity to 
utilize glucose and rely on CC to supply metabolic intermediates for energy production 
(Sutton et al. 2003). Furthermore, previously it has been reported that GLUT4 is one of the 
glucose transporters expressed in CC and its role may be critical in the correct development of 
the oocyte (Roberts et al. 2004).   
 
5.2 Materials and Methods  
 
In total, 68 women were allocated into four study groups as previously described (see 
Chapter 2 and 4). Hormonal stimulation, COC collection, embryo culture and transfer and 
luteal support were all performed as described in the General Methodology (Chapter 2 and 4, 
Appendix 2.1-2.2, 3.1-3.3). For quantification of target mRNA levels in individual CC 
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masses, quadriplex reaction mixes were prepared containing forward and reverse primers and 
TaqMan probes for the candidate genes (HAS2, FSHR, GLUT4) and a housekeeping gene 
(RPL19) at optimized concentrations. A detailed description of the QPCR methodology is 
presented in General Methodology (Chapter 2). Gene expression levels of the candidate 
genes in each sample are presented as fold-changes as previously described. 
 
Statistical analyses  
 
Gene expression levels are reported as mean fold change  S.E.M, whilst biological and 
treatment variables are reported as mean  S.E.M. Data were analysed by either one-or two-
way ANOVA using the SPSS statistical package (PASW Statistics 18, IBM, New York, 
USA). Mean  S.E.M. gene expression levels were calculated for each woman from mRNA 
levels of individual COC and their relationship with the following variables were calculated: 
1) biological variables: age, BMI, ethnicity, basal serum FSH, and where possible AMH, 
levels and; 2) treatment variables: daily doses of FSH used for ovarian stimulation, length of 
ovarian stimulation (days of stimulation with FSH), number of ≥14 mm follicles at ovarian 
follicle aspiration, serum oestradiol levels on the day of ovulation trigger and number of COC 
collected. All correlations between gene expression levels, biological and treatment variables 
were undertaken using 2-tailed Pearson’s R test. For group comparisons of the proportions of 
samples with measurable GLUT4 gene expression levels, a Chi-Square test was performed 
(SPSS statistical package, IBM). 
 
5.3 Results  
 
Biological variables: comparison of age, BMI, serum FSH and AMH levels between 
study groups 
The results of these studies are summarized in Table 5A. 
 
Age 
Amongst the young women in Gp 1-3, the mean age was significantly higher (P<0.05) for 
those in Gp 3 (i.e. those with diminished ovarian reserve) compared to those in Gp 1 
(healthy) and Gp 2 (PCOS). There were no age differences between Gp 1 and Gp 2.  
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BMI 
One of the conditions of enrolment for inclusion into Gp 1, Gp 3 and Gp 4 was a BMI of less 
than <28 kg/m
2
. However, for women with PCOS (Gp 2), a BMI equal to or higher than 28 
was accepted, according to FA clinicians’ recommendations. However, no statistical 
differences with respect to BMI were noted between the four study groups.  
 
Serum Anti-Müllerian hormone (AMH) levels  
Serum AMH levels were measured (as requested by FA clinicians) in 48.5% (33/68) of 
women enrolled for this study. The respective proportions for Gp 1-4 were 40% (10/25), 
36.4% (4/11), 91.7% (11/12) and 40% (8/20). Serum AMH levels were significantly higher in 
Gp 2, compared to Gp1, (P=0.001) Gp 3 (P<0.0001) and Gp 4 (P<0.0001) women. Gp 1 
women had higher serum AMH levels than that of Gp 3 and 4 women (P<0.0001), whilst 
there were no differences between women from Gp 3 and Gp 4.  
 
Basal serum FSH 
Basal serum FSH levels were significantly higher in women from Gp 3 compared to that in 
Gp 1 (P<0.0001), Gp 2 (P<0.0001) and Gp 4 (P<0.005). Women in Gp 4 had higher serum 
FSH levels than those in Gp 1 or 2 (P<0.0001), whilst there were no differences between Gp 
1 and Gp 2 women. 
 
Treatment variables: amount of rFSH, serum oestradiol levels, follicle number and the 
number of COC collected 
These results are also summarized in Table 5A. 
 
Exogenous rFSH treatment 
There were no differences in the duration of ovarian stimulation with exogenous rFSH 
between the four treatment groups (Table 5A). There were also no differences in the amount 
of exogenous rFSH used each day for ovarian stimulation for women in Gp 3 and 4. However 
the mean daily dose of rFSH administered to these groups were significantly higher 
(P<0.0001) compared to that administered to Gp 1 and 2. Moreover, the mean daily doses of 
rFSH used in Gp 2 women were lower (P<0.0001) than those used in women from Gp 1.  
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Serum oestradiol levels 
The mean serum oestradiol levels measured on the day of the ovulation trigger were the 
highest in women from Gp 1 and 2, and lowest in women from Gp 3 (Gp 2, P=0.004; Gp 1, 
P=0.016) with the levels in Gp 4 women being intermediate.  
 
Numbers of large (≥14 mm) follicles and COC collected  
The mean number of ≥14 mm follicles on the day of the ovulation trigger and the mean 
number of COC collected following transvaginal follicle aspirations were highest in women 
from Gp 1 and 2. The women in both these groups had significantly higher numbers of 
follicles present allowing for more COC to be collected, compared to that in Gp 4 (follicles, 
P<0.0001, COC, P<0.05) and Gp 3 (follicles and COC, P<0.0001) women. Women in Gp 4 
had significantly higher number of follicles (P<0.05) and subsequently COC collected 
(P<0.005) compared to that in Gp 3 women.  
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Table 5A: Summary of the biological and treatment variables and CC gene expression levels 
in the four study groups.  
 
Variable Unit 
Gp 1 
[mean ± SEM] 
Gp 2 
[mean ± SEM] 
Gp 3 
[mean ± SEM] 
Gp 4 
[mean ± SEM] 
Biological      
Age Year 32.1 ± 0.7 
c
 
30.6 ± 1.0 
c 
34.4 ± 0.7 
b
 
41.7 ± 0.5 
a 
BMI kg/m
2 
24.3 ± 0.6 25.5 ± 1.3 25.7 ± 1.0 24.7 ± 0.6 
AMH ng/mL 2.9 ± 0.3 
b 
7.7 ± 1.8 
a 
0.4 ± 0.1 
c 
0.5 ± 0.1 
c
 
Basal FSH IU/L 5.6 ± 0.3 
c
 4.8 ± 0.5 
c
 11.2 ± 0.6 
a
 8.6 ± 0.5 
b
 
Treatment      
rFSH (days) # 11.0 ± 0.3 11.6 ± 0.5 11.4 ± 0.5 11.4 ± 0.3 
rFSH (daily) IU 147 ± 3.5 
b
 100 ± 7.1 
c
 293 ± 6.2 
a
 279 ± 8 
a
 
E
2
 trigger pmol/L 7343 ± 622 
a
 8242 ± 534 
a
 4529 ± 967 
b
 6486 ± 682 
ab
 
≥14 mm follicles # 11.0 ± 0.5 
a
 11.6 ± 1.2 
a
 4.3 ± 0.6 
c
 6.5 ± 0.7 
b
 
COC collected # 11.0 ± 0.8 
a
 11.6 ± 1.1 
a
 4.1 ± 0.7 
c
 8.1 ± 0.8 
b
 
CC gene expression      
HAS2 
Arbitrary 
value 2.87  ± 0.15
 b
 2.18 ± 0.15
 c
 3.99  ± 0.30
 a
 4.24 ± 0.22
 a
 
FSHR 
Arbitrary 
value 0.55 ± 0.02
 c
 0.70 ± 0.02
 a
 0.56 ± 0.04
 bc
 0.64 ± 0.02
 ab
 
CC with measurable 
GLUT4 
% 5.19
 b
 3.91
 b
 6.12
 ab
 14.91
 a
 
 
Different letters (a, b and c) not shared by variables across the rows denote significant 
differences between Gps 1-4 (age, P<0.05; BMI, not significant (NS); AMH, P<0.001; basal 
serum FSH, P<0.005; days of rFSH, NS; daily rFSH, P<0.0001; total rFSH, P=0.001; E
2
 
trigger, P<0.05; number of ≥14 mm follicles, P<0.05; number of COC, P<0.05; HAS2 gene 
expression, P<0.005; FSHR gene expression, P<0.05; % measurable GLUT4, P=0.001).  
 
 
 
 
 80 
Gene expression levels and interrelationships 
 
Expression levels of HAS2 and FSHR mRNA were detectable in 99.2% (603/608) of the CC 
samples. Overall, the relative mean levels of HAS2 were higher (P<0.0001) than those for 
FSHR mRNA. Furthermore, there was a significant (P<0.0001) overall linear correlation 
between the CT values for HAS2 and FSHR in individual CC masses when the data for the 
four treatment groups were pooled (R
2 
= 0.6761). The respective R
2 
values for the individual 
groups were also highly correlated (Figure 5).  
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Figure 5: Linear regressions of Cycle Threshold (CT) values of HAS2 and FSHR mRNA in 
CC masses from women in Gp 1 (1), Gp 2 (2), Gp 3 (3), and Gp 4 (4).  
           
Expression levels of HAS2 mRNA were not different in CC recovered from women in Gp 3 
and 4 but both were significantly higher (P<0.005) compared to that from Gp 1 and 2. 
Furthermore, HAS2 expression levels were significantly higher (P=0.004) in CC recovered 
from women in Gp 1 compared to Gp 2 (Table 5A). Expression levels of FSHR were lowest 
in CC recovered from women in Gp 1 and 3, and highest in CC recovered from women in Gp 
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2 and 4 (Table 5A). The mRNA expression levels of GLUT4 were detectable in only 7.6% of 
samples. The respective proportions in Gps 1-4 were 5.2% (14/270), 3.9% (5/128), 6.1% 
(3/49) and 14.9% (24/161). The proportion of measurable GLUT4 levels was highest in Gp4 
(Table 5A). Differences in mean GLUT4 gene expression levels between the four groups 
were not analysed due to the low percentage of samples with detectable expression levels. 
 
Interrelationships amongst CC gene expression levels and biological and treatment 
variables 
 
HAS2 gene expression levels  
There was a highly significant linear correlation between the HAS2 gene expression levels 
and basal serum FSH levels (Table 5B) and daily doses of rFSH (Table 5B) used for ovarian 
stimulations. There were highly significant linear correlations of HAS2 mRNA levels with 
patient age (Table 5B) and with serum AMH levels (Table 5B). Furthermore, there were 
highly significant linear correlations between age, basal FSH and AMH levels (Appendix 5). 
However, there was no significant correlation between HAS2 mRNA levels and BMI (Tabel 
5B). In regards to other treatment variables, there were highly significant linear correlations 
between HAS2 mRNA levels and the numbers of ≥14 mm follicles present on the day of the 
ovulation trigger, and also the mean number of COC collected following transvaginal follicle 
aspirations (Table 5B). However, there were no correlations between HAS2 mRNA levels and 
serum oestradiol levels (Table 5B). The amounts of rFSH used for ovarian stimulation in 
individual woman were highly correlated with oestradiol levels (P=0.001) and the numbers of 
≥14 mm follicles (P<0.0001) measured on the day of ovulation trigger, as well as the number 
of COC collected (P<0.0001) following transvaginal follicle aspiration (Appendix 5). There 
was also a highly significant correlation between the numbers of follicles ≥14 mm and 
number of COC collected (P<0.0001), and with oestradiol levels measured on the day of 
ovulation trigger (P<0.0001) (Appendix 5). 
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Table 5B: Summary showing the Pearson correlation coefficients and significance levels (P 
values) between HAS2 or FSHR mRNA levels and biological and treatment variables in the 
68 women recruited in the four study groups. NS refers to no correlation (P>0.05).  
 
Variable HAS2 FSHR 
 Pearson’s R  Sig. (P value) Pearson’s R  Sig. (P value) 
Biological     
Age 0.324 0.007 -0.029 NS 
BMI 0.042 NS -0.072 NS 
AMH -0.512 0.002 0.055 NS 
Basal FSH 0.309 0.011 -0.064 NS 
Treatment     
rFSH (days) -0.031 NS 0.080 NS 
rFSH (daily) 0.453 <0.0001 0.034 NS 
E
2
 trigger -0.205 NS -0.178 NS 
≥14 mm 
follicles 
-0.375 0.002 -0.016 NS 
COC collected -0.321 0.008 0.009 NS 
 
………………………………………………………………………………………… 
 
FSHR gene expression levels 
There were no significant linear correlations between FSHR mRNA levels in CC and 
biological or treatment variables (Table 5B). 
 
GLUT4 gene expression levels 
The proportion of samples with measurable GLUT4 expression was not correlated with 
patient age when the data were analysed for individuals (Pearson’s R=0.222, P=0.069) but 
was significantly correlated when the data for each of the treatment groups were pooled 
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(Pearson’s R=0.987, P<0.05) (data not shown). With regards to GLUT4 expression and other 
biological and treatment variables, no other correlations were observed. 
 
5.4 Discussion  
 
Our data supports the concept that the ovarian and endocrine status, as well as rFSH 
treatment, seems to have profound effects on the levels of gene expression in CC 
(Adriaenssens et al. 2010). This interpretation is based on an examination of the levels of the 
two highly expressed genes (HAS2 and FSHR) and the abundance of a lowly-expressed gene 
(GLUT4) which, to varying degrees differed in individuals recruited in the four study groups.  
  
The mean expression levels of HAS2 mRNA were the highest in women with diminished 
ovarian reserve (young and older) and the lowest in women with PCOS. On the other hand, 
expression levels of FSHR mRNA were the highest in young women with PCOS and lowest 
in young and healthy women. Furthermore, the proportion of CC masses with measurable 
GLUT4 levels was highest in women ≥40yr of age (Gp 4). Previous studies that have 
investigated CC and GC gene expression levels in relation to infertility reported that some 
genes (i.e. the IGF gene family, Gremlin 1) are impaired in young women with diminished 
ovarian reserve compared with those with a normal age-related reserve, highlighting the 
importance of ovarian factors (Greenseid et al. 2011; Jindal et al. 2012).  
 
The mean expression levels of FSHR mRNA in individual CC masses were the highest in 
women with PCOS. This finding correlates well with previous reports, where it was noted 
that FSHR mRNA levels are higher in GC (pooled from several follicles) from women with 
PCOS compared with women with normal ovarian function and women with poor ovarian 
reserve (Almahbobi et al. 1996; Cai et al. 2007; Catteau-Jonard et al. 2008; Gonzalez-
Fernandez et al. 2010). However, in these studies, the FSHR mRNA expression levels in 
pooled GC were lower in women with poor ovarian reserve compared with control whereas 
in the present study no differences were found for individual CC with the same comparison.  
 
The relationship analyses revealed that the HAS2 mRNA levels showed the strongest 
association with the exogenous rFSH used for ovarian stimulation. There is substantial 
evidence to show that HAS2 expression is markedly up-regulated in COC undergoing 
cumulus expansion and final oocyte maturation under the regulation of gonadotrophins 
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(Kimura et al. 2002; Ochsner et al. 2003; Schoenfelder and Einspanier 2003; Su et al. 2003; 
Romero et al. 2011). Indeed, cumulus expansion requires gonadotrophin-dependent up-
regulation of several key mucification genes including PTGS2, PTX3, TNFAIP6 as well as 
HAS2 (Elvin et al. 1999; Fulop et al. 2003; Salustri et al. 2004). Therefore, the strong 
correlation between the mean HAS2 and FSHR expression levels in CC is not surprising and 
is consistent with the increased production of hyaluronic acid in COC in response to FSH 
(Eppig 1979; Salustri et al. 1989; Buccione et al. 1990b). Furthermore, HAS2 gene 
expression level was positively correlated with basal serum FSH and age, and negatively 
correlated with serum AMH levels, numbers of large follicles (≥14 mm) on the day of 
ovulation trigger and also with numbers of oocytes collected. The tight correlations between 
basal FSH levels with certain biological variables and treatments are consistent with previous 
reports. For example, previously it has been shown that basal serum FSH levels increase 
progressively with reproductive age (Ahmed Ebbiary et al. 1994) and the age-related 
increases in doses of gonadotrophins used for ovarian stimulation in IVF (Sharif et al. 1998). 
Moreover, basal FSH levels have been reported to be negatively correlated with serum AMH 
levels (Pigny et al. 2003), peak serum oestradiol levels (Hohmann et al. 2005), numbers of 
large follicles present on the ovaries and thus oocytes collected (Scott et al. 1989; Ebrahim et 
al. 1993). In regards to previous gene expression studies, HAS2 mRNA levels in CC have 
been reported to be positively correlated to age (Adriaenssens et al. 2010), however positive 
associations of HAS2 mRNA levels to other variables such as basal serum FSH 
concentrations, doses of rFSH used for stimulation, serum oestradiol levels, numbers of large 
follicles present and thus to numbers of oocytes collected have not been reported hitherto. 
The highly significant correlation between HAS2 expression levels, the amount of rFSH used 
for stimulation and the basal serum FSH concentrations, taking into account the role of FSH 
in regards to hyaluronic acid synthesis in CC, confirms that HAS2 gene expression levels in 
CC is primarily correlated to serum FSH levels. The influence of age may only be a 
secondary factor, as this correlation could be, at least partly, attributed to increased basal 
serum FSH levels associated to older women (Ahmed Ebbiary et al. 1994).  
 
With regards to biological and treatment variables, the expression levels of FSHR mRNA in 
CC showed no relationship to any of the variables.  
 
The finding that the proportion of measurable GLUT4 samples tended to be positively 
correlated with age is perhaps surprising as the risk of developing insulin resistance increases 
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with age (Defronzo 1979): the abundance of GLUT 4 mRNA is tightly correlated with insulin 
responsiveness in porcine and human granulosa cells (Yan et al. 2009; Rice et al. 2011) and 
human adipocytes (Rosenbaum et al. 1993). Interestingly, expression levels of GLUT 1 and 
3, and to a lesser extent GLUT 4, were similar in bovine follicles at all developmental stages, 
with the exception of dominant oestrogen-inactive follicles undergoing atresia whereby 
message levels were significantly higher and inversely proportional to glucose concentrations 
in follicular fluid (Nishimoto et al. 2006). Therefore, it is possible that a higher proportion of 
COC obtained from the older women in this study were from follicles beginning to undergo 
atresia. 
 
In conclusion, the present study provides further evidence that the expression of some 
candidate genes in CC may be affected by various biological and/or treatment variables. 
Thus, in searching for gene expression markers in CC to determine the selection of oocytes 
for positive pregnancy outcomes these and other possible variables should always be taken in 
consideration. 
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Chapter 6 MESSENGER RNA LEVELS IN CUMULUS CELLS: RELATIONSHIPS 
TO EMBRYOLOGICAL AND PREGNANCY OUTCOMES  
 
6.1 Introduction 
 
In recent years, several research groups have explored the possibility that gene expression 
activity in CC may provide a non-invasive method during IVF of selecting oocytes with a 
greater likelihood of a successful pregnancy outcome. The first genes investigated were genes 
responsible for the synthesis of the COC extracellular matrix proteins, hyaluronidase synthase 
2 (HAS2), pentraxin 3 (PTX3), tumour necrosis factor α–induced protein 6 (TNFAIP6) and 
those involved in cumulus cell signalling such as gremlin 1 (GREM1) and prostaglandin-
endoperoxide synthase 2 (PTGS2) (McKenzie, Pangas et al. 2004). Several subsequent 
studies investigated the same group of genes, however the results have proved to be 
inconclusive and variable (Zhang, Jafari et al. 2005; Cillo, Brevini et al. 2007; Anderson, 
Sciorio et al. 2009). Currently, many  more genes have been investigated, such as those 
involved in the secretion of COC extracellular matrix (versican), cumulus cell signalling 
(amphiregulin, connexin 43, aryl hydrocarbon receptor, steroid sulfatase, steroidogenic acute 
regulatory protein, syndecan 4, calmodulin 2, etc), metabolic pathways (stearoyl-CoA 
desaturase 1 and 5, aldolase A, lactate dehydrogenase A, phosphofructokinase, pyruvate 
kinase, etc) (Feuerstein, Cadoret et al. 2007; Adriaenssens, Wathlet et al. 2010; Gebhardt, 
Feil et al. 2011; Wathlet, Adriaenssens et al. 2011). Although some of these studies showed 
that mRNA levels in CC have the potential to fulfil the criteria for oocyte quality markers in 
selected groups of oocytes, none have reported significant associations of gene expression 
levels to good blastocyst development and pregnancy outcome in relation to total number of 
oocytes available after follicular aspirations. 
 
The aims of the present study were to investigate the abundance of and interrelationships 
amongst a selected number of CC expressed genes and to determine whether the mRNA 
expression levels of these genes were correlated to oocyte quality as measured by blastocyst 
development and pregnancy outcome after follicular aspirations in young and healthy 
women.  
 
For these investigations the following six candidate genes were selected:  
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hyaluronidase synthase 2 (HAS2) and follicle stimulating hormone receptor (FSHR) (see 
Introduction part of Chapter 5 for details);  
 
versican (VCAN) is a chondroitin sulfate proteoglycan, a major component of the COC 
extracellular matrix that binds to hyaluronan (Naso et al. 1994). Versican has major roles in 
the control of cellular growth, cell differentiation (Naso et al. 1994), cell adhesion, migration 
and regeneration (Lebaron 1996). Furthermore,  it has previously been reported as one of the 
most promising oocyte quality markers in CC (Adriaenssens et al. 2010; Gebhardt et al. 2011; 
Wathlet et al. 2011); 
 
activated leukocyte cell adhesion molecule (ALCAM), is a gene that belongs to the 
immunoglobulin family, which mediates homophilic (ALCAM - ALCAM) and heterophilic 
(ALCAM-CD6) cell to cell interaction (Bowen and Aruffo 1999). It is known to be involved 
in cell adhesion and/or signaling (Bowen and Aruffo 1999), cell migration (Sanders et al. 
2011), in  the formation and function of the lymphatic system (Iolyeva et al. 2012) and in the 
initial step of human embryo implantation (Fujiwara et al. 2003). More importantly it is 
expressed in CC and it has been proposed that could be a potential oocyte quality marker 
(Adriaenssens et al. 2010; Wathlet et al. 2011);  
 
progesterone receptor (PR), a gene expressed in humans in the dominant follicle following 
the initiation of the LH surge and continues to be expressed also in the active corpus luteum 
(Iwai et al. 1990). The expression of PR is critical for follicular growth and development, 
luteinization and successful ovulation (Robker et al. 2009). It is also essential for a successful 
implantation although little is known about the role of this gene during the peri-conception 
period (Robker et al. 2009) and;  
 
neuropilin 1 (NRP1) is a membrane-bound co-receptor to tyrosine kinase receptor for 
vascular endothelial growth factor and members of the semaphorin family proteins. 
Neuropilin 1 is involved in the angiogenic and neuronal traffic through the cytoskeleton, in 
cell assembly and interaction and more importantly in vesicle guidance and transport in 
follicles following oestradiol induction. Moreover, in a preliminary study it was reported that 
its up-regulation gene expression in CC may potentially indicate oocyte with positive 
pregnancy outcome (Assidi et al. 2011). 
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6.2 Materials and Methods  
 
In total, 270 COC were collected from 25 young and healthy women (Gp 1). Hormonal 
stimulation, COC collection, embryo culture and transfer and luteal support were all 
performed as described in the General Methodology (Chapter 2 and 4, Appendix 2.1-2.2 and 
3.1-3.3). For quantification of target mRNA levels in individual CC masses, multiplex 
reaction mixes were prepared containing forward and reverse primers and TaqMan probes for 
the candidate genes [HAS2, FSHR, GLUT4 (Reaction 1); SFRP2, ALCAM (Reaction 2); and 
VCAN, PR and NRP1 (Reaction3)] and the housekeeping gene (RPL19) at optimized 
concentrations. A detailed description of the QPCR methodology including measurements of 
relative gene expression levels using the calibrator and RPL19 are presented and/or validated 
in General Methodology (Chapter 2) and Chapter 3. 
 
Statistical analyses  
 
Gene expression levels are reported as mean fold change  S.E.M. Data were subjected to 
either one-or two-way ANOVA using the SPSS statistical package (PASW Statistics 18, 
IBM, New York, USA). The expression levels of candidate genes were assessed in relation to 
oocyte developmental stages as described in Chapter 4 so that appropriate comparisons with 
published reports can be made (Adriaenssens et al. 2010; Wathlet et al. 2011). In brief, 
statistical differences were calculated for candidate mRNA levels in relation to 1) COC 
morphology, 2) oocyte maturity, 3) fertilization rate, 4) good embryonic development on day 
3, 5) blastocyst development, 6) pregnancy rate and, 7) live birth outcome. All comparisons 
were made relative to the total number (N=270) of oocytes collected following follicle 
aspirations. 
 
6.3 Results 
 
Gene expression levels in cumulus cells 
 
Expression levels of HAS2, FSHR, ALCAM, VCAN, NRP1 and PR mRNA were detectable in 
98.5% (266/270) of samples, whilst the proportion of samples with detectable levels of 
GLUT4 and SFRP2 were low (5.2 and 0.4% respectively). Overall, the relative expression 
levels of VCAN mRNA were the highest, followed by those of NRP1, HAS2, ALCAM, FSHR 
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and PR: the statistical differences were VCAN vs NRP1, P<0.0001; NRP1 vs HAS2, 
P<0.0001; HAS2 vs ALCAM, P<0.05; ALCAM vs FSHR, P<0.0001 and; FSHR vs PR, NS). 
There were highly significant (P<0.0001) linear correlations in raw CT values between all six 
abundant candidate genes in individual CC masses (Figure 6A). The relationship between 
these six genes (normalized gene expression (2
^(-ΔΔCT)
 values)) was also verified using 
principal component analysis (PCA) using the software R (www.r-project.org/), where 
similar results were noted. Analysing the expression data of the six genes derived from the 
227 COC, it was found that the first two principal components explained 67.7% of the total 
variance (Appendix 6).   
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Figure 6A: Linear regressions of Cycle Threshold (CT) values of HAS2 and FSHR (1), HAS2 
and ALCAM (2), HAS2 and VCAN (3), HAS2 and NRP1 (4), HAS2 and PR (5), VCAN and 
FSHR (6), VCAN and ALCAM (7), VCAN and NRP1 (8), VCAN and PR (9), FSHR and 
ALCAM (10), FSHR and NRP1 (11), FSHR and PR (12), ALCAM and NRP1 (13), ALCAM 
and PR (14) and, NRP1 and PR (15) mRNA in CC masses. 
 
Gene expression levels related to COC morphology  
Mean mRNA levels for ALCAM were significantly lower (P<0.05) in COC classified as light 
compared to those classified as dark, whilst the expressions of all other candidate genes were 
similar (Figure 6B). 
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Figure 6B: Relative expression levels of candidate genes in CC associated with light (light 
blue histogram) and dark (dark blue histogram) COC. Values represent the means and SEM. 
*P<0.05, NS. 
 
Gene expression levels related to oocyte maturity  
Mean mRNA levels for VCAN and HAS2 were significantly lower (VCAN, P<0.0001; HAS2, 
P<0.05), whilst those of FSHR and ALCAM tended to be lower (P=0.086, P=0.054) in CC 
associated with oocytes that progressed to metaphase II (mature oocytes; MII) compared to 
those CC that remained immature (e.g. GV and MI). The mean NRP1 and PR mRNA were 
not different in CC associated with mature or immature oocytes (Figure 6C).  
 
 
Figure 6C: Relative expression levels of candidate genes in CC associated with MII oocytes 
(light blue histogram) and with MI and GV oocytes (dark blue histogram). Values represent 
the means and SEM. ****P<0.0001, *P<0.05. 
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Gene expression levels related to fertilization  
Mean mRNA levels for all genes were similar in CC associated with oocytes that fertilized 
normally (2PN) compared with those that either failed to fertilise or were abnormal (i.e. 1PN, 
3PN) (Figure 6D).  
 
 
Figure 6D: Relative expression levels of candidate genes in CC associated with oocytes that 
fertilized normally (light blue histogram) and with oocytes that failed to fertilize or were 
abnormal (i.e. 1PN, 3PN) (dark blue histogram). NS. 
 
Gene expression levels related to early embryonic development 
Mean mRNA levels for all genes were similar in CC associated with oocytes that progressed 
to embryonic cleavage quickly (≥7 cell on day 3) compared with those that resulted in slow 
embryonic cleavage (≤6 cell on day 3) and arrested development (Figure 6E).  
 
 
Figure 6E: Relative expression levels of candidate genes in CC associated with oocytes that 
progressed to embryonic cleavage quickly (≥7 cell on day 3) (light blue histogram) and with 
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oocytes that resulted in slow embryonic cleavage (≤6 cell on day 3) and arrested development 
(dark blue histogram). NS. 
 
Gene expression levels related to blastocyst development 
Mean mRNA levels were significantly higher for HAS2 (P<0.05); VCAN (P<0.005); PR 
(P<0.05) in CC associated with oocytes that progressed to a good quality blastocyst 
compared to CC associated with oocytes that failed to reach a viable blastocyst stage (Figure 
6F). The expression levels for FSHR, ALCAM and NRP1 did not differ in CC that formed 
good blastocysts or failed to reach that stage. 
 
 
 
Figure 6F: Relative expression levels of candidate genes in CC associated with oocytes that 
progressed to good quality blastocyst (light blue histogram) and to oocytes with failed 
development (dark blue histogram). Values represent the means and SEM. ***P<0.005, 
*P<0.05, NS. 
 
Gene expression levels related to pregnancy outcome 
Mean mRNA levels for VCAN were significantly higher (P<0.05) and HAS2 tended to be 
higher (P=0.079) in CC associated with oocytes that progressed to a positive hCG level 
compared to levels in CC associated with negative outcome (data of CC associated with 
oocytes that progressed to good quality blastocysts and were frozen, were not included in this 
comparison). Mean mRNA levels for all other genes were not different for the same 
comparisons (Figure 6G).  
 97 
 
Figure 6G: Relative expression levels of candidate genes in CC associated with oocytes that 
progressed to positive pregnancy (light blue histogram) and with oocytes associates with 
failed development (dark blue histogram). Values represent the means and SEM. *P<0.05, 
NS. 
 
Gene expression levels related to live birth outcome 
Mean mRNA levels for VCAN were significantly higher (P<0.05) in CC associated with 
oocytes that resulted in a healthy term live birth outcome compared to CC associated with 
negative outcome (data of CC associated with oocytes that progressed to good quality 
blastocysts and were frozen, were not included in this comparison). Mean mRNA levels for 
all other genes were similar in the same comparison (Figure 6H). 
 
 
Figure 6H: Relative expression levels of candidate genes in CC associated with oocytes that 
resulted in a healthy term live birth (light blue histogram) and to oocytes associated with 
failed development (dark blue histogram). Values represent the means and SEM. *P<0.05, 
NS. 
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6.4 Discussion 
 
The present study is the first to investigate the gene expression levels of multiple candidate 
genes in individual human CC samples in relation to blastocyst development and pregnancy 
outcome by multiplex TaqMan QPCR.  
 
The major finding in this study was the highly significant increase in mRNA expression 
levels of HAS2, VCAN and PR in CC from oocytes that developed into embryos that 
progressed to pregnancy and/or blastocysts that were selected for freezing compared to the 
expression levels in CC associated with oocytes with failed development. Moreover, the 
present study is the first to report a significant increase in mRNA expression levels of VCAN 
in CC from oocytes that resulted in a live birth relative to the total number of MII oocytes 
available after follicle aspiration. 
 
From a review of twelve previous reports on the relationship between CC gene expression 
levels and human embryological and pregnancy outcomes in which numerous genes have 
been investigated (e.g. GREM1, HAS2, PTGS1, PTGS2, PTX3, TNFAIP6, PR, STAR, COX2, 
CX43, AREG, SCD1, SCD5, BCL2L11, PCK1, NFIB, ALCAM, SDC4, VCAN, CALM2), no 
previous study has found a statistically significant correlation between mRNA expression 
levels in CC and blastocyst and pregnancy outcome of the associated oocyte within the total 
number of MII oocytes available following oocyte retrieval (McKenzie et al. 2004; 
Hasegawa et al. 2005; Zhang et al. 2005; Cillo et al. 2007; Feuerstein et al. 2007; Assou et 
al. 2008; Hamel et al. 2008; van Montfoort et al. 2008; Anderson et al. 2009; Adriaenssens et 
al. 2010; Gebhardt et al. 2011; Wathlet et al. 2011). 
 
In human IVF, where the majority of MII oocytes appear morphologically identical, the ideal 
set of oocyte quality markers would be those able to predict embryo potential from all MII 
oocytes available. Our study is the first to accurately determine the mRNA expression levels 
of HAS2, VCAN and PR in individual human CC masses associated with oocytes that 
developed into good quality blastocysts (embryos that progressed to pregnancy and blastocyst 
frozen for subsequent use) following IVF with respect to the number of MII oocytes 
recovered. Previous QPCR studies reported (1) lower (P<0.05) mRNA expression levels for 
STAR, COX2, CX43, AREG, SCD1, SCD5 genes in CC associated with oocytes that 
developed to blastocyst compared with oocytes that did not become blastocyst (Day 5 or Day 
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6 assessment) (Feuerstein et al. 2007) and (2) higher SDC4 (P<0.05), ALCAM (P<0.01) and 
lower VCAN (P<0.01) levels of oocytes that developed to blastocyst on Day 5 (Wathlet et al. 
2011). However, neither of these studies reported statistical differences in relation to the total 
number of MII oocytes recovered. Perhaps this may be the underlying reason why these 
authors found that higher ALCAM and lower VCAN mRNA levels in CC were associated with 
blastocyst development, whilst our results show that blastocyst formation is correlated to 
higher CC mRNA levels of VCAN, whilst mRNA levels of ALCAM are not correlated to good 
blastocyst development. 
 
Similarly, no previous study has reported statistical differences in CC-derived gene 
expression levels in regards to pregnancy outcome when considering the total number of MII 
oocytes recovered. One previous study reported higher (P<0.01) levels of CC-derived PTX3 
levels associated with 8-cell (Day 3) embryos that progressed to pregnancy compared with 
oocytes with failed fertilization, but no significant differences compared with 8-cell (Day 3) 
embryos with failed implantation (Zhang et al. 2005). Another study reported no significant 
differences in the expression levels of HAS2, BDNF, GREM1, PTGS2, TNFAIP6 and PTX3 
genes, in relation to pregnancy. However, most of the women involved in the aforementioned 
study had double embryo-transfers thereby preventing a clear analysis of embryo outcome 
(Anderson et al. 2009). A recent study using antagonist rFSH, but not agonist HP-hMG, 
stimulated IVF cycles reported that CC mRNA levels of SDC4, VCAN (P<0.001), ALCAM, 
TRPM7, ITPKA (P<0.01), GREM1 and PTGS2 (P<0.05) were higher in CC associated with 
transferred embryos that progressed to pregnancy compared with CC associated with 
transferred embryos with failed implantation (Wathlet et al. 2011). In a similar analysis it was 
confirmed that VCAN and PTGS2 levels are higher in CC associated with transferred 
embryos that resulted in live births compared to CC associated with transferred embryos with 
failed implantation (Gebhardt et al. 2011). In the present study, comparing data obtained 
from the small number of oocytes that resulted in an embryo transfer and culminated into a 
live birth against the data obtained from the large number of oocytes that resulted in negative 
outcome, VCAN expression levels were significantly higher and HAS2 expression levels were 
more frequently higher in CC of oocytes associated with live birth (data from CC associated 
with oocytes that resulted in good quality blastocysts and were frozen for subsequent use 
were left out of this analysis, as outcome of those embryos is not known yet). 
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It is evident that the expression levels of HAS2 and VCAN are good predicators of oocyte 
maturity. This is in line with previous reports by Adriaenssens et al (2010) and Wathlet et al 
(2011) who showed that VCAN expression in CC was negatively correlated with oocyte 
maturity. With respect to previous studies of HAS2 in relation of oocyte maturity, the results 
have generally been variable (McKenzie et al. 2004; Anderson et al. 2009; Adriaenssens et 
al. 2010). Overall, the mRNA levels of the eight genes presented in this study are poor 
predictors of successful fertilization and early embryo cleavage. These findings are consistent 
with those in previous reports (McKenzie et al. 2004; Hasegawa et al. 2005; Cillo et al. 2007; 
Anderson et al. 2009; Adriaenssens et al. 2010; Wathlet et al. 2011).  
 
In conclusion, the results from this study suggest that the mRNA levels of VCAN, HAS2 and 
PR in CC have the highest potential to serve as molecular markers for key indicators of 
oocyte development, namely blastocyst formation and live birth outcome.  
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Chapter 7 RANKING OF INDIVIDUAL COC ACCORDING TO CC GENE 
EXPRESSION LEVELS AND CC NUMBERS AND THE SELECTION OF OOCYTES 
WITH HIGH DEVELOPMENTAL POTENTIAL  
 
 
7.1 Introduction 
 
Stimulated IVF cycles result in significantly higher pregnancy rates compared to natural IVF 
cycles (Pelinck et al. 2002), however live birth rates arising from the numbers of oocytes 
recovered  is very low (~7%) (Li et al. 2008; Patrizio and Sakkas 2009). This is perhaps not 
surprising as most follicles within the ovary have different endocrine and nutrient 
microenvironments, as well as somatic cells at different stages of maturation (McNatty et al. 
2010). Moreover, studies in sheep have shown that super-ovulation regimes do not effectively 
override the hierarchical pattern of follicular development, where most, if not all, antral 
follicles within an ovary respond individually and not identically to gonadotrophins (McNatty 
et al. 1990; McNatty et al. 1999; McNatty et al. 2010). Currently, there are no reliable non-
invasive methods which enable the selection of good quality oocytes to be distinguished from 
poor quality oocytes following their recovery in stimulated IVF cycles (Rienzi et al. 2011).  
 
Two important questions are still waiting to be answered for human gonadotrophin-stimulated 
IVF cycles. The first is “Can we develop reliable markers for the selection of good quality 
oocytes following the stimulation of multiple pre-ovulatory follicles?” and the second is 
“What is the level of synchronization of the MII oocytes collected following gonadotrophin 
stimulation?” To answer these questions, the mRNA levels of six candidate genes (HAS2, 
FSHR, ALCAM, VCAN, NRP1, PR) in CC, and numbers of CC from individual COC using 
multiplex QPCR techniques were assessed: (1) in relation to oocyte development (as indicated 
by blastocyst development and pregnancy) and; (2) the extent to which the mRNA levels in 
CC are consistently uniform amongst MII oocytes.   
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7.2 Materials and Methods 
 
From the 25 women recruited in Gp 1 in which COC were collected, the CC masses were 
removed from their associated oocytes and processed individually by TaqMan QPCR for 
expression levels of six candidate genes (HAS2, FSHR, ALCAM, VCAN, NRP1, PR). The 
expression levels of a housekeeper gene (RPL19) were also measured for correction of 
candidate gene expression levels and for determining the number of CC present for each CC 
mass. The methodologies including hormonal stimulations, COC collections, embryo culture 
and transfer, luteal support, calculation of CC numbers and quantification of target mRNA 
levels were all performed as previously described (Chapter 2-4 and 6, Appendix 2.1-2.2 and 
3.1-3.3).  
 
Oocyte selection by random selection 
The probability of selecting at least one good quality oocyte (measured by good blastocyst 
development and pregnancy) from a random selection of one or three COC from the total 
number of MII oocytes recovered from one woman was calculated according to the formula: 
 P = 1 – (xneg/xtot)n 
where P = probability, x
neg
 = number of oocytes with negative outcome, x
tot
 = number of total 
oocytes collected, n = number of COC selected. From these probability values, the mean 
probability ± SEM of selecting a good quality oocyte was calculated for Gp 1 women.  
 
Ranking analysis of CC numbers in individual COC 
The number of CC and 2xStDev were calculated from the repeated measurement (N=68) of 
the reference gene of the calibrator sample present in every QPCR run. Following the 
calculation of CC numbers for each COC, these were ranked with 1 being indicated for the 
lowest and thereafter sequentially to the highest. Individual COC within each patient were 
considered statistically different from each other if the number of CC differed by 2xStDev. 
Samples that showed similar CC numbers with two or more separate ranks (i.e. 1 and 2), were 
grouped in the lower ranks (i.e. 1) to simplify the analysis.  
The proportion of individual COC with different CC numbers (i.e. different ranks) was 
calculated for each woman and the mean proportion ± SEM was then determined.  
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Ranking of gene expression in individual COC 
For the individual CC samples, the 2
-ΔCT
 values were calculated for each of the six candidate 
genes as described in the General Methodology (Chapter 2). Similarly, the 2xStDev of 2
-ΔCT
 
values were calculated for each gene from the repeated measurement of the calibrator sample. 
Individual COC samples from each woman were then ranked from lowest to highest with 
respect to gene expression levels (2
-ΔCT
). The individual values within each patient were 
considered statistically different from one another if their expression values (2
-ΔCT
) differed 
by 2xStDev. In each patient, the gene expression level with the lowest 2
-ΔCT
 value was ranked 
1, whilst those with significantly higher 2
-ΔCT
 values were ranked 2, and those with 
significantly higher 2
-ΔCT
 values compared with rank 2 were ranked 3, etc. Samples that 
showed similar gene expression (2
-ΔCT
) values to two or more separate ranks (i.e. 1 and 2), 
were grouped in the lower ranks (i.e. 1) to simplify the analysis. 
The proportion of individual COC with different gene expression levels (i.e. different ranks) 
was calculated for each gene within each patient and a mean proportion ± SEM was 
calculated for the women in Gp 1. Finally, the mean proportion ± SEM of COC showing 
significantly different expression levels for each of the genes was then determined.  
 
Ranking of individual COC for oocyte selection 
The COC from each patient were ranked according to CC numbers and mRNA expression 
levels for each of the six candidate genes. These COC ranks were then analysed for each 
individual parameter, or collectively for groups of parameters, in relation to the outcome of 
their associated oocyte (good blastocyst and live birth) to determine potential indicators of 
oocyte quality.  
 
To determine the most successful method for selecting at least one good quality oocyte, all 
selection methods i.e. 1) using all COC recovered, 2) randomly selecting one or three of the 
recovered COC and 3) selecting one or three of the recovered COC according to ranking (see 
previous paragraph) were compared by one- and/or two-way ANOVA (SPSS).   
 
To determine the level of heterogeneity of MII oocytes, the level of synchronization of the 
number of CC and levels of mRNA (HAS2, FSHR, ALCAM, VCAN, NRP1, PR) in individual 
COC was assessed. The level of heterogeneity of MII oocytes was further analysed in regards 
to the level of synchronization of the pre-ovulatory follicles (≥14 mm). 
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7.3 Results 
 
Follicle diameters on the day of hCG treatment 
 
From the 11 ± 0.5 follicles of ≥14 mm in size that were present on the day of administration 
of hCG, 5.0 ± 0.5 (43 ± 3%) were of identical diameter (data not shown). 
 
Ranking analysis of individual COC 
 
Ranking analysis of individual COC based on CC numbers 
Of the 232 oocytes that developed to the MII stage of maturation, 227 (9.1 ± 0.7/patient, 
range: 3-15) were associated with CC samples that had measurable RPL19 levels from which 
CC numbers were estimated. Of these, 61 ± 3% (5.2 ± 0.3/patient) [range: 40% (Patient #9) to 
100% (Patient #1) or 6/15 to 3/3] COC were significantly different in numbers of CC within 
the total number of COC for each woman (Figure 7A). 
 
 105 
 
 
1) 
0 
20000 
40000 
60000 
80000 
100000 
   P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 
Patients 
C
C
 n
u
m
b
e
rs
 
n
u
m
b
e
rs
 
+ 
+ + + 
+ 
+ 
+ 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
2) 
0 
20000 
40000 
60000 
80000 
100000 
 P13 P14 P15 P16 P17 P18 P19 P20 P21 P22 P23 P24 P25 
Patients 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ + 
+ + 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
C
C
 n
u
m
b
e
rs
 
n
u
m
b
e
rs
 
+ 
+ 
+ 
+ 
 106 
Figure 7A: Rankings of individual COC within each patient, in regards to estimated CC numbers 
for all women in this study. Each patient (P1-P25) is indicated on the X axis and the individual 
COC belonging to each patient are separated by grey vertical lines. Individual COC are plotted 
from left to right according to their numerical order assigned at the time of egg collection, where 
COC #1 is plotted on the left vertical line. “+” marks are associated to dots (oocytes) with a 
positive outcome (blastocyst development and/or positive pregnancy). Different dots denote 
different ranks (○=1, =2, ●=3, =4, =5, ▲=6, ○=7, =8 and, ●=9).  
 
Ranking analysis of individual COC based on the expression of a single gene 
Of the 227 (9.1 ± 0.7/patient, range: 3-15) MII oocytes associated with CC samples that had 
measurable levels of mRNA, the proportions of CC masses with different pattern of gene 
expression within the total number of CC masses per woman were: 55 ± 2% [4.8 ± 0.4/patient, 
range: 33% or 4/12 (Patient #7) to 83% or 5/6 (Patient #14)] for HAS2;  55 ± 4% [4.8 ± 
0.4/patient, range: 20% or 1/5 (Patient #23) to 100% or 4/4 (Patient #9 and #15)] for FSHR; 69 ± 
3% [5.9 ± 0.4/patient, range: 38% or 3/8 (Patient #15) to 100% or 3/3 (Patient #1) and 4/4 
(Patient #9 and #15)] for ALCAM; 61 ± 3% [5.2 ± 0.3/patient, ranage: 33% or 4/12 (Patient #13) 
to 100% or 3/3 (Patient #1) and 4/4 (Patient #9)] for VCAN: 56 ± 3% [5.0 ± 0.4/patient, range: 
33% or 3/9 (Patient #24) to 100% or 3/3 (Patient #1)] for NRP1 and: 62 ± 4% [5.2 ± 0.4/patient, 
range: 36% or 4/11 (Patient #10) to 100% or 3/3 (Patient #1) and 4/4 (Patient #9 and #15)] for PR 
(Figure 7B). 
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Figure 7B: Rankings of individual COC from each patient, with respect to the expression levels 
of six candidate genes.  Each patient (P1-P25) is represented on the X axis, where all the COC for 
each patient are separated by the grey vertical lines. Individual COC are plotted from left to right 
according to their numerical order assigned at the time of egg collection, where COC #1 is 
plotted on the left vertical line. “+” marks are associated to dots (oocytes) with a positive 
outcome (blastocyst development and/or positive pregnancy). Different dots denote different 
ranks (○=1, =2, ●=3, =4, =5, ▲=6, ○=7, =8 and, ●=9). Gene expression is presented in 2-
ΔCT
 values (HAS2: 2000x 2
-ΔCT
, FSHR: 10000x 2
-ΔCT
, ALCAM: 5000x 2
-ΔCT
, VCAN: 100x 2
-ΔCT
, 
NRP1: 500x 2
-ΔCT
 and, PR: 10000x 2
-ΔCT
).  
 
Ranking analysis of individual COC based on the expression of six genes 
The proportion of COC with significantly different expression levels for at least one of the six 
candidate genes was 99.7%. Of the 227 COC analysed, only two (COC #3 and #14 from Patient 
#19) shared the same gene expression levels for all six genes (although were ranked differently in 
the analyses according to FSHR and ALCAM). These two individual COC also shared the same 
number of CC, and both were associated with oocytes with a negative outcome (Figure 7C and 
Appendix 7). 
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Figure 7C: Rankings of individual COC according to gene expression for patient # 19. Individual 
COC are spread along the X axis for each candidate gene (HAS2, FSHR, ALCAM, VCAN, NRP1 
and PR) from left to right according to their numerical order assigned at the time of egg 
collection. Expression results for each gene are separated by grey vertical lines. “+” marks are 
associated to dots (oocytes) with a positive outcome (blastocyst development and/or positive 
pregnancy). Different dots denote different ranks (○=1, =2, ●=3, =4, =5, ▲=6, ○=7, =8 
and, ●=9). Gene expression is presented in 2-ΔCT values (HAS2: 2000x 2-ΔCT, FSHR: 10000x 2-
ΔCT
, ALCAM: 5000x 2
-ΔCT
, VCAN: 100x 2
-ΔCT
, NRP1: 500x 2
-ΔCT
 and, PR: 10000x 2
-ΔCT
) (data 
presented in this figure originates from figure 7B). 
 
Selection of good quality oocytes 
 
Following the insemination of all 227 MII oocytes, 96% (24/25) of woman had at least one 
oocyte considered to be of good quality as measured by good blastocyst development and/or 
pregnancy.  
 
Random selection 
The random probability of selecting a good quality oocyte from selecting a single oocyte from 
each woman was 22.9 ± 2.7% for the 25 women. The random probability of selecting at least one 
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good quality oocyte from selecting three oocytes from each woman was 50.3 ± 4.4% across the 
same group of women. 
 
The use of ranking analyses for oocyte selection 
The combination (sum) of the ranking of four genes (HAS2, FSHR, VCAN and PR) in individual 
CC masses provided the highest chance of selecting a single oocyte with good developmental 
potential (blastocyst and pregnancy) when the CC mass with the highest ranking was selected. In 
this analysis, there were six cases where the highest-ranking CC mass shared a similar rank to a 
second CC mass that was associated with a negative outcome, further selection was made 
between the equally ranked samples according to the VCAN rank. In any case in which the 
VCAN rank was also equal, then further selection was made according to the FSHR rank. This 
method resulted in a 52% (13/25 women) success rate of picking a good quality oocyte by 
selecting a single COC (Table 7 and Figure 7D).  
 
In the case of selecting three COC (highest three) by the ranking method above described 
(according to four genes), the efficiency of selecting at least one oocyte with good developmental 
potential was 76% (19/25 women) (Figure 7D). However, the combination of the rankings for the 
two genes HAS2 and FSHR, provided the highest efficiency (80%; 20/25) for selecting at least 
one good quality oocyte (Table 7 and Figure 7D). 
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Table 7: Summary of the percentage (N=25 patients) success rate in selecting a single oocyte 
with good developmental potential using the ranking of various combinations of CC-derived 
expression levels of different candidates genes and estimated numbers of CC. The first column 
represents the parameter that was used for ranking. The second column (1x COC) shows the 
success rate when selecting a single COC with the highest ranking value. The third column 
(Shared Rank
1
) shows the number of patients where at least two COC shared the same highest 
ranking. The fourth column (3x COC) represents the success rate when three COC are selected 
according to the three highest rankings. The fifth column (Shared Rank
2
) shows the number of 
patients where all good quality oocytes within the three highest ranking COC shared rankings 
with at least a fourth COC.   
 
Ranking 1x COC 
Shared 
Rank
1
 
3x COC 
Shared 
Rank
2
 
HAS2 40% (10/25) 4/10 80% (20/25) 4/20 
FSHR 56% (14/25) 8/14 84% (21/25) 7/21 
ALCAM 28% (7/25) 3/7 60% (15/25) 4/15 
VCAN 44% (11/25) 4/11 84% (21/25) 4/21 
NRP1 40% (10/25) 5/10 72% (18/25) 4/18 
PR 40% (10/25) 3/10 68% (17/25) 4/17 
CC numbers 32% (8/25) 5/8 68% (17/25) 4/17 
HAS2+FSHR 48% (12/25) 5/12 80% (20/25) 0/20 
HAS2+FSHR+VCAN+PR 56% (14/25) 6/14 76% (19/25) 0/20 
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Figure 7D: The combined rankings of individual COC from 25 patients (P1-P25) according to 
mRNA levels of (i) HAS2 and FSHR or (ii) HAS2, FSHR, VCAN and PR. The blue circles 
represent those COC associated with oocytes that progressed to good quality blastocysts and/or 
pregnancy, whilst the red circles represent individual COC that were associated with oocytes with 
a negative outcome. The rankings are presented in proportions. To calculate the combined 
ranking value for individual COC within each patient 1) the rankings for individual COC for each 
gene was converted to proportions, by dividing the ranking number with the total number of COC 
ii) 
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within a patient and, 2) the ranking (in proportions) of each parameter was added and divided 
with the number of parameters taken in consideration for each individual COC. 
 
Oocyte selection efficiency 
The success rate (96%) of recovering at least one good quality oocyte after follicle aspiration (i.e. 
when using all MII oocytes available) was significantly higher (P<0.0001) compared to that when 
a single oocyte was selected by the ranking method based on CC gene expression (52%) or by 
random (23%) and compared to that when three oocytes were randomly selected (50%). 
However, when three oocytes were selected by the ranking method based on CC gene expression, 
the success rate of yielding at least one good quality embryo was similar that from using all 227 
MII oocytes for injection (80%; P=0.085). Selecting COC according to the ranking method 
provided a significantly higher chance of selecting at least one good quality oocyte compared to 
random selection (1x COC: 52% vs 23%, P=0.008; 3x COC: 80% vs 52%, P=0.002). 
 
Oocyte selection based on the ranking method was further tested in women from Gp 2 and Gp 3 
using the available HAS2 and FSHR expression data. However, the number of women recruited 
in Gp 2 (N=11) and Gp 3 (N=12) were significantly lower (less than half, P<0.0001) compared 
with those recruited in Gp 1 (N=25). Furthermore in Gp 2 and Gp 3 the proportion of women 
with at least one good quality blastocyst available following treatment was further reduced [Gp 1: 
63.6% (7/11), Gp 2: 25% (3/12)] compared to Gp 1 [96% (24/25)].  For these reasons no 
statistical analyses were possible for the outcomes in Gp 2 and 3 women. Nevertheless, the 
efficiency of the ranking method was examined in Gp 2 but only in women who had at least one 
good quality blastocyst (N=7);  the results were compared with those from Gp 1 (N=24) women 
who had at least one good quality blastocyst available for treatment. In Gp 2 women (N=7), the 
selection of a single COC according to the ranking method provided a 28.9% chance of selecting 
an oocyte that resulted in a good quality blastocyst whereas random selection provided a 24.2% 
chance. The selection of three COC according to the ranking method provided an 85.7% chance 
of selecting an oocyte that resulted in a good quality blastocyst whereas random selection 
provided a 52.1% chance. The results (ranking compared to random: 1x COC: 28.9% vs 24.2%, 
3x COC: 85.7% vs 52.1%) for the Gp 2 women while not reaching statistical significance with 
respect to the advantages in applying a ranking method of selection because of the lower 
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numbers, they showed similar tendencies to those for the Gp 1 women (N=24, ranking compared 
to random: 1x COC: 54.2% vs 23.9%, 3x COC 83.3% vs 52.4%).  
In Gp 3 women there were too few data points and for this reason no meaningful 
results/conclusion were possible.  
 
In the quest of identifying good quality oocytes further, a principal component analysis (PCA) 
was performed. However, no significantly different pattern of clustering was observed between 
oocytes associated with arrested development and those associated with good blastocyst 
development (Appendix 6).  
 
7.4 Discussion 
 
The most important finding of this study is that the measurement of candidate gene levels in CC 
and using a ranking analysis for individual COC provides a more reliable method for selecting 
good quality oocytes then by random selection. Moreover, using an mRNA-based ranking 
approach, it is possible to reduce the number of oocytes for ICSI to three. Not surprisingly, the 
most successful combinations of rankings for selecting good quality oocytes proved to be the 
combination of genes with the highest potential as molecular markers for blastocyst and 
pregnancy outcomes described in Chapter 6. The combination of the expression levels of four 
genes (HAS2, FSHR, VCAN and PR) provided the highest chance (52%) for selecting a good 
quality oocyte when attempting to select only one oocyte for IVF. Although this method provided 
76% efficiency for selecting at least one good quality oocyte when three oocytes were selected, 
the combination of the gene expression of two genes (HAS2 and FSHR) provided an even higher 
(80%, P<0.05 compared with selecting one oocyte using the ranking of four genes (52%)) 
efficiency for the same analyses.  
 
The selection potential of the ranking method using HAS2 and FSHR data was also tested in the 
much smaller groups of young women in Gp 2 and Gp 3 but not Gp 4 (due to all women having 
DET procedures).  The differences in selection efficiency between ranking and random selections 
for Gp 2 showed similar trends to those in Gp 1 although the results did not reach statistical 
significance due to the lower number of women and COC available for analysis. These results 
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however, are promising and show that the application of hierarchical ranking method may also be 
applicable to oocytes from young women with PCOS. For the Gp 3 women no meaningful 
conclusion can be drawn as there were too few data points: the good blastocyst rate was only 
7.9% (3/38). For these reasons, the ranking method for oocyte selection described in this study 
would be recommended for investigation in future larger studies dealing with young women with 
PCOS and young women with diminished ovarian reserve.  
 
As presented in Table 7, the selection of good quality oocytes using a single candidate gene 
approach can often reach very similar levels in comparison to selections based on multiple 
combinations. However, when using single genes, in the case of equally ranked COC, it is 
impossible to decide which COC should be selected. In contrast, when combinations of multiple 
genes were used, the number of COC sharing similar ranks was highly reduced (i.e. all patients 
who had good quality oocytes in the three highest ranking COC, had at least one good quality 
oocyte that did not share similar rankings with a fourth COC within a patient), and even in the 
case of equally ranking COC (i.e. selecting the single highest ranking COC), differentiation 
between two COC could be made by adding more weight to one or two of the genes (i.e. VCAN 
and FSHR) selected in the prediction model. Further, we report that the ranking of individual 
COC, according to CC numbers added no beneficial value to the selection efficiency, and again 
this highlighted the poor selection potential of morphological markers (Rienzi et al. 2011). The 
present study also reports that the principal component analysis conducted for the six genes in the 
227 individual CC masses has not shown any clear differential clustering in regards to blastocyst 
development, and added no power to the selection of good quality oocytes. However, it is 
believed that PCA would likely be a very powerful analytical tool for examining large numbers 
of genes following DNA microarray or RNA-Seq as this could be used to select the most strongly 
associated genes for further ranking studies (Guo et al. 2010).  
 
To the best of our knowledge, the present study is the first to investigate the uniformity of MII 
oocytes according to mRNA levels in associated CC and somatic cell composition of individual 
COC in relation to blastocyst development and pregnancy outcome. Most studies that investigate 
candidate mRNA levels in CC in relation to blastocyst development and pregnancy outcome 
report their findings as group means and, in the majority of cases, these outcomes are not relative 
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to total number of MII oocytes retrieved (Feuerstein et al. 2007; Gebhardt et al. 2011; Wathlet et 
al. 2011). In this study, the results are reported for individual COC and relative to the total 
number of MII oocytes collected following follicle aspirations. 
 
In stimulated IVF cycles, OCP and GnRH agonists are often administered to suppress 
gonadotrophin secretion and reduce the occurrence of large dominant follicles. This allows a 
cohort of small antral follicles to respond to exogenous rFSH treatment in a more co-coordinated 
manner, thereby enhancing the numbers of mature oocytes for recovery and facilitating the 
timing of egg collections (Gonen et al. 1990; Merton et al. 2003; Huirne et al. 2004; Huirne et al. 
2006). However, despite a high degree of standardization and synchronization of the stimulated 
IVF cycles in the present study, the results from this paper demonstrate a high level of 
heterogeneity in CC cell numbers and gene expression levels notwithstanding the large number 
of oocytes progressing to MII.   Following pre-treatment with OCP, down-regulation with GnRH 
agonist and stimulation with exogenous rFSH, 43% of pre-ovulatory follicles were of identical 
size on the day of administration of the ovulatory hCG. However, from the 227 MII oocytes 
collected, only two had similar CC numbers and shared similar mRNA levels in CC for all six 
candidate genes. Thus, it becomes evident now that the current ovarian gonadotrophin assisted 
stimulation regimens do not synchronize follicular development in humans (measured by mRNA 
levels and cell composition of individual COC). These results add further evidence to the 
findings that follicular recruitment and development is continuous and sequential (Peters et al. 
1975), and that gonadotrophin assisted stimulation regimens do not override the hierarchical 
pattern of follicular development (first documented in sheep) and are unlikely to improve 
developmental synchrony of the follicles recruited (McNatty et al. 2010). 
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Chapter 8 DISCUSSION 
 
8.1 Introduction 
 
The aim of every assisted reproduction treatment is to assist the birth of a single healthy infant 
(Land and Evers 2003). Although significant increases in pregnancy rates have been achieved 
(Gardner and Sakkas 2003), there are still substantial improvements which could be made. One 
such improvement would be the development of a reliable method for selecting oocytes with the 
best developmental potential to become a viable blastocyst and result in a positive pregnancy and 
a healthy baby (Rienzi et al. 2011).  
 
In the present study, the main objective was to investigate the feasibility of CC markers for the 
selection of oocytes to develop into good quality blastocysts and/or positive pregnancy outcomes. 
To address this objective the relative expression levels of eight candidate genes and the CC 
compositions of individual COC were determined. These parameters then were compared with 
subsequent developmental indicators namely good blastocyst development on day 5/6 and 
pregnancy outcome (Day 14 serum hCG ≥ 18iu/l and live birth) after all MII oocytes were 
subjected to ICSI.  
 
8.2 Validation of a multiplex QPCR method 
 
The first major achievement of the present study was the validation of a multiplex QPCR method 
that allowed the simultaneous measurement of four genes (quadriplex QPCR) in CC of individual 
COC in a single reaction. To our knowledge, the present study is the first to investigate candidate 
mRNA levels in human CC from individual COC by a quadriplex TaqMan QPCR method 
(McKenzie et al. 2004; Feuerstein et al. 2007; Adriaenssens et al. 2010; Gebhardt et al. 2011; 
Wathlet et al. 2011). The validation and the use of the multiplex (triplex and quadriplex) QPCR 
methods in this paper have the advantage over singleplex QPCR reactions by increasing the 
efficiency by measuring the expression of multiple genes in a single reaction: this results in 
several advantages such as reducing the amount of time and labour, savings in reagents and 
maximizing the use of template required (Swango et al. 2007; Hudlow et al. 2008). In the present 
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study, the measurements of eight candidate genes (HAS2, FSHR, SLC2A4 (or GLUT4), VCAN, 
ALCAM, SFRP2, PR and NRP1)) are reported using approximately 7 µl (out of a total 20 µl) of 
available template. If all 20 µl of the template was used, this would allow the measurement of at 
least 20 candidate genes in CC from individual COC. 
 
The key aspects of the validation process of the present multiplex method were: 1) Verifying the 
quality of the CC samples by measuring the viability (86.4%) of the CC after denudation, before 
freezing the samples (-196ºC) for mRNA extraction. This was a key issue considering the 
possible negative effects of enzyme treatment (hyaluronidase) and mechanical denudation (glass 
pipette) on viability of the CC. High cell viability was also important considering the well 
documented negative effects of cell apoptosis on DNA integrity that impact the appropriate 
quantification of genes in tissue studies (Koppelkamm et al. 2011). The aforementioned 
validation step had not previously been reported for expression studies on human CC (McKenzie 
et al. 2004; Feuerstein et al. 2007; Adriaenssens et al. 2010; Gebhardt et al. 2011; Wathlet et al. 
2011). Another key validation step was that concerning the housekeeping gene, RPL19. 
Importantly, this gene was expressed in a similar range to many of the target genes in this study. 
The validation of the RPL19 gene was achieved by demonstrating a strong correlation between 
mRNA (CT values) in CC and numbers of CC and also the mRNA levels of a widely recognized 
and highly abundant housekeeping gene, 18S. Given its abundance, 18S was unsuitable for 
quantitation of genes in CC which were expressed at much lower levels.  
 
A significant advantage in using the housekeeping gene (RPL19) was that it was possible to 
determine the CC numbers from individual COC (Chapter 3 and 4). Moreover, from using 
RPL19, it was determined that the minimal number of CC needed to accurately measure the 
expression levels of multiple genes by multiplex QPCR was ~70. 
 
Whilst there are clear advantages of multiplex TaqMan QPCR over singleplex QPCR (SYBR 
Green or TaqMan) (Swango et al. 2007; Hudlow et al. 2008), the limitation of the multiplex 
TaqMan QPCR is that it only allows a maximum of four genes to be measured in a single 
reaction. Recently it was reported that the application of a GeXP genetic analytical system 
permits the quantitation of up to 35 genes simultaneously in a single reaction (Rai et al. 2009). 
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Similarly to the TaqMan QPCR method, the GeXP system allows the analyses of target and 
housekeeping samples in the same experiment. A further advantage of this method is that the 
entire procedure, after RNA isolation can be completed in six hours (Rai et al. 2009). For these 
reasons, for future studies it is suggested that the application of the GeXP genetic analytical 
system would significantly increase the chances of identifying many more informative candidate 
genes in CC more rapidly. 
 
8.3 CC numbers in individual COC 
 
The validation of the housekeeping gene, RPL19, also permitted an investigation of the 
relationship between CC numbers and oocyte developmental indicators. Based on an analysis of 
608 individual CC samples, the mean number of CC present in an individual COC recovered 
before IVF treatment was 28872; this number is much higher than 11500 which had been 
reported previously in a much smaller study (Feuerstein et al. 2007). Correlation analyses (see 
Chapter 4) showed that CC numbers in individual COC were found not to be related to good 
blastocyst development and/or pregnancy adding further evidence to the hypothesis, that 
morphological characteristics of individual COC are poor markers of oocyte quality (Ng et al. 
1999; Rattanachaiyanont et al. 1999; Lee et al. 2001; Moffatt et al. 2002; Corn et al. 2005). 
 
 
8.4 CC mRNA levels in individual COC 
 
In the present study, the mRNA levels of eight candidate genes were assessed in CC. Six of these 
genes (HAS2, FSHR, ALCAM, VCAN, NRP1 and PR) were detectable in 98.5% of the samples, 
whereas the expression levels of GLUT4 were low and those for SFRP2 were undetectable in 
individual CC masses. These findings are in agreement with previous reports, showing that most 
CC expressed genes can be quantified in single COC (McKenzie et al. 2004; Hasegawa et al. 
2005; Adriaenssens et al. 2010; Assidi et al. 2011; Wathlet et al. 2011). Furthermore, using linear 
correlation analyses it was found that the mRNA levels (CT values) of the six abundant genes in 
individual CC masses were significantly correlated, where the relative expression levels of VCAN 
mRNA were the highest, followed by those of NRP1, HAS2, ALCAM, FSHR and PR. It has to be 
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acknowledged however, that comparing relative expression levels (CT values) by QPCR methods 
has its limitations, for instance it is known that the type of dye used, and the composition of the 
sequence can influence the sensitivity of the QPCR measurement (Gudnason et al. 2007) 
 
CC mRNA levels in CC are affected by the endocrine status of the individual as well as by the 
exogenous rFSH treatment 
In the process of identifying reliable oocyte quality markers, it was important to investigate the 
possible effects of biological and treatment variables on mRNA levels in the CC. For this study 
three candidate genes were selected (HAS2, FSHR and GLUT4) and were investigated in women 
(N=68) enrolled in the four study groups (young and healthy women, young women with PCOS, 
young women with diminished ovarian reserve and, older and healthy women). 
 
The expression levels of these genes were investigated in relation to the infertility background of 
the women that had been recruited for these studies. It was found that the expression levels of 
FSHR in CC are significantly up-regulated in young women with PCOS compared with young 
and healthy women and young women with diminished ovarian reserve. This finding correlates 
well with other reports studying the expression of FSHR in pooled GC samples from women with 
PCOS, normal ovarian function and with poor ovarian reserve (Almahbobi et al. 1996; Cai et al. 
2007; Catteau-Jonard et al. 2008; Gonzalez-Fernandez et al. 2010).  Further, it was found that the 
expression levels of HAS2 were elevated in older women and in young women with diminished 
ovarian reserve, and were the lowest in women with PCOS. The measurement of mRNA levels of 
GLUT4 added little to these analyses, due to the low levels of expression in individual CC 
masses. 
 
The expression levels of HAS2 and FSHR in individual CC masses were also examined in 
relation to certain biological and treatment variables. It was found that FSHR mRNA levels were 
not correlated to any of the biological or treatment variables. On the other hand, the mRNA levels 
of HAS2 were correlated with age (a finding previously described by Adriaenssens et al. (2010)), 
basal serum FSH and AMH levels. However, HAS2 mRNA showed the strongest correlation with 
the amount of exogenous rFSH used for stimulation, and to the ovarian response (follicle 
numbers and COC collected). Taking into account the role of FSH in regards to hyaluronic acid 
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synthesis, it is reasonable to assume that the HAS2 mRNA levels are primarily correlated to 
serum FSH levels, whilst the influence of age is, at best, a secondary factor. This is further 
supported by the finding that HAS2 mRNA levels in CC of young women with diminished 
ovarian reserve and older women were similar. 
 
These investigations highlight the heterogeneity of CC expressed genes in relation to background 
characteristics. The expression of some genes (i.e. FSHR), are affected by the endocrine status of 
the individual, whilst others (i.e. HAS2), are affected primarily by the exogenous rFSH treatment.  
 
CC mRNA levels are predictive of oocyte maturity 
The present paper adds further evidence to the findings that HAS2 and VCAN are good predictors 
of oocyte maturity (McKenzie et al. 2004; Adriaenssens et al. 2010; Wathlet et al. 2011). Both of 
these genes were significantly up-regulated in CC associated with immature oocytes (GV and 
MI) compared with CC with MII oocytes. Studies in mice COC report that the expression of 
these genes is rapidly initiated after exposure to ovulatory hCG and then gradually decrease 
during and after ovulation (Adriaenssens et al. 2011). However, as evidenced in the present 
study, the expression of these genes is higher in CC associated with good quality oocytes 
compared with CC from oocytes with negative outcomes (Chapter 6). It is reasonable to believe 
that during ovulation, poor quality oocytes fail to maintain appropriate expression levels of these 
genes in CC which, in turn, leads to a low level of mucification of the CC mass.  
 
CC mRNA levels are predictive of blastocyst development and live birth outcome 
A significant finding reported in this study is that the mean mRNA levels of HAS2, VCAN and 
PR are significantly increased in CC of oocytes associated with embryos that progressed to 
pregnancy and/or good quality blastocysts compared to the expression levels in CC associated 
with oocytes with failed development (Chapter 6). Furthermore, it was found that the mean 
mRNA levels of VCAN in CC of oocytes associated with live birth were significantly higher 
compared to those in CC associated with oocytes with failed development. A highly important 
aspect of these findings is that these results are relative to the total number of MII oocytes 
available after follicular aspiration. Previous studies that showed elevated expression levels of 
candidate genes in CC associated with blastocyst development and/or pregnancy outcome 
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reported most of their findings for selected groups (i.e. positive and negative groups of embryos 
selected for transfer) and not relative to total MII oocytes retrieved (Feuerstein et al. 2007; 
Gebhardt et al. 2011; Wathlet et al. 2011).  Whilst, the findings of the latter studies are 
informative, it would be of much greater value to identify good quality oocytes within the total 
number of MII oocytes available.  
 
The present study further confirmed that blastocyst development and live birth outcome are the 
critical stages against which the value CC gene expression should be assessed (Gebhardt et al. 
2011; Wathlet et al. 2011). Any earlier assessment of oocyte quality leads to variable and 
inconsistent results. However, for a better understanding in the CC gene functions it is proposed 
that future studies should report data on every possible embryological assessment from Day 0 to 
Day 6; these data would greatly assist in reducing the variability and enabling better comparisons 
to be made between published reports. 
 
Candidate genes recommended for future investigations 
As highlighted in the above section and in Chapter 6 and 7, the most informative genes used in 
this research experiment were HAS2, FSHR, VCAN and PR and these are suggested for inclusion 
with other potential candidates in future investigations. 
 
To our knowledge, the present study is the first to investigate hyaluronan synthase 2 (HAS2) 
mRNA levels in relation to blastocyst development and pregnancy outcome relative to total MII 
oocytes collected following follicular aspirations.  HAS2 is one of the key proteins involved in 
the formation of the extracellular matrix and the expansion of the CC mass (Fulop et al. 1997; 
Salustri et al. 1999). Furthermore, HAS2 mRNA expression is induced by the ovulatory LH surge 
and it is regulated by OSF in the presence of FSH (Gui and Joyce 2005).  
 
The present study examined the relationship between follicle stimulating hormone receptor 
(FSHR) mRNA levels and oocyte developmental indicators. Although, the mean expression level 
of FSHR showed only a tendency towards higher levels in CC associated with good quality 
oocytes, the mRNA levels of individual COC provided new information when the levels in CC 
associated with MII oocytes within individual women were subjected to ranking analysis 
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(Chapter 7). The finding that FSHR was one of the more informative genes in this analysis is not 
surprising considering that the acquisition of FSHR in CC is vital for the action of FSH and that 
this acquisition is regulated by OSF (Otsuka et al. 2005). Furthermore in a non-stimulated mono-
ovulatory animal model (bovine) it was reported that FSHR mRNA levels in CC increased with 
follicle diameter (Caixeta et al. 2009) highlighting the critical role that FSHR have in the 
development of the dominant follicle.  
 
Versican (VCAN) is a hyaluronan binding factor involved in the formation of the extracellular 
matrix of the COC (Russell et al. 2003). In this research, the expression levels of VCAN were 
significantly higher in CC associated with oocytes that developed to blastocyst and pregnancy. 
More importantly, the mRNA levels of VCAN were higher in CC associated with oocytes that 
resulted in live births. Previously, the expression levels of VCAN showed conflicting results, in 
one study they showed lower expression levels in CC associated with oocytes that progressed to 
blastocyst, but higher levels in CC associated with oocytes that progressed to pregnancy 
(Gebhardt et al. 2011; Wathlet et al. 2011). However in these reports the expression levels of 
VCAN in regards to blastocyst development were not investigated relative to total number of MII 
oocytes submitted for fertilization (Wathlet et al. 2011). Similarly, in relation to pregnancy, 
expression levels of VCAN were only investigated in embryos transferred and again not relative 
to total number of oocytes retrieved (Gebhardt et al. 2011; Wathlet et al. 2011). The findings 
presented in this research are related to all MII oocytes available for each woman, again highlight 
the importance of analysing the data in relation to total oocytes collected.  
 
The finding that progesterone receptor (PR) levels were significantly higher in CC associated 
with good quality oocytes is perhaps not surprising considering the well documented increase in 
PR expression levels in GC of pre-ovulatory large follicles following the pituitary LH surge 
(species: rat and mice) (Park and Mayo 1991; Kim et al. 2008; Robker et al. 2009). However, in 
the single study that investigated the PR expression levels in CC in relation to embryo 
development, the author’s results were inconclusive (Hasegawa et al. 2005). However, it is 
important to note that these results were reported for early embryo cleavage. Therefore, this 
emphasizes once more that the critical stages for which CC gene expression should be compared 
to, are blastocyst development and pregnancy outcome. 
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Based on evidence of previous reports (Gebhardt et al. 2011; Wathlet et al. 2011) and results 
presented in this study, for future interrogations it is recommended that these include other genes 
involved in the formation of the extracellular matrix of the COC, such as prostaglandin-
endoperoxide synthase 2 (PTGS2). Indeed the expression levels of PTGS2 were significantly 
higher in CC of oocytes that progressed to pregnancy/live birth compared to negative outcomes 
amongst oocytes that resulted in a transfer (Gebhardt et al. 2011; Wathlet et al. 2011). A further 
candidate gene recommended is syndecan 4 (SDC4), an anticoagulant heparan sulphate 
proteoglycan, that is synthesized in granulosa cells under the influence of gonadotrophins 
(Princivalle et al. 2001). Moreover, higher expression levels of SDC4 were reported in CC 
associated with positive outcomes (good blastocyst or pregnancy) compared to negative 
outcomes in human IVF cycles (Wathlet et al. 2011). The mRNA levels of these two genes in CC 
associated with blastocyst development and live birth outcome relative to all MII oocytes 
retrieved however still remains to be investigated.  
 
Candidate genes with poor potential for oocyte selection 
The present study confirmed when all MII oocytes retrieved are considered in the analysis the 
mRNA levels of GLUT4, ALCAM, SFRP2 and NRP1 in CC are poor predicators for oocyte 
development. Unlike in previous reports where it was reported that the mean expression levels of 
ALCAM (Adriaenssens et al. 2010; Wathlet et al. 2011) and NRP1 (Assidi et al. 2011) were 
higher in positive groups compared to negative groups, the present study found that the mean 
expression level of these genes are not indicative of good blastocyst development and/or 
pregnancy outcome. Whilst GLUT4 and SFRP2 are abundant genes in mice CC during the final 
steps of oocyte maturation (Roberts et al. 2004) and ovulation (Hernandez-Gonzalez et al. 2006), 
these genes were lowly expressed in individual COC in humans in the present study and thus 
cannot be investigated in regards to embryo development. 
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8.5 The ranking of individual MII oocytes according to CC mRNA levels, and the 
application of this ranking system for oocyte selection  
 
The most important finding of the present paper is that it demonstrated that the selection of good 
quality oocytes in stimulated IVF cycles is possible. This finding is based on the results of the 
ranking method (see Chapter 7) which showed that: 1) good quality oocytes (at least one) can be 
selected with an 80% efficiency, whilst reducing the number of oocytes required for insemination 
to no more than three (in the case of this study from 9.1 to 3 (67% reduction)) and; 2) further 
evidenced that exogenous FSH treatment does not override the hierarchical pattern of follicular 
development (McNatty et al. 2010). 
 
Based on present evidence, the ranking method described in this study is superior to any current 
morphological criteria for oocyte selection (Ng et al. 1999; Rienzi et al. 2003; Rienzi et al. 
2011), morphological evaluation of the COC (Ng et al. 1999; Rattanachaiyanont et al. 1999; Lee 
et al. 2001; Moffatt et al. 2002) or metabolomic profiling of the oocyte culture media (Nel-
Themaat and Nagy 2011). Moreover this system offers a similar chance of identifying good 
quality oocytes (at least one) compared to classical treatments where all MII oocytes are used for 
fertilization.  
 
As evidenced in Chapter 6, analysing mean mRNA levels in CC is a suitable method for 
identifying good candidate genes for oocyte selection. However, as presented in Chapter 7, for a 
successful implementation of an oocytes selection method, mRNA levels in CC must be 
interrogated for individual COC. Not surprisingly, the highest success rates for the selection of 
good quality oocytes (at least one) resulted following the various combinations of rankings of the 
four genes (HAS2, VCAN, PR and FSHR) that showed higher mean mRNA levels for good 
blastocyst development and/or pregnancy across all samples. 
 
In the ranking analyses, two scenarios were investigated: a) the selection of a single oocyte and, 
b) the selection of three oocytes. These numbers were chosen keeping in mind current ethical, 
legal, social and religious requirements for oocyte selection (Kufner et al. 2009; Mohler-Kuo et 
al. 2009; Levi Setti et al. 2011). Whilst the selection of a single oocyte according to the ranking 
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method was significantly more successful than random selection, the selection of three oocytes 
by the ranking method provided the best chance of selecting good quality oocytes. Not only was 
this method significantly better than the random selection of three oocytes, it also provided a 
similar chance of selecting good quality oocytes compared to using all MII oocytes available 
after follicle aspiration. When all MII oocytes are used for treatment, as many as six good quality 
embryos may be produced with one to be transferred and five to be frozen, (see Chapter 7), 
showcasing the high probability of producing surplus embryos. The insemination of only three 
oocytes doesn’t necessarily mean that the potential of those not inseminated have to be discarded 
as surplus oocytes can be cryopreserved, in the case that further siblings are required later 
(Ubaldi et al. 2010). Furthermore this method could be used to overcome the ethical and legal 
challenges associated with cryopreservation of surplus embryos which is common in treatments 
where all available oocytes are used for insemination (Fabbri et al. 1998; Bankowski et al. 2005). 
 
An equally important aspect of the mRNA based ranking method is the high pregnancy rates 
achieved in young and healthy women. When all MII oocytes collected were taken in 
consideration a positive hCG pregnancy of 84% (21/25) and a live birth in 76% (19/25) of 
women was achieved following fresh SET. When the highest three ranked MII oocytes were 
selected using the sum of ranks for HAS2 and FSHR mRNA levels, a pregnancy rate of 60% 
(15/25) and a live birth rate of 52% (13/25) was calculated. This rate was achieved by adding the 
cases where the three highest ranking oocytes included the oocyte that was selected for transfer 
and resulted in a live birth, with the cases where although the three highest ranking oocytes did 
not include the oocyte that progressed to live birth, included at least one good quality blastocyst 
that could have been selected for transfer. To calculate the potential success rate of these 
blastocyst Fertility Associates (Wellington clinic) fresh and frozen-thawed blastocyst SET 
pregnancy (fresh: 67%, frozen: 43%) and live birth (fresh: 42%, frozen: 29%) results were 
considered (year 2009-2011, unpublished data). These results (pregnancy rate of 60% and live 
birth rate of 52%) although seem lower, are similar (hCG pregnancy: P=0.061, live birth: 
P=0.080) to those achieved by using all MII oocytes for insemination. Nevertheless the success 
rates achieved by the ranking selection method are more than comparable with international 
standards that use all MII oocytes for inseminations (Gardner et al. 1998; Abdalla 2010; Levi 
Setti et al. 2011; Zander-Fox et al. 2011). 
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The limitations of the ranking method presented in this paper lie in: 1) its relatively lengthy 
process (mRNA extraction ~3 hours, reverse-transcription ~2 hours, TaqMan QPCR method 2-4 
hours, and the time for operator manipulations); and 2) it has only been validated for young and 
healthy women, thus there is no information on how biological (i.e. PCOS) and treatment 
variables impact on rankings Until these questions are answered, this selection method has the 
limitations that it can only be used in oocyte freeze cycles or to enhance embryo selection in fresh 
IVF cycles in young and healthy women. However, with the use of the GeXP genetic analytical 
system, these limitations associated to CC markers could be addressed and minimized. By further 
automation of the GeXP method, the time required for mRNA measurement could be shortened, 
and up to 35 genes could be simultaneously investigated (Rai et al. 2009) and thus possibly 
further increasing the efficiency of oocyte selection. 
 
8.6 Investigations regarding the developmental synchrony of individual COC based on 
CC mRNA levels and CC numbers 
  
After analysing individual MII oocytes by the ranking method it became evident that, although 
43% of the pre-ovulatory follicles were identical in diameter on the day of ovulation trigger, only 
two of the 227 COC (0.3%) shared an identical CC number and  mRNA levels for all six genes 
(HAS2, FSHR, ALCAM, VCAN, NRP1 and PR) . The level of heterogeneity for individual COC 
associated with MII oocytes for individual parameters were 55% (HAS2), 55% (FSHR), 69% 
(ALCAM), 61% (VCAN), 56% (NRP1), 62% (PR) and, 61% for CC number).  
 
These findings for CC parameters are in line with those reported by McNatty (McNatty 1978; 
McNatty and Baird 1978) in humans and McNatty et al. (2010) in sheep. These authors showed 
that few if any antral follicles share identical endocrine microenvironment (steroid and 
gonadotrophin concentrations in the follicular fluid) and somatic cell composition (granulosa 
cells) even when they are of equal size (McNatty 1978c; McNatty et al. 1981b; McNatty et al. 
1984). Furthermore, evidence in mono-ovulatory animal models (sheep) show that there is a 
considerable heterogeneity with respect to responsiveness to gonadotrophins in individual 
follicles within an individual (McNatty et al. 2010). Taking in consideration the aforementioned 
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findings, the very low birth rates (~7%) from oocytes collected in stimulated IVF cycles (Li et al. 
2008; Patrizio and Sakkas 2009) and the results from the present study, it can be concluded 
superovulation regimens do not improve developmental synchrony of the follicles 
recruited/oocytes collected. In other words, the exogenous rFSH treatment does not override the 
hierarchical pattern of follicular development. The higher success rates obtained in stimulated 
IVF cycles compared to natural IVF cycles (Fishel et al. 1985; Pelinck et al. 2002) are likely 
attributed to the higher number of follicles recruited and triggered at any moment in time. These 
findings on CC gene expression raise the possibility that even when several oocytes go on to 
form blastocysts, the gene expression profiles in these embryos may be rather different. Moreover 
these findings confirm what is already acknowledged that current hormonal stimulation protocols 
are inefficient and that alternative follicular maturation methods are required to enhance the 
yields of viable oocytes. 
 
8.7 Clinical implications of the findings presented in this study 
 
The findings of the present paper may have important implications for the future management of 
IVF procedures. The ranking method presented in this thesis for the selection of good quality 
oocytes, could provide a starting point to address the ever-increasing demand for oocyte 
selection. This demand is driven by several ethical, legal, financial and health factors. The ethical 
demands are highlighted by the increasing numbers of surplus embryos following super-
stimulated IVF cycles (Bankowski et al. 2005). There are religious considerations especially in 
the case of those believers who place high moral values on the status of the embryo and for 
whom embryo preservation is not an option (Schotsmans 1998; Mohler-Kuo et al. 2009). In some 
countries (i.e. Germany, Switzerland and Italy) there are legal restrictions on the number of 
embryos (in most cases to three embryos) that can be generated in any one treatment cycle 
(Kufner et al. 2009; Mohler-Kuo et al. 2009; Levi Setti et al. 2011) and this can sometimes 
compromise pregnancy rates (Levi Setti et al. 2011). Oocyte selections paired with early stage 
(i.e. Day 1 or Day 2) embryo replacements could also minimize the possible negative effects of 
extended in vitro culture of embryos on the health of the children conceived (Nelissen et al. 
2012). There are financial benefits from an improved oocyte selection method through increased 
efficiencies with management and decreased financial costs of treatment (see Chapter 1). There 
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are also benefits in cases where women undergoing oocyte cryopreservation could be more 
appropriately advised of the quality and number of oocytes needed to be frozen in order to 
achieve a live birth. Finally, there are also benefits with respect to assisting SET procedures and 
minimizing the prevalence of multiple gestations (Bissonnette et al. 2007). 
 
8.8 Conclusions 
 
The main objective of the present thesis was to assess the feasibility of CC markers for the 
selection of good quality oocytes in super-stimulated IVF treatments in humans. From these 
investigations, three major milestones were achieved. Firstly, a multiplex QPCR technique was 
validated, that was capable of measuring simultaneously the mRNA levels of four genes in CC 
and permitting an accurate measure of CC numbers in individual COC. Secondly, the ranking 
method based on the three multiplex QPCR reactions described herein permitted the selection of 
good quality oocytes (at least one) with 80% efficiency, whilst reducing the number of oocytes 
required for insemination by 67% (to no more than three). Moreover, the efficiency of selecting 
good quality oocytes (at least one) with a live birth outcome achieved by the ranking method 
provided similar rates to fresh IVF treatments using all MII oocytes for insemination. Thirdly, the 
finding that 99.7% of individual COC were significantly different in CC mRNA levels and in cell 
composition added further evidence to the findings that super-ovulation regimens do not improve 
developmental synchrony of the follicles recruited and do not override the hierarchical pattern of 
follicular development (McNatty et al. 2010). 
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APPENDICES 
 
The protocols presented in appendices 2.1, 2.2, 3.1, 3.2 and 3.3 are the intellectual property of 
Fertility Associates (FA) Ltd. These protocols are published according to FA’s formatting 
policies. Permission for the publication of these protocols in the present thesis was granted by Dr. 
John Peek, Group Operation Manager, Fertility Associates Ltd.  
 
APPENDIX 1 
Patient Consent Form 
 
Research about Proteins Secreted by the Egg 
into the Surrounding Cumulus Cells 
 
We, …………………………………   and ………………………………….. have been 
approached by the staff of Fertility Associates when we were advised of our ovulation  
“trigger” about a research study on cumulus cells. 
 
We have been provided with the information sheet entitled “Research about Proteins secreted by 
the Egg in to the Surrounding Cumulus Cells” dated November 2008 which we have read, and 
understand and accept. 
 
We have had all our questions since we were approached about the research satisfactorily 
addressed by our scientist (name)……………………. today. 
 
We agree for cumulus cells that are removed from each egg prior to fertilization to be frozen and 
stored for subsequent analysis of proteins secreted by the egg rather than discarded. The samples 
will be stored using only our clinic number ID. 
 
Woman’s signature: …………………………            Partner’s signature……………………… 
 
Date 
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APPENDIX 2.1 
Title  Long course stimulation with pill for IVF, protocol 5.85 
Author  Dr. John Peek, Fertility Associates Ltd. 
Purpose Routine stimulation for IVF/ICSI treatment, enabling adjusting the week of  
egg collection to smooth clinic workload  
Responsibility Patient’s doctor, doctor on duty for the day, authorised nursing and laboratory 
staff 
Definitions Items in bold italics are mandatory, other items are guidelines 
 
 
SUPPRESSION   
 Microgynon 30 preferably starting on 1st day of period, but at least within 4 days of 
period 
 400 ug Buserelin sc / day, starting 14-28 days after starting Microgynon 
 Stop Microgynon 5-7 days after starting Buserelin 
 
DOWN-REGULATION CHECK 
E2 to check down-regulated after >= 14 days Buserelin, usually on Monday or Tuesday: 
 If E2 < 200 pM, then down-regulated. 
 If E2 200-300 pM, then check hCG. If not pregnant, do scan.  
Consider down-regulated if all follicles =< 5 mm AND endometrial thickness =< 3 mm 
 If E2 > 300 pM then check hCG. If not pregnant, do scan. If follicle(s) >= 16 mm then 
trigger with 2500 iu hCG. E2 to recheck for down-regulation in 7 days (whether hCG 
trigger on not). 
 
STARTING GONAL F / PUREGON  
 For starting dose, see ‘Guidelines for dose of Gonal F/Puregon in IVF/ICSI’ 
 Dose of Gonal F/Puregon must be signed off on the management plan by a doctor 
 Start Gonal F / Puregon once patient down-regulated 
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 Reduce Buserelin to 200 ug/d 
 Adjust starting day of Gonal F/Puregon according to the starting dose: 
 
Starting dose  < 150 iu / day  Thursday 
150-300 iu / day Wednesday 
 
MONITORING AND CHANGING DOSE  
 Any changes in dose must be checked and signed by a doctor within 48 hours 
 
First step:  
 E2 Tuesday (= day 7 Gonal F/Puregon for average responder) 
o If E2 < 300 pM then increase Gonal F/Puregon dose by 75 IU , plan E2 Friday, E2 
& scan Monday 
o If E2 300-3000 pM then E2, scan Thursday, Friday OR Saturday (depending on 
E2 level and convenience) 
o If E2 >= 3000 pM then scan next day and decide whether to continue  
 
Further steps:  
 E2 and scan every 2-3 days until triggered with hCG 
 If E2 rise between day ~7 and day ~10 >= 1 day behind ideal line, then increase Gonal 
F/Puregon dose providing E2 on day 7 >= 500 pM and not 1 or 2 dominant follicles 
 E2 day of trigger  
 
STOPPING    
 Decision to stop or coast must be made by a doctor or confirmed with a doctor 
 If E2 remains low, OR follicles do not grow at expected rate (2-3 mm/day), then 
recommend stopping 
 If < 3 preovulatory follicles, then discuss whether to continue or stop with patient 
 If projected E2 day of hCG would be > 12,000 pM, then discuss coasting with doctor 
 If abdominal discomfort, then doctor to discuss stopping with patient 
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TRIGGER 
 Trigger ovulation with 250 ug Ovidrel and stop Buserelin, when: 
o 2 follicles >= 20 mm, or 3 follicles >= 18 mm, OR 
o Coasted and E2 falls to < 10,000 pM 
 If wanting to change trigger day to smooth workload, trigger day earlier rather than later 
where possible. 
 Do not give hCG trigger if E2 > 20,000 pM 
 If the E2 rise is significantly steeper than the standard line on the tracking sheet in the 
days leading to trigger, then a doctor must make the decision whether or not to trigger. 
 If E2 low for expected number of follicles, then consider repeating scan. 
 
OPU   (= luteal day 0) 
 36 h after hCG trigger 
 Premedication of 2 Panadol tablets (500 mg each).  
 Other medication requires doctor's prescription. 
 
EMBRYO REPLACEMENT  
 At least 45 h after insemination in IVF, 43 h after injection in ICSI insemination 
 If E2 > 12,000 pM day of hCG trigger or >= 20 eggs at OPU, then freeze all embryos 
 If 15-20 eggs at OPU, then doctor’s discretion whether to freeze all embryos 
  
LUTEAL SUPPORT AND MONITORING 
 Utrogestan intravaginal 2 x 100 mg 3x / day from luteal day 1 
 HCG test luteal day14 
 If hCG >= 5 iu/l day 14, then consider pregnant, and do E2, P4, hCG day 18 
 HCG result day 18: 
o If P4 > 80 nM, reduce to 100 mg Utrogestan 3 x / day for 4 days, then stop. 
o If P4 < 80 nM, stay on Utrogestan until scan with foetal heart at 10 weeks, then 
reduce to 100 mg Utrogestan 3x / day for 4 days then stop. 
 Further monitoring at patient’s request as early pregnancy monitoring service OR 
continue monitoring if any concern about possible ectopic pregnancy 
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DRUG SUMMARY 
 
Day 1 (to 4)   Start Microgynon 30 
Day 14-28    Start Buserelin 
After 7 days Buserelin  Stop Microgynon 
After >= 14 days Buserelin E2 to check down regulation  
Next Thursday (+/- 1 day) Start Gonal F/Puregon 
After 7 days Gonal F  E2 to check response, increase dose if no response, no 
dominant follicle 
Every 2-3 days   E2, scan to decide when to trigger 
Follicles >= 18-20 mm  Trigger 
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APPENDIX 2.2 
Title  Microdose flare stimulation for IVF, protocol 5.9 
Author  Dr. John Peek, Fertility Associates Ltd. 
Purpose Stimulation for IVF/ICSI treatment when poor response expected 
Responsibility Patient’s doctor, doctor on duty for the day, authorised nursing and laboratory 
staff 
Definition Items in italics are mandatory, other items are guidelines 
 
 
ORAL CONTRACEPTIVE PILL  
 Start Microgynon 30, preferably on 1st day of period, but at least within 4 days of 
period, and continue for at least 21 day, or shorter duration between 14 and 21 with a 
doctor’s approval. 
 
STARTING STIMULATION  
 Dose of Gonal F/Puregon must be signed off on the management plan by a doctor 
 Start 50 ug Buserelin sc twice daily (bid) third day after stopping Microgynon  
OR 0.015 mg (0.15 ml) Decapeptyl sc twice daily 
 Start Gonal F / Puregon two days after starting Buserelin 
 For starting dose, see ‘Guidelines for dose of Gonal F/Puregon in IVF/ICSI’  
 Adjust starting days according the starting dose of Gonal F/Puregon: 
 
225 IU / day  300 IU / day 
  Last day Microgynon pill  Sunday  Friday 
  Start Buserelin (= day 1 stimulation) Wednesday  Monday 
  Start Gonal F/Puregon  Friday   Wednesday 
  First E2 test    Monday (day 6) Monday (day 8) 
 
MONITORING AND CHANGING DOSE  
 Any changes in dose must be checked and signed by a doctor within 48 hours 
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 Normally dose not changed for poor response (expect OPU ~ 2 days later than initially 
expected) 
First step:  
 E2 on 6th-8th day of stimulation 
o If E2 < 300 pM then discuss with doctor 
o If E2 300-3000 pM then E2, scan 1-3 days later depending on E2 level 
o If E2 >= 3000 pM then scan next day  
Further steps:  
 E2 and scan every 2-3 days until triggered with hCG 
o If leading 2-3 follicles on a Friday scan >=15 mm and no trigger decision made, 
then rescan on Sunday, not Monday 
o If leading 2-3 follicles on a Friday scan =< 14 mm and trigger decision not yet 
made, then E2 and scan on Monday 
 If E2 rise between day ~6 and day ~9 >= 1 day behind ideal line, then increase Gonal 
F/Puregon dose providing E2 on day 7 >= 500 pM and not 1 or 2 dominant follicles 
 Always do E2 day of trigger when expected E2 >= 10,000 pM, or > 20 follicles on scan 
 
STOPPING 
 Decision to stop or coast must be made by a doctor 
 If E2 remains low, OR follicles do not grow at expected rate (2-3 mm/day), then 
recommend stopping 
 If < 3 preovulatory follicles, then discuss whether to continue or stop with patient 
 If projected E2 day of hCG would be > 12,000 pM, then discuss coasting with doctor 
 If abdominal discomfort, then doctor to discuss stopping with patient 
 
TRIGGER 
 Trigger ovulation with 250 μg Ovidrel and stop Buserelin, when: 
o 2 follicles >= 20 mm, or 3 follicles >= 18 mm, OR 
o Coasted and E2 falls to < 10,000 pM 
 If need to adjust trigger day to avoid a weekend, trigger 1 day earlier rather than 1 day 
later. 
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 Do not give hCG trigger if E2 > 20,000 pM 
 If the E2 rise is significantly steeper than the standard line on the tracking sheet in the 
days leading to trigger, then a doctor must make the decision whether or not to trigger. 
 
OPU   (= luteal day 0) 
 36 h after hCG trigger 
 Premedication of 2 Panadol tablets (500 mg each). 
 Other medication requires doctor's prescription. 
 
EMBRYO REPLACEMENT  
 At least 45 h after insemination in IVF, 43 h after injection in ICSI insemination 
 If E2 > 12,000 pM day of hCG trigger or >= 20 eggs at OPU, then freeze all embryos 
 If 15-20 eggs at OPU, then doctor’s discretion whether to freeze all embryos 
 
LUTEAL SUPPORT AND MONITORING 
 Utrogestan intravaginal 2 x 100 mg 3x / day from luteal day 1 
 HCG test luteal day14 
 If hCG >= 5 iu/l day 14, then consider pregnant, and do E2, P4, hCG day 18 
 HCG result day 18: 
o If P4 > 80 nM, reduce to 100 mg Utrogestan 3 x / day for 4 days, then stop. 
o If P4 < 80 nM, stay on Utrogestan until scan with foetal heart at 10 weeks, then 
reduce to 100 mg Utrogestan 3x / day for 4 days then stop. 
 Further monitoring at patient’s request as early pregnancy monitoring service OR 
continue monitoring if any concern about possible ectopic pregnancy. 
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APPENDIX 3.1  
 
Title  ICSI Protocol 
Author  Dr. Bert Stewart, Fertility Associates Ltd. 
Purpose To describe the method used for ICSI 
Scope  Laboratory staff 
Responsibility Laboratory Team Leader 
 
 
Materials 
Equilibrated G-IVF+ in labelled Nunc 4-well dishes in CO2 incubator. 
Equilibrated G-IVF+ in labelled organ culture dishes in CO2 incubator  
HYASE diluted to 30IU/ml with G-MOPS+  
OVOIL 
10% polyvinylpyrrolidone solution (ICSI, Vitrolife)  
5ml pipette (Falcon 357543) 
Nunc 4-well dishes (44444). 
Petri dishes (Falcon 353652). 
Fire polished, washed, sterilized Pasteur pipette. 
Long drawn Pasteur pipette. 
Denudation pipette.  
ICSI injection pipette  
Oocyte holding pipette. 
 
Method 
1.0  Day before Procedure 
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 Set up G-IVF+ OPU, rinse and culture dishes according to Laboratory Protocol, 5828.21 
Procedure 
2.0   Timing: 
Optimal injection time is 38-40h post hCG (2-4 hours post OPU). 
On the Day of the procedure, dishes should be set up for denudation of oocytes and the 
ICSI procedure itself. 
 
3.0 Hyaluronidase dishes 
One Hyaluronidase dish should be made for each ‘batch’ of oocytes to be injected. (see 
Denudation and Injection of Oocytes below) 
3.1 Nunc 4-well dishes (44444) are labelled with the patient’s name.  
3.2 Lines are drawn on the base of the dish connecting wells 1 to 2, 2 to 4 and 4 to 3.  
3.3 Well 1 is highlighted by drawing a ring around it.  
3.4 0.5ml of HYASE solution (2.9ml G-MOPS+ added to 0.1ml HYASE concentrate) is placed
 in well 1. 
3.5 0.5ml G-MOPS+ is placed in each of the other 3 wells.  
3.6 All wells are covered with 0.4ml OVOIL.  
3.7 The dish (denudation) is equilibrated to 37oC in air. 
 
4.0 ICSI dishes 
1 or 2 injection dishes should be set up depending on the number of oocytes, see Denudation and 
Injection of Oocytes below. 
4.1 Using a micro-pipettor place a 5µl drop of PVP in the centre of the Petri dish (353652). 
4.2 Arrange sufficient drops of G-MOPS+ (5µl) around the central drop.  
4.3 Cover with 4.5ml oil.  
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4.4 Immediately suck out G-MOPS+ drops from under the oil and replace with 10µl G-
MOPS+.  
4.5 Leave the central 5µl PVP drop. Equilibrate to 37oC in air. 
4.6 Set up manipulators ready for injection. 
 
Denudation and Injection of Oocytes 
To minimize stress to oocytes through exposure to sub-optimal conditions, total time out of the 
incubator should not exceed 30 minutes. Only remove as many oocytes from the OPU dish as can 
be processed through denudation and injection in this time. Number will vary according to ease 
of denudation and quality/quantity of sperm available for injection. 
 
5.0  Denudation of Oocytes: 
Oocytes must first be stripped of their cumulus and coronal cells to assess nuclear 
maturation and aid visualisation of the injection procedure. This is achieved through a 
combination of exposure to hyaluronidase and mechanical disruption. Hyaluronidase is a 
toxic enzyme, so oocytes should be exposed for as short a time as is possible. No more 
than one minute is recommended. 
5.1 FA: The OPU dish containing the patient’s oocytes is removed from the incubator along 
with the denudation dish and placed on the heated stage of a dissecting microscope. 
OFS: The OPU dish containing the patient’s oocytes is removed from the incubator along 
with the denudation dish and placed in the IVF chamber with the CO2 turned off. 
Using a fire polished Pasteur, transfer oocytes to well 1 of the denudation dish. The OPU 
dish is immediately replaced in the CO2 incubator unless another is available. 
5.2 With the Pasteur, gently aspirate the oocytes for 5-10 seconds (the aim is to remove the 
bulk of the cumulus cells. Hyaluronidase will not disrupt the junctions that hold the 
coronal cells to the zona pellucida). Using a long drawn Pasteur or flexipet (OFS), remove 
the oocytes from the hyaluronidase and rinse in well 2. Using a new long drawn Pasteur or 
flexipet (OFS), move the oocytes to well 4 and gently rinse. 
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5.3 Assist removal of remaining cumulus/coronal cells by gently aspirating with a Cook Flexi-
pet/Swemed Denudation Pipette, and transfer denuded oocytes into final well of clean G-
MOPS+. When all oocytes are denuded, place in 1
st
 injection dish. 
 
6.0  Sperm Injection Procedure 
6.1  Take patient’s prepared sperm sample from incubator, consciously identifying patient’s 
name and checking against Semen Preparation Sheet. Place in rack in workstation. 
Transcribe script from tube onto IVF tracking sheet. 
6.2 Using a micropipettor and new sterile tip, add ~1µl of prepared sperm sample to the centre 
of the PVP drop. (For prepared samples with less than 500,000 motile sperm per ml, 1-5µl 
of sample should be added to a peripheral G-MOPS+ droplet to allow ‘swim-out’). 
6.3 Inject oocytes as per normal practice. 
6.4 Remove patient’s ‘post-ICSI rinse/culture dish’ from CO2 incubator. Gently rinse and move 
oocytes through each of first row of rinse drops and finally hold in groups (up to 4 per 
microdrop) in the mid row. 
6.4 If there are more oocytes to inject, return rinse dish to Minc/CO2 incubator. 
6.6 Repeat above stages 5.0-6.5 with new denudation dish until all oocytes are denuded. 
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APPENDIX 3.2 
 
Title  Fertilisation Check 
Author  Dr. Bert Stewart, Fertility Associates Ltd. 
Purpose To describe the process of checking fertilisation 
Scope  Laboratory staff 
Responsibility Laboratory Team Leader 
 
 
Fertilisation Check (2006) 
All oocytes (IVF and ICSI) should be checked for the presence of pronuclei between 14 and 18 
hours post insemination; optimal is 16hrs.  
 
Materials 
Equilibrated G1v5 culture microdrops in labelled Petri dishes (Falcon 353652) in CO2 incubator, 
(prepared day before fertilisation check). 
Oocyte denuding pipette and holder.  
Long drawn Pasteur pipette. 
 
Afternoon before fertilisation check 
1.1 Check patient tracking sheet for expected number of embryos. Label lid and base of Petri 
dish with patient’s first name, surname and file number. Label lid with D1 G1v5.)  
1.2 Depending on number of inseminated/injected oocytes, make up to three rows of three 
microdrops (20µl). Cover with 7ml OVOIL. Remove all drops and replace with 40µl 
fresh G1v5. Place in CO2 incubator overnight to equilibrate. 
 
Morning of fertilisation check 
3.1 Identify patient’s tracking sheet and fill in Date, Time and hours after OPU on IVF sheet 
2. 
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3.2 Identify patient’s culture dish containing oocytes in the incubator.  
3.2.1 FAA, FAH, FAW: Place dish on heated stage of stereo microscope. 
3.2.2 OFS: Place dish in IVF workstation. 
3.3 For IVF: strip off adhering cumulus cells by gently drawing oocyte in and out of 
denudation pipette. 
3.4 For IVF and ICSI, record: number of pronuclei, number of polar bodies, any other 
significant findings, e.g. vacuoles, uneven sized or separated pronuclei. 
3.5 After all oocytes have been checked, remove patient’s ‘Rinse/culture” dish from CO2 
incubator. First, move all normal 2PN zygotes into the first G1v5 rinse drop. Using a new, 
rinsed pipette, rinse through all three drops and group evenly (up to four per group) in the 
mid row of microdrops. Abnormal 2PN zygotes (separated or very uneven sized PN, 
vacuoles or large polar bodies) should be discarded; however, if retained, they should be 
rinsed as above and grouped together in a third row microdrop. 
3.6 Oocytes with 0PN or 1PN should be retained and re-examined at 22h post-insemination. 
3.7 Oocytes with >2PN should be discarded.  
3.8 Return dish containing viable embryos to CO2 incubator. Check patient’s consent before 
discarding non-viable oocytes/embryos. 
3.9 Complete tracking sheets. 
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APPENDIX 3.3  
 
Title  Embryo grading and selection 
Author  Dr. Bert Stewart, Fertility Associates Ltd. 
Purpose To describe the steps for grading and selecting embryos 
Scope  Laboratory staff 
Responsibility Laboratory Team Leader 
 
 
Embryo Grading and Selection (2005.1) 
Selection of the ‘best’ embryos for fresh replacement in an IVF cycle can have a major influence 
on the chance of conception. Embryos are assessed according to the rate and symmetry of their 
cleavage and translucency of their cytoplasm degree of fragmentation. It is also worth noting 
unusual characteristics that may impact on developmental potential.  
Materials: 
Stereo Microscope with heated stage (FAA, FAH, FAW), or in IVF workstation (OFS) 
ICSI microscope. 
Washed, sterilised, finely drawn Pasteur- pipettes. 
Patient’s tracking sheets. 
 
Method:  
1. Day 0. The oocyte 
In practice, assessment of abnormal oocyte phenotypes is limited to ICSI cycles where the 
denuded oocyte can be examined on the ICSI microscope. Features associated with poor 
developmental potential (on-going pregnancy, NOT embryo morphology) are; 
 Very large first polar bodies, 
 Cytoplasmic vacuoles (large or many), 
 Very large perivitelline space. 
 
Presence of any of these features at injection should be noted. 
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2. Day 1 morning 
A degree of negative selection can be made at the pronucleate stage. 
 
Features visible on the stereo microscope and are indicative of extremely low implantation 
potential are: 
 Pronuclei of obviously uneven size (smallest <50% diameter of largest), 
 Pronuclei not in contact, 
 
At fertilisation check, the above poor prognosis features should be recorded.  
 
The remaining ‘normal’ zygotes should be quickly checked on the ICSI microscope for: 
 Multiple cytoplasmic vacuoles, 
 Supernumerary (micro) pro-nuclei. 
Any zygotes displaying these features should also be regarded as poor prognosis. 
 
>2PN zygotes: these should be discarded.  
1PN zygotes and 0PN oocytes should be re-checked at 22h and at 25h post insemination. 2PN 
must be seen together at some point for these to be regarded as normally fertilised. If not, they 
should be discarded. 
3. Day 1 (25 hours post insemination/injection) 
All cultured embryos should be assessed for early cleavage or nuclear envelope breakdown at 25 
hours post insemination.  
 
3.1  Remove dish containing zygotes from CO2 incubator and place on heated stage of stereo 
microscope. 
3.2 Score each zygote according to developmental stage, and record any untoward observations 
(e.g. fragmentation*). 
3.3 Complete appropriate section of IVF sheet 2 in patient’s tracking sheets. 
 *Some aspects are undoubtedly grossly abnormal, e.g. 3 or more cells. Others depend on degree, e.g. 10% fragmentation may not be 
detrimental while >30% probably is. 
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4. Day 2 (44h post insemination) 
On the ICSI microscope, check embryos for presence of multinucleated blastomeres. Each 
blastomere should have one visible nucleus (or no visible nucleus). The presence of 2 or more 
nuclei within a blastomere is abnormal, and greatly decreases the implantation potential of that 
embryo. Affected embryos should not be replaced (unless only embryos available) and should not 
be frozen. 4-cell embryos should be tetrahedral in orientation. 
 
5. Day 3 (68h post insemination) 
Progressive development: 
Embryo cell number must increase between day 2 and day 3. 
On ICSI microscope count cells and note any untoward features such as multi-nucleation 
vacuoles or highly asymmetrical cleavage. 
Early Cleavers: Choose from the early cleavage group when possible (2>1) as long as they are 
1
st
 or 2
nd
 choice stage appropriate.  
Morphology: After initial selections above, chose embryos with highest morphological grades 5.  
Embryo Replacement (Day 3): 
The ‘best’ embryos for replacement should have none of the poor prognosis features 
described above at any stage then be chosen after consultation the ‘embryo development’ 
matrix available in each lab. 
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APPENDIX 4 
Tables for recording COC and oocyte morphological features 
 
Cumulus mass morphological features 
 
Cumulus # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
0. No abnormalities                
1. Small Cumulus (Ball)                
2. Dark Cumulus                 
3. Cumulus with dark patches                
 
 
Oocyte morphological features 
 
Oocyte # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
0. MII (mature)                
1. MI (immature)                
2. GV (immature)                
3. Abnormal                
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APPENDIX 5 
 
Table 5C: Summary showing the Pearson correlation coefficients and significance levels (P 
values) between biological and treatment variables in the 68 women recruited in the four study 
groups.  
 
 
Variables 
Age 
[Years] 
BMI 
[kg/m2] 
AMH 
[ng/mL] 
Basal 
FSH 
[IU/L] 
Stim. 
Days 
[Days] 
rFSH 
[IU] 
E
2
  
trigger 
[pmol/L] 
N Foll. 
[#] 
N COC 
[#] 
Age 
[Years] 
Pearson's 
R 
1 0.021 -0.565 0.488 0.080 0.686 -0.127 -0.448 -0.300 
Sig. (P 
value) 
 0.869 0.001 0.000 0.517 0.000 0.315 0.000 0.013 
BMI 
[kg/m
2
] 
Pearson's 
R 
0.021 1 -0.042 0.056 0.096 0.058 -0.213 -0.194 -0.191 
Sig. (P 
value) 
0.869  0.816 0.655 0.438 0.639 0.091 0.116 0.122 
AMH 
[ng/mL] 
Pearson's 
R 
-0.565 -0.042 1 -0.668 0.043 -0.774 0.448 0.740 0.669 
Sig. (P 
value) 
0.001 0.816  0.000 0.810 0.000 0.011 0.000 0.000 
Basal 
FSH 
[IU/L] 
Pearson's 
R 
0.488 0.056 -0.668 1 0.092 0.789 -0.342 -0.626 -0.571 
Sig. (P 
value) 
0.000 0.655 0.000  0.458 0.000 0.006 0.000 0.000 
Stim.  
Days 
[Days] 
Pearson's 
R 
0.080 0.096 0.043 0.092 1 0.099 -0.091 -0.110 -0.145 
Sig. (P 
value) 
0.517 0.438 0.810 0.458  0.423 0.472 0.374 0.239 
rFSH 
[IU] 
Pearson's 
R 
0.686 0.058 -0.774 0.789 0.099 1 -0.406 -0.721 -0.601 
Sig. (P 
value) 
0.000 0.639 0.000 0.000 0.423  0.001 0.000 0.000 
E
2
  
trigger 
[pmol/L] 
Pearson's 
R 
-0.127 -0.213 0.448 -0.342 -0.091 -0.406 1 0.672 0.608 
Sig. (P 
value) 
0.315 0.091 0.011 0.006 0.472 0.001  0.000 0.000 
N Foll. 
[#] 
Pearson 
Correlation 
-0.448 -0.194 0.740 -0.626 -0.110 -0.721 0.672 1 0.751 
Sig. (2-
tailed) 
0.000 0.116 0.000 0.000 0.374 0.000 0.000  0.000 
N COC 
[#] 
Pearson's 
R 
-0.300 -0.191 0.669 -0.571 -0.145 -0.601 0.608 0.751 1 
Sig. (P 
value) 
0.013 0.122 0.000 0.000 0.239 0.000 0.000 0.000  
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APPENDIX 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6I: Biplots of the six genes (HAS2, FSHR, ALCAM, VCAN, PR and NRP1) along the first 
and second principal component (PC1 and PC2). A) dots represent each CC mass (N=227) from 
Group 1 women. In this analysis PC1 accounted for 50.3%, whilst PC2 accounted for 17.4% of 
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the observed variance; B) dots represent each CC mass (N=175) associated with an oocyte with 
negative outcome (arrested embryo) from Group 1 women. In this analysis PC1 accounted for 
53.2%, and PC2 15.4% of the observed variance; C) dots represent each CC mass (N=52) 
associated with an oocyte that progressed to a good quality blastocyst from Group 1 women. In 
this analysis PC1 accounted for 42.5% and PC2 22.1% of the observed variance. The closer the 
dots, the more similar the gene expression pattern is for individual CC masses according to the 
two principal components. The closer the arrows to each other, the more the gene expressions 
(normalized values) are correlated. 
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APPENDIX 7    Figure 7C (full data set) 
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Figure 7C: Rankings of individual COC according to gene expression for patient # 19. Individual 
COC are spread along the X axis for each candidate gene (HAS2, FSHR, ALCAM, VCAN, NRP1 
and PR) from left to right according to their numerical order assigned at the time of egg 
collection. Expression results for each gene are separated by grey vertical lines. “+” marks are 
associated to dots (oocytes) with a positive outcome (blastocyst development and/or positive 
pregnancy). Different dots denote different ranks (○=1, =2, ●=3, =4, =5, ▲=6, ○=7, =8 
and, ●=9). Gene expression is presented in 2-ΔCT values (HAS2: 2000x 2-ΔCT, FSHR: 10000x 2-
ΔCT
, ALCAM: 5000x 2
-ΔCT
, VCAN: 100x 2
-ΔCT
, NRP1: 500x 2
-ΔCT
 and, PR: 10000x 2
-ΔCT
) (data 
presented in this figure originates from figure 7B). 
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